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Abstract 
Ulcerative colitis and colorectal cancer are progressively spreading in developed and 
developing countries. However, the current therapeutics does not provide complete 
cure to these conditions. It has been reported that inflammatory cytokines, 
overstimulated NF-kβ and overexpressed HIF-1α play pivotal role in inflammation 
and colorectal cancer. The traditional method of treatment offers not only 
detrimental effects on health due to non-selectivity but also burdens financially. 
Additionally, in a chronic condition of ulcerative colitis and colorectal cancer 
patients undergo bowel surgery which makes the life difficult to live. Therefore, 
there is pressing need to utilize natural therapeutic compounds to treat ulcerative 
colitis and colorectal cancer. These natural compounds possess potent inhibition 
potential against inflammatory cytokines, NF-kβ and HIF-1α. These compounds 
treat the inflammatory condition and colorectal cancer with minimum or no side 
effects as documented in clinical trials. However, these natural compounds have 
limited solubility in aqueous media due to which therapeutic potential of natural 
compounds are compromised. Therefore, nanotechnology can be employed to 
overcome the solubility issue of these natural compounds.  
In the current work, we have formulated nanoparticles of low soluble natural anti-
inflammatory and anticancer agents such as curcumin, piceatannol and Caffeic acid 
phenethyl ester. Characterization and optimization have been performed to obtain 
suitable formation for the in vitro and in vivo experiment. Morphological studies 
were carried out by scanning electron microscopy. Significant increase in solubility 
has been confirmed in nanoparticles form. Cellular localization has been observed 
under phase contrast microscopy in MDA-MB-231, A549, HT-29 and CaCo-2 cells. 
Nanoparticles treated colon cancer cells has depicted the higher degree of 
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cytotoxicity, lower migration, less colony formation and decrease level of invasion 
than free drug in cancer cell lines. Nanoparticles treated cells have demonstrated low 
expression of inflammatory cytokines such as INF-γ, IL-6, IL-1β, TNF-α, and IL-10 
in cancer cell lines. Stabilisation of nuclear proteins p65 and HIF-1α has been 
demonstrated significantly more in nanoparticles treated in lung cancer, breast 
cancer and colon cancer cell lines. The anti-inflammatory activity of these 
nanoparticles has been tested in mouse model of ulcerative colitis and it has been 
found that nanoparticles have higher therapeutic potential in inflammation than free 
drug. 
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Chapter 1 
Introduction 
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1.1 Inflammatory bowel disease 
Inflammatory bowel disease (IBD) is an idiopathic disorder categorised chiefly as 
Crohn`s disease (CD) and ulcerative colitis (UC) (Xavier and Podolsky, 2007a., de 
Souza and Fiocchi, 2016). The characterization of IBD depends upon the location, 
depth and severity of the intestinal mucosa (Abraham and Cho, 2009). CD is linked 
with the small intestine and has complications such as stomach cramp, fever, 
diarrhoea, irregular ulceration strictures, abscesses and fistulas (Laass et al., 2014., 
de Souza and Fiocchi, 2016). UC is restricted to the large intestine. It instigates from 
the rectum and propagates to the superficial layer of bowel with inflammation, 
cryptitis and crypt abscesses (Neurath, 2014b., Pekow, 2015). CD and UC have 
common symptoms such as rectal bleeding, diarrhoea, abdominal pain, weight loss, 
fatigue and fever. Generally, both disorders exert long lasting and reverting 
inflammation (Strober et al., 2007). Although the main cause of IBD is still unclear, 
factors such as mucosal dysfunction, aberrant activation of NF-kβ, compromised 
immune system, environmental and genes have been linked to its pathogenesis 
(Fiocchi, 1998) (Danese et al., 2004., Zhang and Li, 2014). It has been documented 
that the alteration in the mucosa of the intestine is responsible for CD and UC 
(McCole, 2014., Dulai et al., 2015). 
IBD has affected millions of people in the United States, Europe; and Asian 
countries (Engel and Neurath, 2010). The chronic nature of IBD involves a period of 
alternating remission thereby making it difficult for clinical investigation of active 
disease Current treatments used in IBD, such as immunomodulator, corticosteroids 
and antibiotics do not provide a permanent cure but instead produce side effects due 
to the non-selectivity and long-term exposure (Moura et al., 2015).  Approximately 
30-40% of patients need to undergo surgical removal of inflamed tissue in majority 
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of cases (Ferrari et al., 2016b) which is not only expensive but inconvenient to 
patients. Moreover, ulcerative colitis patients are prone to develop colorectal cancer 
in later stages (Kim and Chang, 2014). The current strategy for management of 
ulcerative colitis and colorectal cancer depends on suppressing inflammation but 
associated with no complete cure.  The primary focus of the work in this thesis is to 
understand the disease mechanism of UC and associated colorectal cancer with the 
aim of developing novel therapeutics. 
 
1.2 Ulcerative colitis 
UC is an inflammatory condition of the colon and rectum, which damages the 
superficial layers of mucosa by forming granulomatous patches (Lunney and Leong, 
2012). UC leads to weight loss, stomach ache, diarrhoea, blood in stool, loss of 
appetite, and fatigue (Conrad et al., 2014). In North America and Europe it is 
reported that 250 out of 10000 people suffer from UC (Danese and Fiocchi, 2011., 
Molodecky et al., 2012).  In severe inflammatory conditions, patients undergo entire 
colon removal (Kornbluth and Sachar, 2010). It has been postulated that UC triggers 
an alteration in the mucosal layers and damages superficial mucosal protective layer 
(Qin, 2013) as presented in the Figure 1.1. Froslie  and colleagues postulated that 
mucosal repair could present a potential  cure for UC (Frøslie et al., 2007).  
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Figure 1.1: Representative diagram of healthy and inflamed colon. Tight junctions and the 
mucus layer are fully intact in healthy tissue, whereas in the inflamed colon this arrangement 
of tight junctions is disrupted giving rise to epithelial leakage and loss of the mucus layer. 
 
1.3 Colorectal cancer 
The prolonged inflammation of gastrointestinal tract results in colorectal cancer 
(Rubin et al., 2012). Colorectal cancer is a major health issue causing high mortality 
rates in cancer patients. It is the third most commonly diagnosed cancer and third 
leading cause of cancer death in the United States of America  (Tariq and Ghias, 
2016). Clinical investigations demonstrate that 110 out of 55000 UC patients 
develop colorectal cancer in 10 years and this trend increases to 440 and 990 after 20 
and 30 years, respectively (Triantafillidis et al., 2009). The contribution of UC 
patients towards colorectal cancer is higher than CD patients (Grivennikov, 2013). 
The probability of developing colorectal cancer in Crohn's disease depends upon the 
stage of inflammation (Mellemkjaer et al., 2000). Ulcerative colitis patients are more 
prone to develop colon cancer which increases mortality rate in colorectal cancer 
patients (Bergmann et al., 2017., Abdalla et al., 2017). The event of colorectal cancer 
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will be higher in future, which will increase the death rate in patients (Kim and 
Chang, 2014). Sometimes the treatment used to cure IBD such as 5-aminosalicylic 
acid, azathioprine, sulfasalazine and 6-mercaptopurines produce adverse effect and 
worsen the condition. It also produces side effects such as organ depletion, 
hepatoxicity, bone marrow depletion and infertility (Connell et al., 1994., Dubinsky 
et al., 2000). 
Millions of people suffer from IBD and colorectal cancer in United States. It has 
been stated that IBD and colorectal cancer are interrelated diseases because prolong 
IBD conditions results in colorectal cancer (Kimura et al., 2000., Triantafillidis et al., 
2009). IBD and colorectal cancer are not only confined to these countries but is also 
spreading to Asian and Gulf countries  (Kaplan, 2015). It hampers the quality of life 
of patients because they have to face the burden of long term  treatment in term of 
hospitalization and surgery  (Ananthakrishnan, 2015). The factors which govern IBD 
include genetic factors, environmental factors and alteration in mucosal barrier 
functions (Ponder and Long, 2013., Zhang and Li, 2014., Castaño-Rodríguez et al., 
2015). However, the damaged intestinal mucosal layer promotes IBD and colorectal 
cancer  with different stage of tumour development as shown in the Figure 1.2 
(Wlodarska et al., 2015., Zeng et al., 2017).  It has been estimated that occurrences 
of colorectal cancer may increases in future due to increase in IBD disease (Kim and 
Chang, 2014).  The chronic inflammatory condition alters the microbes of the 
mucosal layer and results in colon cancer (Oke and Martin, 2017). 
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Figure 1.2: Representation of different stage of cancer development. It starts from the 
formation of harmless polyps to adenomatous polyps and later turns to malignant cancer. 
 
 1.4 Pathogenesis of ulcerative colitis and colorectal cancer 
Colorectal cancer and ulcerative colitis share common factors, such as condition age, 
family history, hygiene, diet, cigarette smoking and obesity, which contributes to 
disease induction (Haggar and Boushey, 2009., Scarpa et al., 2014b). It has been 
scripted that factor such as compromised immune response, oxidative stress, 
hereditary and damage to intestinal mucosa are the key regulators of colorectal 
cancer and ulcerative colitis (Kim and Chang, 2014., Kim et al., 2017). However, 
mucosal damage plays pivotal role in the prognosis of colorectal cancer and 
ulcerative colitis (Tanaka et al., 2006.,  Meira et al., 2008). In both condition 
alteration and abscess have been documented to disrupt the mucosal barrier of 
intestine (Rogler, 2014., Rafa et al., 2017). This mucosal damage is a result of  
increased expression of pro-inflammatory cytokines such as TNF-α, interferons, 
interleukins and DNA damaging agents etc. in ulcerative colitis patients 
(Hassanzadeh, 2011., Klampfer, 2011., Műzes et al., 2012., Scarpa et al., 2014a., 
Hyper-
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Francescone et al., 2015., Sreedhar et al., 2016). These over-triggered agents result 
into aberrant activation of nuclear factor kappa beta (NF-kβ) and HIF-1α which play 
the main role in maintaining the homeostasis of the mucosal layer (Pal et al., 2014., 
Manzat-Saplacan et al., 2015., Serra et al., 2017). Therefore, inhibition of 
overactivated pro-inflammatory cytokines may control the level of NF-kβ and HIF-
1α and provide a therapeutic cure to colorectal cancer and ulcerative colitis. 
 
1.5 Diagnosis of ulcerative colitis and colorectal cancer 
Early detection of ulcerative colitis and colorectal cancer is the key for their control 
and prevention. Diagnostic tools such as information of patient’s history and visual 
observation help in detecting the disease condition as mentioned in the table 1.1. In 
mild to moderate inflammatory condition, clinical investigation of body fluid and 
blood components is recommended. Sometime microbiological test of stool is also 
necessary to find out the strain of bacteria responsible for inflammation. The extent 
of colitis is also determined by microscopic imaging method. 
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Table 1.1 Modes of clinical diagnosis (Taghipour et al., 2016) 
Sr. No.         Methods of  
                     diagnosis                              Examples
 
1 History Age of onset, Type of stool, lifestyle, previous 
bowel infection and medication, smoking.  
2 Visual observation Pulse, BP, temperature, weight, height, BMI, 
abdominal pain, rectal inspection, examination 
of eyes, skin, joints and muscles 
3 Clinical investigation  Electrolytes, urea, creatinine, complete blood 
count, ESR, liver enzymes, bilirubin, alkaline 
phosphatase, transferrin, ferritin, vitamin B12, 
B folic acid, CRP, urinalysis 
4 Faecal investigation  Stool testing for bacterial organisms  
5 Microscopic 
observation 
Endoscopy and colonoscopy 
6 Imaging  Ultrasound and MRI 
 
1.6 Inflammation and colorectal cancer therapeutics 
Researchers are targeting receptors in colorectal cancer treatment, such as vascular 
endothelial growth factor, epidermal growth factor receptor and receptor tyrosine 
kinase (Moriarity et al., 2016). Monoclonal antibodies are approved by FDA to treat 
colorectal cancer such as Bevacizumab, Cetuximab, Trastuzumab, Panitumumab and 
Ramucirumab (Pileri et al., 2016). Some monoclonal antibodies are also prescribed 
in combination for the treatment of colorectal cancer at chronic stages of disease 
(Samant and Shevde, 2011). Recently, angiogenesis inhibitors have been suggested 
in the treatment of inflammation and colorectal cancer. These inhibitors are found in 
the human body, natural agents and synthetic compound etc. (Khan et al., 2017b). 
Proteasome inhibitors are another category of the anticancer agent used in 
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inflammation and  colorectal cancer treatment which stimulate apoptosis and prevent 
overactivation of NF-kβ and HIF-1α (Hochwald et al., 2003). 
 
1.7 Side effects of treatments prescribed in ulcerative colitis  
Table 1.2, summarises the side effects due to longterm exposure and drug interaction 
of commonly prescribed ulcerative colitis drugs (Carter et al., 2004). These 
therapeutic require multiple longterm exposure which disturbs normal lifestyle. 
Ulcerative colitis patients fail to stick to these treatment because of the negative 
consequence of the therapeutics, which increases the possibility of disease remission, 
colon cancer and lead to colon surgery  (Kane, 2006). 
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Table 1.2: Different treatment of ulcerative colitis with side effects 
Treatment Side effects Reference 
5-
aminosalicylic 
acid 
Headache, epigastric pain, diarrhoea, 
idiosyncratic reactions, Renal impairment 
(Loftus et al., 2004., 
Van Staa et al., 
2004) 
Corticosteroids mood disturbance, dyspepsia, glucose 
intolerance, posterior sub-capsular 
cataracts, osteoporosis, osteonecrosis of 
the femoral head, myopathy, and 
susceptibility to infection, adrenal 
insufficiency, myalgia, malaise, and 
arthralgia, raised intracranial pressure 
 
methotrexate nausea, vomiting, diarrhoea, stomatitis, 
hepatotoxicity, and pneumonitis 
(Te et al., 2000., 
Fraser, 2003),  
Cyclosporine tremor, paraesthesia, malaise, headache, 
abnormal liver function, gingival 
hyperplasia, and hirsutism, renal 
impairment, infections, and neurotoxicity 
(D'Haens et al., 
2001., Van Assche 
et al., 2003) 
Infliximab joint pain and stiffness, fever, myalgia, and 
malaise 
(Ljung et al., 2004., 
Colombel et al., 
2004) 
 
1.8 Side effect of treatment prescribed in colorectal cancer 
Conventional therapeutics fail to provide a cure for colorectal cancer because of non-
selectivity, overdose due to frequent and combination therapy and systemic toxicity 
(Kemp et al., 2016). They also have serious side effects, such as nausea, vomiting, 
loss of appetite, decreased immunity, oral ulcers, sleep disorder, tiredness, 
depression, anxiety, infertility, bone marrow depletion, impairment of neuron and 
renal function (Denlinger and Barsevick, 2009). Compounds, like monoclonal 
antibodies have efficient therapeutic potential in colon cancer.  Although they have 
adverse effects on patients such as papulopustular rash, mucosal toxicity, electrolyte 
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imbalances (notably hypomagnesemia), diarrhoea, acne-like rash, nail disorder, 
infusion reactions and pruritus (Hofheinz et al., 2017b).  The angiogenesis inhibitors 
also exert an adverse effects on colorectal cancer patients such as hypertension, 
proteinuria, ruptured bowel, bleeding, fatigue, inflammation of mucous membrane 
and diarrhoea (Aalders et al., 2017). Proteasome inhibitors offer some disadvantages 
such as therapeutic failure in patients, resistance development for long term use, and 
induction of neuropathy (Dou and Zonder, 2014). 
 
1.9 Disease models of ulcerative colitis 
The preclinical animal studies play a pivotal role in providing preliminary data in 
drug discovery. They also help in finding factors responsible for the etiology or 
target particular factor involve in clinical disease (Low et al., 2013). Animal model 
of inflammatory bowel disease is already documented as given in the table 1.3 and 
have been used to detect novel sites for disease cure. It also use to evaluate the 
efficacy of different compounds (Maxwell et al., 2009). There are different method 
available to induce inflammatory condition which mimics either UC or CD such as 
gene knockout mice, transgenic mouse, spontaneous colitis model, induce colitis 
model and adoptive transfer model (Mizoguchi, 2012). However, it has been 
documented that the above models do not completely resemble human ulcerative 
colitis (Jurjus et al., 2004). However, chemically (dextran sodium sulphate) induce 
model of ulcerative colitis mimic the human ulcerative colitis more prominently 
(Maxwell et al., 2009., Low et al., 2013., Kiesler et al., 2015., Taghipour et al., 
2016). 
12 
 
Dextran sodium sulfate (DSS) is a widely used chemical to mimic human UC with 
more common features of inflammation than any other methods (Okayasu et al., 
1990). Additionally, DSS is readily available, cost effective and easy to induce 
inflammation as it can be orally administered through drinking water. Also, 
Dieleman and colleagues demonstrated the redevelopment of the colon after stopping 
DSS administration in few weeks periods (Dieleman et al., 1998).  It alters mucosal 
layer of colon epithelium and uncovers submucosa and lamina propria to luminal 
antigens and mucosal bacteria as shown in Figure 1.3 (Yan et al., 2009). This 
alteration induces inflammation due increased expression of inflammatory markers 
(Hakansson et al., 2015). The injured epithelial layer produces similar symptoms of 
UC colitis, such as loss of weight, diarrhoea, bleeding, blood in faeces, abdominal 
pain, shortening of colon length, cryptic abscess and epithelial distortion  (Randhawa 
et al., 2014). The acute and chronic inflammation depends on the dose of DSS, 
molecular weight of DSS, time period of DSS administration, strain and sex of 
animal use to induce inflammation (Okayasu et al., 1990., Chassaing et al., 2014a). 
Acute and chronic inflammation can be induced in mice (C57BL\6), hamsters or 
guinea-pigs upon administration of 1% to 5% DSS in drinking water for 6 to 7 days 
(Wirtz et al., 2007., Low et al., 2013). 
 
 
 
 
 
13 
 
 
 
 
 
Figure 1.3: Schematic representation of acute colitis. The above image shows faeces 
(yellow dots) blood clot (red dots) and inflammatory markers (blue dots). This figure also 
demonstrates leakage in the epithelial layer and altered epithelial layer due administration of 
DSS in drinking water. 
Table 1.3:Animal model of colitis (Low et al., 2013) ( (Kanneganti et al., 2011) 
 
Model of colitis UC CD 
Gene knockout 
mice 
IL-2 knockout mice, T cell 
receptor (TCR) mutant mice 
IL-10 knockout mice, TNF-3, 
untranslated region (UTR), 
Trefoil factor receptor mice 
Transgenic mouse 
and rat model 
IL-7 transgenic mice, Signal 
transducer and activating 
transcription (STAT)-4 
transgenic mice, HLA B27 
transgenic mice 
 
Spontaneous 
colitis model 
C3H/HejBir mice SAMP1/Yit mice 
Induce colitis 
model 
Acetic acid induced colitis, 
TNBS induce colitis, 
Oxazalone colitis, DSS colitis, 
Peptidoglycan polysaccharide 
colitis 
Indomethacin induced 
enterocolitis 
 
Adaptive transfer 
model 
Induction of colitis by heat 
shock protein, CD45RB 
transfer model 
 
Tight junction Leakage in tight junction Blood 
Pro-inflammatory  
markers 
Luminal contents Mucus layer 
Intestinal  
epithelial cells 
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1.10 Nuclear factor kappa beta (NF-kβ) in ulcerative colitis and 
colorectal cancer 
Sen and Baltimore discovered NF-kβ in 1986 (Aggarwal, 2004). Dysregulation of 
NF-kβ is associated with clinical diseases such as cancer, asthma, alzheimers 
disease, AIDS, atherosclerosis diabetes, arthritis, heart attack, muscle fatigue and 
viral infections as shown in Figure 1.4 (Gupta et al., 2010b., Shih et al., 2015). 
Colonic specimens from ulcerative colitis and colorectal cancer patients have been  
reported to exhibit irregular overexpression of transcription factor nuclear factor 
kappa beta (NF-kβ) (Ardite et al., 1998., Atreya et al., 2008., Jani et al., 2010., 
Viennois et al., 2013). 
 
 
 
 
 
 
 
 
 
Figure 1.4: Pivotal role of NF-kβ in various disease conditions. The above figure shows 
that NF-kβ is overexpressed in number of human disease. 
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NF-kβ is upregulated by factors, such as smoking, free radicals, tumour necrosis 
factor (TNF-α), interleukin (IL), interferon, and chemokines, DNA damaging agent 
and bacterial cell wall components and lipopolysaccharide during chronic 
inflammatory condition as shown in Figure 1.5 (Xavier and Podolsky 2007., Atreya 
et al., 2008., Viennois et al., 2013., Serasanambati and Chilakapati, 2016). 
 
 
 
 
 
 
Figure 1.5: Stimulatory action of pro-inflammatory on NF-kβ. The inflammatory markers 
such as interleukins, interferons and TNF-α phosphorylates inhibitory molecules Ikβ and 
cause translocation of NF-κβ subunits from cytoplasm to nucleus.  
 
NF-κβ regulates host inflammatory, immune responses and cellular growth 
properties by increasing the expression of specific cellular genes (Yamamoto and 
Gaynor, 2001., Baker et al., 2011). NF-kβ plays a vital role in immunity and cell 
maintenance (Zhang and Sun, 2015). It also contributes in the initiation of 
inflammation by producing inducible nitric oxide which generates nitric oxide and 
cyclooxygenase (COX-2) (Zhang and Sun, 2015). Inhibitors of NF-kβ, such as 
aspirin, 5 amino-salicylic acid, 5-fluorouracil, and oxaliplatin have been prescribed 
therapeutically in inflammation and cancer. Though side effects and the economic 
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burden makes these drug less effective  (Hassanzadeh, 2011). Therefore, inhibition 
of NF-kβ is the novel research topic in the treatment of inflammation and cancer. 
 The NF-kβ is composed of five different protein molecules namely p50, p52, p65, 
RelB, and c-Rel (Tak and Firestein, 2001., Serasanambati and Chilakapati, 2016). 
NF-kβ is sequestered in the cytoplasm bound with inhibitory proteins called Ikβ. The 
inhibitory molecules Ikβ is degraded by inflammatory mediators which cause the 
nuclear location of NF-kβ as shown in Figure 5. The translocation of NF-kβ into the 
nucleus is mediated by classical and alternative pathways as shown in Figure 1.6 
(Weber et al., 2000., Atreya et al., 2008). It has been found that NF-kβ is 
overactivated in intestinal mucosa of ulcerative colitis with increased subunits such 
as p50, p52 and p65 binds to DNA upon Ikβ phosphorylation (Andresen et al., 
2005). 
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Figure 1.6: The NF-kβ sequestered in the cytoplasm with the inhibitory Ikβ molecule. The 
inflammatory agents cause translocation of NF-kβ by canonical and noncanonical pathways.  
In the canonical pathway, the inflammatory stimuli trigger overactivation of core NF-kβ 
element IKK complex, which causes phosphorylation of Ikβ through ubiquitin binding 
activity of NEMO. Phosphorylation of Ikβ further leads to proteasome degradation of Ikβ 
and translocate the molecules of NF-kβ such as p52, RelB and RelA into the nucleus. In 
non-canonical pathway, the inflammatory agents provoke activation of NF-kβ inducing 
kinase (NIK) which phosphorylates and activates IKK complex which in turn incite 
phosphorylation of Ikβ.  Phosphorylation of Ikβ results in liberation of p52 and RelB 
molecules of NF-kβ into the nucleus. After NF-kβ molecules enter into nucleus it increases 
the expression of genes responsible for immune and inflammatory response ((Kumar et al., 
2004., Aggarwal et al., 2004). 
 
1.11 Hypoxia in ulcerative colitis and colorectal cancer  
The small intestine was reported to contain 8% of oxygen, with the intestinal lumen 
containing 2% oxygen.  Percentage of oxygen concentration changes based upon on 
the blood pressure, food intake, disease condition and intestinal cellular structure 
(Taylor and Colgan, 2007., Fisher et al., 2013). Hypoxia is produced in cells and 
tissue upon disease induction and is responsible for  pathological process in diseases 
such as intestinal disease, colon cancer, arthritis and heart disease (Semenza, 2012) 
(Biddlestone et al., 2015a). Therefore, treating the hypoxic condition may provide 
therapeutics to cure cellular disease. 
Colitis and colorectal cancer  produced by inflammatory cytokines (Sanchez-Muñoz 
et al., 2008., Fang et al., 2013) increase the consumption of oxygen at site of 
inflamed epithelial tissue and leads to hypoxic condition (Colgan and Taylor, 2010., 
Wilson and Hay, 2011., Campbell et al., 2014). 
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1.12 Hypoxia inducible factor (HIF) in ulcerative colitis and 
colorectal cancer  
HIF is a transcription factor, which plays a major role in the maintenance of oxygen 
homeostasis under hypoxic condition. Live cells in the body respond to this hypoxic 
condition via transcription factor hypoxia inducible factor 1 (HIF-1). HIF-1 consists 
of two subtypes HIF- 1α (oxygen and cellular hemostasis) and HIF- 1β  (Ziello et al., 
2007., Zeitouni et al., 2016). It has been reported that HIF exerts protective 
therapeutic action against chronic inflammation in TNBS induced and HIF-1 
knockout mice (Karhausen et al., 2004., Robinson et al., 2008). Mucosal protective 
effect of HIF-1 has been documented via oxygen-sensing enzymes pan hydroxylate 
through DMOG (Cummins et al., 2008). However, HIF- 1α also provide oxygen to 
cancerous cells while its activation in hypoxic condition (Ziello et al., 2007). 
Induction of  HIF-1α  has been also reported in the mucosal tissue of inflamed bowel 
(Giatromanolaki et al., 2003).  The HIF- 1α is hydroxylated at Pro 402 and Pro564 
by prolyl hydroxylases in the presence of ferrous iron (Fe+3) and catalyzed by 2-
oxoglutarate. This hydroxylated HIF-1 α is a target for E3 ubiquitin degradation 
ligase von Hippel-Lindau (pVHL) which leads to the ubiquitin and proteasome 
degradation (Kaelin and Ratcliffe, 2008., Shah, 2016). HIF- 1α repair damaged 
epithelial layer in colitis through energy metabolism via initiation of energy 
metabolism and cell migration process through apoptosis (Furuta et al., 2001., 
Synnestvedt et al., 2002., Louis et al., 2005). 
 
19 
 
1.13 NF-kβ and HIF in ulcerative colitis and colorectal cancer  
The inflammatory disease produces hypoxia and inflammation (Biddlestone et al., 
2015b). Activation of HIF1-α has been reported in hypoxic condition and activation 
of NF-κB has been documented in inflammatory condition as illustrated in Figure 
1.7 (Bandarra and Rocha, 2013). In another review, HIF-1α and NF-kβ have been 
postulated as interdependent on each other (Cummins et al., 2006., Culver et al., 
2010). 
 
 
 
 
Figure 1.7: Overexpressed NF-kβ and HIF-1α in colonic tissue. The above image shows 
faeces (yellow dots) blood clot (red dots) and inflammatory markers (blue dots). This figure 
also demonstrates leakage in the epithelial layer and altered epithelial layer.  
 
1.14 Natural compounds in ulcerative colitis and colorectal cancer  
Based on the non specificity, side effects, drug resistance, ineffectiveness, 
inconvenience and high cost of conventional therapeutics, there is a urgent need of 
safe, effective and economical chemotherapeutics  for inflammation and cancer care 
(Singh et al., 2017d., Schuster et al., 2017., Grosser et al., 2017). Colorectal cancer 
and ulcerative colitis treatments with natural compounds is an evolving approach in 
cancer therapeutics (Debnath et al., 2013., Xiao et al., 2016). Natural constituents 
have been recommended to possess therapeutic potential against inflammation and 
Mucus layer 
Intestinal  
epithelial cells Pro-inflammatory  
markers 
NF-kβ  HIF-1α  
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cancer for many years as given in the table 1.4 (Miyata, 2007., Espin et al., 2007).  
These natural elements retain medicinal values against a number of disease with little 
or no side effects (Patel et al., 2010., Aung et al., 2017). 
Table 1.4: Active therapeutic components in natural compounds  
 
Administration of natural compound as a therapeutic agent in various diseases is 
limited due to inadequate solubility, low permeability and poor bioavailability. 
Therefore, nanotechnology is being applied to overcome the aforementioned 
therapeutic potential issues of natural compounds (Cragg and Pezzuto, 2016., Puglia 
et al., 2017). 
 
1.15 Role of curcumin in ulcerative colitis and colorectal cancer  
Curcumin is a natural polyphenolic compound derived from Curcuma longa as 
shown in the Figure 1.8. It has been used in a number of diseases such as cancer, 
inflammation, bacterial and viral infection, wounds and skin disease (Stanić, 2017., 
Nelson et al., 2017., Kunnumakkara et al., 2017b., Kunnumakkara et al., 2017a). 
Sr. 
No. 
Natural 
compounds 
Active 
elements 
Sr. 
No. 
Natural 
compounds 
Active elements 
1 turmeric curcumin 8 Green tea polyphenols 
2 garlic  diallyl sulfide 9 honeybee hives CAPE 
3 ginger gingerol 10 vegetables isothiocyanates 
4 grapes Resveratrol, 11 broccoli sulforaphane 
5 grapes piceatannol 12 tomato lycopene 
6 milk silymarin 13 rosemary rosmarinic acid 
7 soybean genistein 18 parsley apigenin 
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Curcumin has an affinity to regulate a number of faulty signaling molecules 
responsible for human disorder due to which it has been under clinical investigation 
for decades (Gupta et al., 2013). It normalizes triggered activation of NF-kβ, 
interleukins, TNF-α and interferons which play a pivotal role in the pathogenesis of 
various human disease (Gu et al., 2013., Karunaweera et al., 2015). It has been  used 
either alone or in combination with conventional medicine such as sulfasalazine or 
mesalamine for the of treatment of colorectal cancer and UC (Patel et al., 2010., 
Taylor and Leonard, 2011., He et al., 2011., Garg et al., 2012). 
 
Figure 1.8: Chemical structure of curcumin. 
 
1.16 Role of Caffeic acid phenethyl ester in ulcerative colitis and 
colorectal cancer 
Caffiec acid phenethyl ester (CAPE) is a polyphenolic compound derived from 
honeybee hives as presented in Figure 1.9 (Tolba et al., 2016a). Anticancer, 
antibacterial, antioxidant, antiviral and anti-inflammatory property of CAPE has 
been documented in various human disease (Kuo et al., 2015, Khan et al., 2017c., 
Morin et al., 2017).  Over stimulation of  NF-kβ have been documented in colorectal 
cancer and ulcerative colitis aggravated by inflammatory medtaiors (Karin, 2009., 
Colotta et al., 2009a., Hoesel and Schmid, 2013., Rashidian et al., 2016., Marelli et 
al., 2017). CAPE inhibits overexpression of NF-kβ either by preventing translocation 
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of NF-kβ or interaction of NF-kβ-DNA binding in colorectal cancer and ulcerative 
colitis (Shepherd et al., 2018). It also reduces the stimulation of inflammatory 
mediators which provoke induction of NF-kβ and HIF-1α (Akyol et al., 2013., 
Murtaza et al., 2014a).  It has not been used in clinical trials therefore, it will be 
worth investigating its potential efficacy in patients. It can also be administered with 
other convention anticancer and anti-inflammatory compounds to verify its 
combinatorial effects with  traditional therapeutics. 
 
 
 
Figure 1.9: Chemical structure of CAPE. 
 
1.17 Role of piceatannol in ulcerative colitis and colorectal cancer  
Piceatannol is a natural polyphenolic constituents which has therapeutic potential in 
cancer, diabetes, heart disease and in inflammatory bowel disease documented (Tang 
and Chan, 2014., Seyed et al., 2016., Lu et al., 2017). Figure 1.10 shows different 
functional groups attached. Piceatannol is extracted from grapes, passion fruit, red 
wines, white tea tree, peanuts and sugar cane, (Lu et al., 2017). It arrests the 
unwanted growth of tumour cell in blood cancer, prostate cancer, breast cancer and 
rectal cancer (Piotrowska et al., 2012., Ko et al., 2012., Tang and Chan, 2014). 
Inhibition potential  of piceatannol against NF-kβ and HIF-1α has been seen in 
different cancer cell lines (Piotrowska et al., 2012., Zhang et al., 2014., Seyed et al., 
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2016). It has not been yet considered for clinical studies either in alone or in 
combination with other conventional medicine.  
 
 
 
 
 
Figure 1.10: Chemical structure of PIC. 
Apart from various medicinal values of curcumin, CAPE and PIC, they have limited 
solubility and bioavailability, which decreases the therapeutic activity of these 
natural compounds  (Ketkar et al., 2016., Inagaki et al., 2016., Gómez-Estaca et al., 
2017). Nanoparticles have been extensively employed to improve solubility, 
specificity for low soluble natural anticancer and anti-inflammatory agents 
(Bonferoni et al., 2017). Therefore, to improve its solubility nanotechnology or green 
technology is required to formulate nanoparticles of these natural compounds to 
maximise efficacy (Jahangirian et al., 2017). 
 
1.18 Nanotechnology approach to improve solubility of natural 
compounds  
Pharmaceutical industry started fabricating nanoparticles from last 30 years to 
overcome the solubility issue of hydrophobic drugs and nanoparticle technology has 
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been used in different fields such as microscopic imaging, tissue architect, 
biopathogens detections, protein and gene targeting etc  (Salata, 2004.,   Muller et 
al., 2011., Zaman et al., 2014). Advectus Life Sciences, Alnis Biosciences, and 
Argonide are some examples of a pharmaceutical company which are involved in 
formulation and marketing of nanoparticles in a different field (Salata, 2004). 
As active constituents such as curcumin, CAPE and piceatannol have limited 
solubility. Due to the difficulties arisisng from the poor solubility of natural 
compounds, it is problemtic to achieve maximum therapeutic benefits. Therefore, to 
resolve this issue fabrication of nanoparticles of these compounds increases the 
solubility with decrease in particle size.  
 
 
 
 
Figure 1.11: Schematic view of polymeric encapsulated nanoparticles. The inner core of  
polymer encapsulate the nanosize drug particle which provide targetd efficeincy in drug 
delivery.  
These nanosized particles can be delivered to mucusal layer of the desired site (Jafari 
and McClements, 2017).  The nanoparticulate delivery increases the efficacy via an 
increase in bioavailability and decreases the cytotoxicity (Yameen et al., 2014). 
Nanoparticles of specific size bypass the interaction with kidney or liver which 
decrease the pressure on these organs (Bobo et al., 2016).  Nanoparticles delivery 
prevents drug degradations, increase residence time and improves cellular uptake at 
the diseased site (Wang et al., 2014).  Solvent evaporation, salting-out, dialysis and 
Polymeric 
coating 
Solubilised  
drug 
Inner core 
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supercritical fluid technology are the methods employed to formulate solid 
nanosphere etc (Soppimath et al., 2001., Rao and Geckeler, 2011).  Solvent 
evaporation method was the first and most widely used techniques to formulae 
nanoparticles by the pharmaceutical industry and research institute for polymeric 
nanoparticles (Rao and Geckeler, 2011). Solvent evaporation methods can be used 
for both hydrophilic as well as hydrophobic drugs (Kilicay et al., 2011). In solvent 
evaporation method, the polymer of choice is dissolved in organic solvents such as 
dichloromethane, chloroform or ethyl acetate. The drug is dissolved or dispersed 
either in polymeric organic solution or an aqueous solution of stabilizer depending 
on the hydrophilic or hydrophobic nature of the drug. This polymeric organic 
solution is then emulsified into an aqueous solution of a surfactant such as gelatin, 
polyvinyl alcohol or polysorbate. The stable emulsion is then stirred to remove 
organic solvent and it leads to solid nanoparticles formulation after lyophilzation as 
shown in Figure 1.11  (Sahoo et al., 2002., Hans and Lowman, 2002). Formulation 
parameter such as, sonication or homogenization speed and time, type and amount of 
organic solvent, concentration of surfactant, concentration of drug, type and amount 
of polymers have an impact on particle size and zeta potential (Sharma et al., 2016., 
Sheikholeslami et al., 2017). Polymer used in the formulation of nanoparticles such 
as, PLGA, chitosan and PLA are well-accepted and biodegradable (Kumari et al., 
2010b). 
 
1.19 Nanoparticles delivery in inflammation and cancer  
Nanoparticles have been widely accepted possessing diagnostic and therapeutic 
potential (Revia and Zhang, 2016.,  Kang et al., 2017). They deliver chemical agents 
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to the tumour site, reduce the detrimental effects on healthy tissues and enhance the 
accumulation of active compound at desired site due to its nanosize (Baetke et al., 
2015., Chen et al., 2016., Torrice, 2016). The nanomaterial is extensively used to 
study the pathogenesis of various diseases, biodistribution of drug,  and mechanism 
of action of chemical compound (Bae et al., 2011., Baetke et al., 2015). Some of the 
nanoparticles are successfully used in inflammation and cancer treatment. 
Nanoparticles of a therapeutic agents such as doxorubicin, paclitaxel, and docetaxel 
are under preclinical and clinical investigation (Baetke et al., 2015., Rafiei and 
Haddadi, 2017).  Nanotechnology also enhances stability and can be used for co-
delivery with other pharmaceutical ingredients (Shi et al., 2017). Natural agents from 
plants sources have been extensively applied in treatment and management of cancer 
(Xiao et al., 2016., Sapio et al., 2017., Singh et al., 2017d). However, limited 
solubility hinders its pharmacological property to utilize in inflammation and cancer 
disease. Nanotechnology has been broadly employed to increase the solubility of 
natural compounds so that medicinal value can be improved in cancer treatment 
(Bharali et al., 2011., Watkins et al., 2015b).  These natural compounds formulated 
as nanoparticles with a polymer such as PLGA, PLA, albumin, gelatin, 
polycaprolactone, and chitosan increase the solubility and offer controlled release of 
active pharmaceutical agents (Kumari et al., 2010b.,Watkins et al., 2015a).  
Polymeric nanoparticles do not interact with mononuclear phagocytic system due to 
the small size and bypass first pass effect (Khan et al., 2013). These polymeric 
nanoparticles aggregate at the desired site due to enhanced permeability and 
retention effect (Wang et al., 2017). The repository of nanoparticles aggregates at 
tumour site and release the drug in a controlled fashion for an extended period 
(Singh and Lillard, 2009). 
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1.20 PLGA nanoparticles of natural anti-inflammatory and 
anticancer compounds  
Poly(lactic-co-glycolic acid) (PLGA) is one of the extensively used biodegradable 
polymer employed in fabrication of a number of natural and synthetic compounds for 
cancer treatment (Dinarvand et al., 2011., Khan et al., 2016). The safety of PLGA 
has been documented by US FDA to use in drug delivery systems due to controlled 
and sustained- release behavior, low toxicity, and biocompatibility with tissue and 
cells (Rafiei and Haddadi, 2017). PLGA nanoparticles is not recognize by 
mononuclear phagocytic system and deposit at cancer site due to EPR effects as 
shown in Figure 1.12 (Chen et al., 2015). Upon hydrolysis, PLGA breaks into lactic 
acid and glycolic acid which is metabolized in the body by Krebs cycle (Danhier et 
al., 2009., Kumari et al., 2010a).  
 
 
 
 
 
 
Figure 1.12: Mode of action of PLGA nanoparticles. The PLGA nanoparticles were taken 
by endocytosis into cytoplasm. Due to the nanosize of drug and polymeric encapsulation the 
active releases into nucleus and avoid reticuloendopasmic monosystem (RES).  
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1.21 Albumin nanoparticles of natural anti-inflammatory and 
anticancer compounds 
Desovation method is the most widely used technique in the fabrication of albumin 
nanoparticles (Li et al., 2015b., Tarhini et al., 2017., Singh et al., 2017b., Singh et 
al., 2017c). Protein polymers such human serum albumin, bovine serum albumin, 
polypeptide, collagen, casein, silk protein, soya protein,  gelatin and gliadin have 
been extensively using in nanoparticles fabrication for targeted delivery (Akash et 
al., 2016., Tarhini et al., 2017). Protein polymer easily networks with drug and 
solvent use in nanoparticle formulation (Lohcharoenkal et al., 2014).  Therefore, 
albumin has been used in the current work due to its nontoxicity, 
nonimmunogenicity and biodegradability etc (Fallacara et al., 2017., Liu et al., 
2017., Louage et al., 2017). It has been demonstrated that albumin can be used as a 
carrier for hydrophobic drug to improve pharmacokinetic profile and increase 
residence time at the target site (Dennis et al., 2002).   Firstly, albumins attracts 
towards overexpressed interleukins to provide amino acids at inflammed and tumour 
sites, which provides targeted delivery of anti-inflammatory and anticancer agents as 
shown in Figure 1.13 (Jiang et al., 2017).  Secondly, albumin holds several binding 
sites for ligands. It binds to a receptor to induce transcytosis (Larsen et al., 2016). 
Therefore, based on the accumulating evidence fabrication of nanoparticles of 
natural compounds with  albumin as a polymer will improve solubility, 
bioavailability, efficacy and targeting potential of nanoparticles by desolvation 
method. 
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Figure 1.13: Mode of action of albumin nanoparticles. The albumin gets attratced towards 
neutrophils because of release of amino acid during dissociation. It also targets tumour cells 
due to gp60 membrane protein.   
 
1.22 Conclusion 
UC and colorectal cancer are serious human disorders. The associated side effect and 
nonspecificity of the current treatment fail to provide permanent cure to these 
disease. Therfore, there is need to use effective therapeutics with minimum or no 
side effects. Natural compounds exhibit medicinal value against number disease. 
However, limited solubility and low permieability compromised its efficacy. This 
solubility and permeability issue can be resolve by employing nanotechnology. 
Therfore, in the current thesis nanoparticles of natural anti-inflammatory and 
anticancer natural comound were fabricated. PLGA and albumin were used as 
polymer. The anticancer activities of these nanoparticles were studies on cancer cell 
lines. Anti-inflammatory efficacy of these nanoparticlers were evaluated in mouse 
(C57BL\6) model of colitis. 
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1.23 Hypothesis 
In the thesis, we hypothesize that the reduction in particle size will enhance the 
solubility and increase anticancer and anti-inflammatory activities of nanoparticles 
of natural compounds PIC and CAPE. 
 
1.24 Aims and objectives 
• Formulation of PLGA nanopartciles of natural compounds 
• Formulation of albumin nanoparticles of natural compounds 
• Characterisation of PLGA and albumin nanoparticles of natural compounds 
• Evaluation of anticancer activity of PLGA and albumin nanoparticles of 
natural compounds 
• Evaluation of anti-inflammatory activity of PIC/CAPE-loaded albumin 
nanoparticles in ulcerative model of colitis 
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Chapter 2 
Material and methods 
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2.1 Materials 
Poly (lactic-co-glycolic acid) PLGA (50:50 lactide-glycolide ratio; with an average 
molecular weight of 7000-17000kDa), poly (vinyl alcohol) (PVA) 87-89% 
hydrolysed (MW 31.000-50.000), curcumin (log no. 78246, purity≥99.5%, sigma), 
Caffeic acid phenethyl ester (CAPE) (Cat no: -C8221, purity>97%, Sigma) and 
dichloromethane (HPLC grade) were purchased from Sigma Chemical Co. (St. 
Louis, USA).  piceatannol (PIC) (Cat no: -P1928, purity->98%, CAS: -10083-24-6) 
was purchased from Tokyo Chemical Industry. Dextran sodium sulphate (DSS) (Cat 
no: -160110, lot no: -M2356, MW: -36000-50000) was obtained from MP 
Biomedicals. Bovine serum albumin (BSA) (Cat no: -A2153, Lot no-049k1585), 
Glutaraldehyde solution (Cat no: -G5882) was ordered from Sigma. Ethanol (HPLC 
grade, Ulster University) and all other reagents were of analytical grade or higher 
purity.  Milli-Q-water was used throughout the study. 
 
2.2 Preparation of PLGA nanoparticles  
Curcumin loaded nanospheres was optimised as shown in the table 2.1. NP was 
formulated using solvent evaporation technique. Briefly, PLGA was dissolved in 2 
ml chloroform. Free curcumin was added to the PLGA/chloroform solution and 
sonicated at 55 W for 3 minutes in a Branson Sonifier model W-350 (Branson, 
Danbury, CT, USA) to produce the s/o primary emulsion. This emulsion was then 
added to a solution of 1.5% PVA and again sonicated at 55 W for 3 minutes to form 
the final s/o/w emulsion. The final s/o/w emulsion was kept for overnight stirring 
and then centrifuged at 1345×g for 30 minutes to assist the removal of residual 
solvents. The nanospheres thus obtained were washed three times with deionized 
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distilled water. They were then freeze dried and lyophilized for 48 hours on an ATR 
FD 3.0 system (ATR Inc., St. Louis, MO, USA).  Lyophilized nanoparticles were 
stored at 4˚C until further use (Mukerjee and Vishwanatha, 2009). 
Table 2.1: Formulation code for PLGA loaded nanoparticles 
Formulation 
Code 
Amount of 
drug (mg) 
Amount of 
Polymer (mg) 
Conc. of 
PVA    
(%w/v) 
F1 25 - - 
F2 50 - - 
F3 75 - - 
F4 - 30 - 
F5 - 60 - 
F6 
F7 
F8 
F9 
F10 
F11 
F12 
- 
- 
- 
- 
90 
- 
- 
- 
- 
1.5 
2.5 
3.5 
 
 
 
 
 
 
 
 
 
Figure 2.1: Schematic diagram of solvent evaporation method 
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2.3 Preparation of albumin nanoparticles  
Drug albumin nanoparticle was optimised as shown in the table 2.2. NP was 
fabricated by desolvation method as described by Chen et al., 2017 with slight 
modification (Li et al., 2015a). Briefly, the drug was dissolved in ethanol. The drug 
solution then added to BSA solution dropwise under constant magnetic stirring 
which leads to the formation of coacervates. Crosslinking agent, glutaraldehyde was 
added after co-acervate formation.  This co-acervates were stirred overnight to 
remove the organic solvent. Later, the resultant colloidal suspension was centrifuged 
to remove the organic solvent and washed with ultra-purified water. After 
centrifugation, the albumin nanoparticles were freeze dried and store at 4°C. 
Table 2.2: Formulation code for albumin loaded nanoparticles 
Formulation 
Code 
Amount of 
ethanol (ml) 
Conc. of 
albumin  
Conc. of 
Glutaraldehyde  
Amount of 
drug (mg) 
F1 4 - - - 
F2 8 - - - 
F3 12 - - - 
F4 - 0.5% - - 
F5 - 2% - - 
F6 
F7 
F8 
F9 
F10 
F11 
F12 
- 
- 
- 
- 
- 
- 
- 
3.5% 
- 
- 
- 
- 
- 
- 
- 
4% 
8% 
12% 
- 
- 
- 
- 
- 
- 
- 
10 
20 
30 
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Figure 2.2: Schematic diagram of conservation method 
 
2.4 Characterisation of particle size and zeta potential  
The particle size and distribution of nanoparticles was determined by using Zetasizer 
(Zetasizer 5000, Malvern Instruments, Malvern, UK) based on dynamic light 
scattering principle technique. A sample of nanoparticle suspension (5 mg/ml) was 
vortexed for 5 minutes. An aliquot from this suspension was diluted by ultrapure 
water and utilized to measure particles size in triplicate. A zetasizer was used to 
measure the zeta potential of nanoparticles. 0.001 M KCl solutions with an adjusted 
conductivity were used to prepare diluted nanoparticle suspension.   The principle of 
electrophoretic mobility under an electric field was used to measure the zeta 
potential values. The average of 3 measurements was reported  (Haggag et al., 2016).  
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2.5 NMR spectra of nanoparticles 
NMR spectra were run on a 500 MHz Bruker AVANCE DRX instrument using a 
broadband probe equipped with a z-gradient coil (Bruker-Biospin, Freemont, CA). 
All NMR samples were 600 íL and run in standard 5 mm NMR tubes at 25 °C. Pulse 
programs used were standard sequences taken from the Bruker XWINNMR pulse 
sequence library. NMR experiments were set up and processed generally using the 
parameters suggested in 200 and More NMR Experiments: A Practical Course. The 
pulse programs selected for the 2D COSY, HMQC, and HMBC experiments 
employed z gradients for coherence pathway selection. 1H and 13C chemical shifts 
were calibrated relative to the solvents and TMS (Payton et al., 2007). 
 
2.6 Determination of entrapment efficiency  
Entrapment efficiency of drugs in nanoparticles was calculated by the indirect 
method to determine drugs content in the supernatant.  The concentration of non-
encapsulated drug in the supernatant was measured by a UV spectrophotometer at 
430 nm, as described earlier (Bisht et al., 2007). A standard plot of drug was 
prepared under identical conditions. The amount of entrapped drugs inside the NP 
was calculated by the difference between the initial amount of drug added and the 
measured non-encapsulated drug remaining in the external aqueous phase after NP 
fabrication.  All measurements were assayed in triplicate and the average of each 
sample was recorded as the percentage curcumin encapsulation efficiency. 
Entrapment efficiency (EE) =
Experimental drug loading
Practical drug loading
× 100…….(1) 
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2.7 Determination of percentage yield  
Percentage yield is calculated as mentioned by Feng  Li. et al., where the weight of 
the nanoparticles was divided by the total weight of drug and polymer used in the 
formulation as described below in the equation (Li et al., 2008b).   
Percentage yield =
Total weight of the nanoparticles
Weight of drug+Weight of polymer
× 100…….(2) 
 
2.8 In-vitro release  
The in-vitro release of drug from NP was carried out in phosphate buffer saline (pH 
7.4, containing 0.1% w/v Tween-80). Briefly, 5 mg of NP was placed in a dialysis 
membrane  (17kD) and suspended in 1ml PBS solution  The sample pouches were 
incubated at a temperature of 37 °C and speed of 100 rpm in a reciprocal shaker 
water bath (Yallapu et al., 2010). The release samples from dialysis membrane were 
taken at predetermined time intervals of 0 minutes, 15 minutes, 30 minutes, 1 hour, 2 
hours, 3 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72hour, 96hour, 120 hours, 
144 hours and 168 hours.  The collected samples were centrifuged for 5 minutes at 
10,000 rpm.  Each experiment was performed in triplicate. 
 
2.9 Determination of water solubility  
Water solubility of nanoparticles was determined by dissolving NP and equivalent 
amount of free drug in distilled water. The mixtures were kept for stirring overnight 
and centrifuged at 13450RPM for 10 minutes. The absorbance of the supernatant 
was measured by UV-spectroscopy (Kim et al., 2011). 
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2.10 Scanning electron microscopy of nanoparticles  
Nanoparticle’s surface morphology was characterized by the aid of scanning electron 
microscopy (SEM) on a FEI Quanta 400 FEG (FEI Company).  A sample of NP was 
mounted on carbon tape and sputter-coated with gold under vacuum in an argon 
atmosphere prior to imaging under SEM. 
 
2.11 Cell culture 
MDA-MB-231 cells (metastatic breast cancer cell line) and A549 cells (metastatic 
lung cancer cell line), CaCo-2 and HT-29 (metastatic colon cancer cell line) were 
generously provided by Keith Thomas, Ulster University  These cells were 
maintained as monolayer cultures in Dulbecco’s Modified Eagle’s Medium–High 
Glucose (DMEM-Hi) medium (Gibco BRL, Grand Island, NY) and McCoy’s media 
supplemented with 10% fetal bovine serum (Gibco BRL, Grand Island, NY) and 1% 
penicillin–streptomycin (Gibco BRL, Grand Island, NY) at 37 °C in a humidified 
atmosphere (5% CO2). 
 
2.12 Cellular uptake of nanoparticles  
Cellular uptake of NP was investigated by seeding 1×105 of A549, MDA-MB-231, 
HT-29 and CaCo-2 cells on chamber slide in 6 well plates. After incubation for 24 
hours, cells were washed 3 times with PBS. Cells were treated with 200µg/ml of NP 
then incubated for 3 hours. After 3 hours incubation, the cell was washed with PBS 
to remove the excess NP from well and fixed with 4% paraformaldehyde for 15 
minutes. The nucleus of cells was stained with 5 µg DAPI in 1 ml normal media and 
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incubated for 15 minutes (Lamichhane et al., 2015). The fluorescence images of 
different groups were obtained from phase contrast microscopy. 
 
2.13 In-vitro cytotoxicity assay 
Cytotoxicity assays were performed as previously reported by (Kumar et al., 2014) 
with minor modifications. MDA-MB-231, A549, HT-29 and CaCo-2 cells (5x104 
cells/well in 500 µl media) were seeded in 24-well plates. The following day, cells 
were treated with the free drug and an equivalent amount of nanoparticles in 
Optimem® media. The cytotoxic effect of free drug and nanoparticles was 
determined every 24 hours using MTT assay to assess the viability of cancer cells. 
The treated cells were washed with 500 µL PBS, and 500 µL of 15% MTT dye 
solution in complete media was added to each well. The plates were incubated at 
37°C and 5% CO2 for an additional 3 hours. The supernatant was discarded and 
formazan crystals were solubilized by adding 500 µL of DMSO and the solution was 
vigorously mixed to dissolve the precipitate. The colour intensity was measured at 
570 nm (reference wavelength 630 nm) in a microplate reader (Fluostar Omega, 
BMG Lab Tech GMBH, Germany). The anti-proliferative effect of the free drug and 
nanoparticles treatment was calculated as a percentage of cell growth with respect to 
the DMSO and blank NP controls. The absorbance of the untreated cells was set at 
100%. All the experiments were repeated three times. 
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2.14 Migration assay  
Migration assay was performed through wound scratch assay as previously described 
by (Liang et al., 2007). MDA-MB-231, A549, HT-29 and CaCo-2 cells were seeded 
(7.5x105/well) into each well of 6-well plates. The cells were pipetted drop by drop 
around the edge of each well and shaken gently to evenly distribute the cells in each 
well. The plates were placed in an incubator to allow cells to grow to confluence.  A 
wound was introduced to confluent cells by using the yellow pipette tip by carefully 
scraping the tip down the center of each well. Old media was removed and 2 ml of 
fresh media with PLGA, albumin NP and an equivalent amount of free drug were 
transfected into respective wells. Medium containing equivalent amounts of blank 
PLGA and albumin NP was used as the control. A photograph for each wound at 0 
hrs was then taken and recorded. A photograph was taken at the same time of day at 
24 hours, 48 hours and 72 hours. To quantify the results from the photographs, 
image J software was used to measure the width of the wound. The width of the 
wound was measured at 3 different points in the photograph and the average was 
recorded. The degree of wound closure over 72 hours was calculated in all the 
treatment and compared with control and blank NP. All the experiments were 
repeated three times. 
 
2.15 Colony formation assay 
For colony formation assay, 500 cells of MDA-MB-231, A549, HT-29 and CaCo-2 
cells were seeded in 2 ml media in 6-well plates and allowed 2 days to attach and 
initiate colony formation (Yallapu et al., 2010). These cells were treated with PLGA 
NP, albumin NP and the same amount of free drugs suspended in Optimem® media 
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over a period of 7 days. The plates were washed twice with PBS, fixed in chilled 
methanol, stained with Crystal Violet, washed with water and air dried. The number 
of colonies was counted by using a magnifying lens. The percent of colony 
formation was calculated by dividing the number of colonies formed in treatment by 
the number of colonies formed in blank NP. 
 
2.16 Invasion assay 
An invasion assay was performed as previously reported (Yuen et al., 2013). This 
was conducted to investigate the effect of nanoparticles and free drug treatment on 
the ability of MDA-MB231, A549, HT-29 and CaCo-2 cells to invade a Matrigel-
coated membrane. A number of 8 µm membrane transwell inserts were inserted into 
the well of 12-well plate (BD Bioscience, San Jose, CA). The membrane transwell 
was coated with Matrigel before seeding the cancer cells.  Matrigel was placed on 
ice and left to thaw at 4°C then diluted 1:1 with water and 135 µl of the solution was 
placed carefully into the required number of inserts. The inserts were shaken gently 
to ensure the Matrigel solution spread evenly on the membrane. The whole plates 
were left in the laminar flow hood to dry for 60 minutes. 4x104 cells were seeded 
into each insert in a suspension of 200 µl of serum free media. Next 100 µl 
containing nanoparticles of drug and equivalent amount of free drug was treated into 
corresponding wells. The same volume of 100 µl containing equivalent amounts of 
blank NP was used as the control. Finally, 700 µl of DMEM media containing 10% 
FBS was added to each well to bath the outer membrane surface and act as 
chemoattractant. The next day, to new 12-well plates, 500 µl of methanol was added 
to the corresponding number of wells used. The media in both chambers were 
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removed and cotton wool scrubbers were used to clean off any remaining cells or 
Matrigel layer. The inserts were placed into methanol for 10 minutes for fixation. 
Once fixation has completed the inserts were left to dry. Using a scalpel the 
membrane was cut out and placed with the original outer surface facing upwards in 
wells of a new 12-well plate. 250 µl of Crystal Violet was then added to each well to 
stain up the cells that invaded through the membrane pores. The plates were left to 
be shaken for 20 minutes. Afterwards, the Crystal Violet solution was pipetted out 
and the membranes were washed thoroughly in their wells with Milli-Q water. The 
membranes were left to air dry for 60 minutes. 250 µl of 70% ethanol was added to 
each membrane in each well and shaken for 30 minutes. Finally, 200 µl was pipetted 
out from each well and placed into the wells of 96-well plate. Absorbance at 590 nm 
was measured using a microplate reader (Fluostar Omega, BMG Lab Tech GMBH, 
Germany). The effect of the free drug and an equivalent amount of nanoparticles 
treatments was calculated as a percentage of cell invasions with respect to blank NP 
controls. The absorbance of the untreated cells was set at 100%. All the experiments 
were repeated three times. 
 
2.17 Immunostaining for cells 
A sterile glass coverslip was placed in six-well plates. MDA-MB-231, A549, HT-29 
and CaCo-2 cell was seeded at 1.9×105 cell density in six-well plates. The plates 
were incubated for 24 hours. Next day, plates were washed with sterile PBS to 
remove the dead cells from each well. 7.5 µg/ml of free drug and nanoparticles were 
transfected for 24 hours. Blank nanoparticles were taken as control. Next day the 
wells were washed with sterile PBS for 5 minutes twice. The cells were fixed with 
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4% paraformaldehyde solution for 30 minutes. Later the cells were permeabilized 
with 0.25% Triton-X for 15 minutes and washed with PBS two times for 5 minutes. 
The blocking was carried out with 2% albumin in PBS for 30 minutes. After binding, 
the cells were incubated with primary antibody 50 µl/ml overnight at 4°C. Next day 
cells were washed with PBS two times for 5 minutes. Later it was incubated with 
anti-rabbit secondary antibody for 1 hour at room temperature. After incubation with 
secondary antibody, it was stained with DAPI for 15 minutes. The cover clip then 
transferred to a glass slide and nail polish was applied to the edges of the coverslip to 
prevent it from drying (Váradi et al., 2017). 
 
2.18 Quantification of p65 and HIF-1α  
MDA-MB-231, A549, CaCo-2 and HT-29 cells (pre-treated for 12 hours with 10% 
oxygen) were treated with free drugs, PLGA nanoparticles and albumin loaded 
nanoparticles for 6 hours. Whole cell lysates were prepared and assayed for HIF-1α 
and p65 levels using Invitrogen HIF1a Human ELISA Kit (EHIF1A) and NF-kβ p65 
(Total) Human ELISA Kit (KHO0371) and used according to the manufacturer’s 
instructions at 450 nm, using a BioTek optical plate reader. Optical density was 
converted to concentration (pg ml-1247) using the standard calibration curve 
provided in the manufacturer's protocol. 
 
2.19 Induction of dextran sodium sulphate model of colitis  
For DSS colitis-induced experiments, 12-week old C57BL/6 female mice were used 
(Charles River U.K.). All procedures described were approved by the Ulster 
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University Animal Research Ethics Committee and UK Home Office, under Project 
license (PL2768). Colitis was induced by administering 2.5% w/v DSS in drinking 
water over a period of 6 days.  The mice were divided into groups such as healthy, 
DSS, free drug and nanoparticles. These groups also received 2.5% DSS in drinking 
water. The DAI score was used to record morphological changes, such as weight 
loss, stool consistency and presence of blood in faeces as explained in the table 2.3. 
Table 2.3: Scoring of disease activity index 
Score Weight loss Stool consistency Faecal blood 
0            None     Normal None 
1      1-5%                            
2 5-10%                      Loose Hemoccult+ 
3 10-20%   
4 >20% Diarrhoea Gross bleeding 
 
On termination of the experiment, mice were sacrificed by cervical dislocation 
(Okayasu et al., 1990., Egger et al., 2000).The isolated colon was excised, washed in 
PBS and laid flat on the moist tissue to measure its length. Sections, approximately 
1.0 cm, of excised colonic tissue were fixed in 10% paraformaldehyde (pH, 7.4; 
phosphate-buffered saline) and embedded in paraffin. Sections (4 μm) were cut and 
stained with haematoxylin and eosin. Histologic assessment and scoring of colon 
tissue sections against inflammation were carried out in a blinded fashion based on 
defined parameters such as severity of inflammation, the extent of inflammation, 
crypt damage and percentage involvement as highlighted in the table 2.4 (Sutherland 
et al., 1987). All tissue slides were imaged using light microscopy. 
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Table 2.4: Scoring of the severity of histological damage.  
feature  Score  Description 
Severity of inflammation 0 None  
 1 Mild 
 2 Moderate 
 3 severe 
Extent of inflammation 0 None 
 1 Mucosa 
 2 Mucosa and submucosa 
 3 Transdermal 
Crypt damage 1 1/3 damaged 
 2 2/3 damaged 
 3 Crypt lost, surface epithelium 
present 
 4 Crypt lost, surface epithelium 
lost 
Percentage involvement 0 0% 
 1 1-25% 
 2 26-50% 
 3 51-75% 
 4 76-100% 
 
 
2.20 Quantification of cytokines and myeloperoxidases in colonic 
tissues  
Post-mortem colon tissue was homogenized using a method adapted from processing 
lung tissue (Mangan et al., 2006). Levels of pro-inflammatory cytokines, such as 
Interferon gamma (INF-γ), IL-6, IL-1β, TNF-α and IL-10 were detected using V-
Plex Assay Plates (Meso Scale Diagnostics; Rockville, MD) and assayed as per the 
manufacturer’s protocol. Myeloperoxidases (MPO) activity was detected using o-
phenylenediamine dihydrochloride as substrate and the data was interpolated from an 
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MPO standard curve (Sigma). Levels of cytokines and MPO were expressed as pg 
per mg or U per mg, respectively, relative to colon protein (Cummins et al., 2008). 
 
2.21 In-vivo intestinal permeability measurements  
Mice were exposed to 7 days of DSS treatment before oral administration of 0.6 mg 
per gram of body weight fluorescein isothiocyanate (FITC)–labelled dextran (4 kDa) 
by standard oral gavage. Mice were euthanized 4 hours later and blood removed by 
cardiac puncture.  Plasma was separated and FITC levels in plasma determined by 
fluorimeter (Tambuwala et al., 2010). 
 
2.22 Immunohistochemistry 
Colon tissues was stored in formalin and embedded into paraffin. 5 μm of paraffin 
molded colonic tissues was sectioned under microtome. The sectioned then placed 
on a superfrost glass slide. The paraffin colonic segments were immersed (10 
minutes twice) in xylene jar to remove the paraffin and rehydrated in decreasing 
concentration of ethanol such as 100%, 95% and 75% each for 5 minutes. It was then 
submerged in a glass jar filled with boiled sodium citrate buffer (95°C, pH6)  for 20 
minutes to break the bond formed during tissue processing due to paraffin in hot 
water bath at 100°C. After heating for 20 minutes, it was taken out and kept to cool 
down at room temperature for 20 minutes. The slide was then washed in PBS twice 
for 5 minutes and blocking was carried out in 5% BSA solution for one hour at room 
temperature. The slide was washed again for 5 minutes twice. After washing, the 
section was incubated with secondary antibody for one hour at room temperature. 
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The tissue section was then stained with DAPI for 15 minutes and antifade was 
applied to laid the coverslip. The sectioned was observed under a microscope 
(Nuñez-Sánchez et al., 2017). 
 
2.23 Statistical analysis 
Results were expressed as mean ± standard error of the mean (SEM) for a series of 
experiments. Data were assumed to be normally distributed and statistical analyses 
were carried out using Prizm GraphPad V6 software (GraphPad, San Diego, CA, 
USA). A paired t test was used for comparisons of paired treatments between two 
groups, unpaired t tests for comparisons of unpaired treatments between two groups, 
and one-way ANOVA using Bonferroni multiple comparisons tests for treatments of 
three groups or more. P values ≤0.05 were considered to be significant. 
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Chapter 3 
Caffeic acid phenethyl ester is protective in experimental ulcerative 
colitis via reduction in levels of pro-inflammatory mediators and 
enhancement of epithelial barrier function 
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3.1 Introduction 
Inflammatory bowel disease (IBD) is an idiopathic disorder, generally categorized as 
either Crohn`s disease (CD) or ulcerative colitis (UC) (Ford et al., 2011., Neurath, 
2014a). There is no therapeutic cure for IBD and the current disease management 
strategies possess challenging drawbacks.  For example, immunomodulatory agents, 
such as azathioprine and 6-mercaptopurine, causes bone marrow depletion and 
damage to both white blood cell and hepatic cell populations.  Furthermore, results 
from recent clinical trials confirm that azathioprine is ineffective in UC (Ardizzone 
et al., 2006., O'Connor et al., 2010., Kamath et al., 2016).  Sulfasalazine causes 
ruptures in liver tissue and decreases platelets count in blood (Rubin, 1994., de 
Abajo et al., 2004). Pulmonary disorders are reported in IBD patients treated with 
chimeric monoclonal antibodies, such as infliximab (Patel et al., 2016). The clinical 
symptoms of IBD range from episodes of relapse and remission, mild inflammation 
and discomfort to a chronic ulcerative disease requiring surgical removal of the 
inflamed gut. The current therapeutic strategies for IBD are limited, but recent 
clinical advancement has occurred in the area of immunotherapy with monoclonal 
antibodies, which are directed against inflammatory mediators, such as TNF-α 
(Targan, 2006., .,Subramanian et al., 2017., Gecse and Lakatos, 2017., Chan and Ng, 
2017). However, these biologicals are not only expensive but have resulted in severe 
side effects and life threatening complication (Cote-Daigneault et al., 2015., Blonski 
and Lichtenstein, 2006., Cohen and Thomas, 2006., Clarke and Regueiro, 2012., 
Côté-Daigneault et al., 2015) Hence, there is an urgent need in the field of IBD 
therapy to develop new therapeutics which are effective, safe and economical.  We 
strongly believe that one way to achieving this goal is by exploring natural anti-
inflammatory compounds and understanding their mechanism of action during IBD. 
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Lack of specificity and the encumbrance of severe side effects necessitates a further 
investigation into effective and safer options for treatment of this chronic 
inflammatory disease (Pichai and Ferguson). This is the issue address in the current 
study. 
Colonic specimens from UC patients have been shown to overexpress transcription 
factor nuclear factor kappa beta (NF-kβ) (Atreya et al., 2008). NF-kβ is upregulated 
by TNF-α, interleukin (IL), interferon, and chemokines, DNA damaging agents 
bacterial cell wall components, lipopolysaccharide, during inflammatory condition  
(Xavier and Podolsky, 2007b., Lawrence, 2009). In UC, the inflammatory mediators 
such as TNF-α, interleukins, and interferons levels increase due to the over 
stimulation of NF-kβ during inflammation (Schreiber et al., 1998). It is feasible, that 
inhibition of NF-kβ may be of therapeutic benefit in UC, which forms the hypothesis 
of our current work. 
Although there are several novel pharmacological inhibitors of NF-kβ currently 
available these compounds suffer from toxic/side effects in humans. Hence, in this 
work, caffeic acid phenethyl ester (CAPE) is used as a phenolic constituent derived 
from honeybee propolis with no known toxic/side effects (Figure 1) (Liao et al., 
2003., Tolba et al., 2016a). CAPE possesses anti-inflammatory properties and is a 
selective inhibitor of NF-kβ (Ozturk et al., 2012., Lin et al., 2013). CAPE represses 
translocation of NF-kβ, either by inhibition of Ikβ degradation or by blocking of NF-
kβ and DNA binding (Wang et al., 2010b., Bezerra et al., 2012). It has been reported 
that inflammatory markers, such as INF-γ, IL-6, IL-1β, TNF-α and IL-10 cause 
degradation of Ikβ, which results in induced overexpression of NF-kβ (Lang et al., 
2004). CAPE has the potential to inhibit this overexpression of NF-kβ via prevention 
of degradation of Ikβ (Liao et al., 2003., Lee et al., 2008., Wang et al., 2010a). 
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3.2 Summary 
Therefore, as per the detrimental effect of IBD and allied adverse effects of 
conventional therapeutics, there is pressing need to practice novel and natural anti-
inflammatory agent in the treatment and control of IBD. As per the control action of 
CAPE on factor responsible for the progression of  UC such as over induction of NF-
kβ, HIF-1α and pro-inflammatory markers, it will provide a better understanding of 
the mechanism of action of CAPE in a mouse model of ulcerative colitis. 
 
3.3 Hypothesis 
In this chapter, we  hypothesize that the natural anti-inflammatory compound CAPE 
will mitigate inflammatory condition during UC. 
 
3.4 Aims and objective 
• To study the effects of free CAPE on macroscopic level such weight loss, and 
DAI and change in colon length in UC. 
• To study effects of free CAPE on mucosal layer in UC 
• Effect of induced level of NF-kβ, HIF-1α and pro-inflammatory markers in 
UC. 
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3.5 Results 
3.5.1 CAPE ameliorates weight loss and DAI in DSS-induced colitis 
Colitis was induced as described in section 2.19. It has been reported by us and 
several researchers mentioned that colitis is the collection of symptoms such as 
weight loss, diarrhoea, blood in faeces collectively known as disease activity index 
(DAI) and shortening of colon length (Ogawa et al., 2004., Chen et al., 2007., 
Chassaing et al., 2014b., Taghipour et al., 2016). To study the protective effect of 
CAPE on mice with DSS-induced colitis, we recorded the weight of each mouse in 
all groups daily for seven days. The graph in the Figure 3.1A shows lowered weight 
loss in DSS + CAPE treated mice when compared to the DSS-only group. Similarly, 
Figure 3.1B shows that mice in the DSS-alone group had the highest DAI score, 
which confirmed the development of colitis.  Mice treated with CAPE showed a 
lower DAI score when the comparison is made to the DSS-only group. This finding 
suggests that CAPE was protecting the mice against weight loss and the occurrence 
of diarrhoea and appearance of blood in faeces during DSS-induced colitis. 
 
3.5.2 Change in colon length  
Shortening of the colon is one of the clinical sign of colitis (Tambuwala et al., 2015). 
Figure 3.2A shows a representative image from the colon of a healthy mouse which 
shows well-formed stool pellets. In contrast, there were no formed stools and blood 
observed in the colon of mice treated with DSS alone.  However, semi-formed stools 
and no blood were visible in the colon of mouse treated with CAPE.  A graphical 
presentation of the average colon length of each group is shown in Figure 3.2B.  It is 
observed that there was a significant reduction in colon length in mice treated with 
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DSS alone when compared to the healthy control and DSS+CAPE treated mice. 
Thus, CAPE treatment profoundly attenuated the impact of DSS on colon length 
reduction and also helps in the formation of stool. 
 
3.5.3 Histological observation of mucosal layer 
Colon H and E staining were performed as stated in the section 2.19. Histological 
examination of colon tissue confirmed that DSS treatment caused extensive colonic 
damage with lose of epithelium and collapse of crypt structure.  This was 
accompanied by oedema and infiltration of inflammatory neutrophils as shown in the 
Figure 3.3A.  In contrast, there was a marked reduction in severity of DSS-induced 
colon injury in CAPE-treated mice. The crypt architecture showed no ulceration or 
evidence of oedema lesser degree of infiltration of inflammatory cells and 
neutrophils were observed in the colon histology of mice receiving CAPE treatment 
as depicted in the Figure 3.3A.  The blinded histological scoring of colon tissue 
histology revealed a significant reduction of damage in the colon of CAPE-treated 
mice relative to healthy control mice (P<0.001) as shown in the  Figure 3.3B. 
 
3.5.4 Quantification of inflammatory markers 
Quantitative analysis was carried out as discribed in section 2.20. investigation of  
CAPE on the expression of markers of colonic inflammation that are increased in 
mice exposed to DSS was performed. DSS alone control mice showed a significant 
increase in MPO activity, a marker for inflammation and leukocyte infiltration; 
Figure 3.4A. However, exposure of CAPE-treated mice to DSS did not result in 
54 
 
increased colon MPO levels as shon in the Figure 3.4A. It was also noted that 
colonic levels of pro-inflammatory cytokines, such as INF-γ, IL6, IL-1β, TNF-α and 
IL-10 as shown in the Figure 3.4(B, C, D, E and F) were significantly increased in 
mice with DSS-induced colitis (P< 0.001).  Co-administration of CAPE resulted in 
small increases in INF-γ, IL6, IL-1β, TNF-α and IL-10, which were not significantly 
different from that of the healthy control. Thus, the DSS-induced increase in MPO, 
INF-γ, IL-6, IL-1β, TNF-α and IL-10 all were diminished significantly in CAPE-
treated mice (P<0.001). Furthermore, treatment of mice with CAPE alone had no 
effects on MPO, INF-γ, IL-6, IL-1β, TNF-α and IL-10 levels in the colon of healthy 
mice (data not shown). 
 
3.5.5 Enhanced epithelial barrier function in mice treated with CAPE 
Intestinal permeability was measured as stated in section 2.21. To investigate the 
effect of CAPE treatment on the intestinal epithelial integrity, the in-vivo barrier 
function was measured in healthy mice, mice exposed to DSS and mice co-treated 
with CAPE and DSS.  An oral dose of FITC-dextran was administered to mice on 
the last day of DSS exposure.  Four hours later, FITC levels in plasma were 
determined as a measure of intestinal permeability. The DSS-only group of mice 
exhibited a significant increase in intestinal permeability, which was reflected by an 
increased appearance of FITC in plasma.  This effect was markedly diminished in 
mice treated with CAPE as depicted in the Figure 3.5, indicating that co-treatment 
with CAPE during DSS-induced colitis reduces the leakiness of the colon and 
maintains the epithelial barrier function. 
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3.5.1 CAPE ameliorates weight loss and DAI in DSS-induced colitis  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Lowered percentage weight loss (A) and DAI (B) score in mice treated with 
CAPE during DSS-induced colitis.(A) Percentage weight loss was assessed in mice treated 
with DSS-alone, DSS and CAPE  and no DSS healthy mice . (B) Disease activity index was 
assessed in mice treated with DSS-alone , DSS and CAPE  and no DSS healthy mice  over 7 
days. N=5-6 individual mice. **P<0.01 and ***P<0.001 
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3.5.2 Change in colon length after treatment with free CAPE 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: CAPE treatment is effective in protecting gross anatomy and colon length. (A) 
Gross appearance of the colonic anatomy shows the effect of CAPE on DSS-induced colon 
shortening and formation of fecal pellets. (B) Colon length was measured at post-mortem 
autopsy. N = 5-6 mice per group. ***P<0.001.  
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3.5.3 Histological observation of mucosal layer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Improved colon histological outcome in mice treated with CAPE. (A) 
Representative histological images of colonic tissue showing the effect of CAPE treatment 
(H&E staning). (B) Histological scores of sections scored blinded. N = 5-6 mice per group. 
***P<0.001. 
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3.5.4 Quantification of inflammatory markers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Effect of CAPE on the expression of pro-inflammatory mediators.  The colon 
tissue homogenates analyzed for (A) MPO, (B) INF-γ, (C) IL-6, (D) IL-1β, (E) TNF-α and 
(F) IL-10. N = 5-6 mice per group. ***P<0.001. 
A B 
C D 
F 
0
50
100
150
200
250
300 *** ***
2.5% DSS
Healthy CAPE (30mg/kg + 2.5%DSS)
M
P
O
 c
o
n
c
. 
( 
g
/m
g
)
0
10
20
30
500
600
700
800
900
1000 *** ***
Healthy
2.5% DSS
CAPE(30mg/kg + 2.5%DSS)
I
L
-
6
 (
p
g
/m
l
)
0
10
20
30
40 *** ***
2.5%DSS
Healthy CAPE (30 mg/kg + 2.5%DSS)
T
N
F

 (
p
g
/m
l)
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
*** ***
Healthy
2.5% DSS
2CAPE(30mg/kg + 2.5%DSS)
IF
N
- 
 (
p
g
/m
l)
0
50
100
150 *** ***
Healthy
2.5% DSS
CAPE(30mg/kg + 2.5%DSS)
IL
-1

 (
p
g
/m
g
)
0
2
4
6
*** ***
Healthy
2.5% DSS
CAPE(30mg/kg 2.5%DSS)
IL
1
0
 (
p
g
/m
l)
E 
59 
 
3.5.5 Enhanced epithelial barrier function in mice treated with CAPE 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: Reduced epithelial permeability in mice treated with CAPE. Mice treated with 
DSS with or without CAPE (30mg/kg) IP and healthy mice were administered 4 kDa-FITC-
labeled dextran orally and serum levels of FITC were assessed. N=5-6 mice. ***P<0.001. 
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3.6 Discussion 
Previous studies have indicated that CAPE is an effective inhibitor of NF-kβ and 
related cytokines in-vitro, and also has the ability induce apoptosis in inflammatory 
cells (Fitzpatrick et al., 2001). In our current study, we have shown for the first time 
that CAPE significantly ameliorates the severity of the disease in a mouse model of 
UC. 
One of the initial events which occur during the onset of IBD is disruption of the 
intestinal epithelial barrier function. This epithelial dysfunction leads to 
compromised epithelial barrier resulting in unwanted movement of luminal antigenic 
material into the lamina propria leading to the activation of mucosal immune cells to 
trigger off an inflammatory response. It has been suggested that one of the critical 
events in the development of inflammation in the intestine could be the regulation of 
intestinal epithelial cell apoptosis (Cummins et al., 2008., Tambuwala et al., 2010). 
In case of chronic inflammation during IBD constant intestinal epithelial cell 
apoptosis could lead the loss of the epithelial barrier which will result in spread of 
inflammation resulting in increased severity of the disease creating an imbalance in 
the innate and adaptive immunity of our gut (Nenci et al., 2007., Zaph et al., 2007). 
Several researchers have indicated that NF-kβ pathway plays an important role 
during intestinal inflammation ((Fitzpatrick et al., 2001, Lawrence, 2009.,  Wei and 
Feng, 2010., Buhrmann et al., 2011) and inhibition of this pathway targets pro-
inflammatory cytokines such as interferons and TNF-α which are known to play key 
role during ulcerative colitis  (Bishop et al., 2014., Baird et al., 2016., Ferrari et al., 
2016a). 
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In the present work, we have shown for the first time that CAPE a potent inhibitor 
NF-kβ is profoundly protective in an in-vivo mouse model of acute colonic 
inflammation. Although it was hypothesized that the protective effects of CAPE are 
mediated through the inhibition of the over activation of the NF-kβ pathway, we 
cannot exclude the possibility of NF-kβ independent mechanism of action such as 
inhibition of hydroxylases and activation of hypoxia inducible pathway (Cummins et 
al., 2008). CAPE treatment significantly ameliorated the severity of disease after 
acute DSS exposure in all parameters studied, including weight loss (Figure 3.1A), 
clinical DAI score (Figure 3.1B), reduction of colon length, appearance of blood in 
faeces (Figure 3.2A & B), and a marked improvement in colon histology was 
observed (Figure 3.3A) along with improved blinded inflammation scores (Figure 
3.3B). In the murine model of DSS induced colitis, the increase in MPO and pro-
inflammatory cytokines occurred after the disruption of the intestinal barrier; that 
CAPE treated mice did not have increased MPO (Figure 4A) and only small increase 
in other pro-inflammatory cytokines as shown in thr Figure 3.4(B, C, D, E, & F) 
suggests that CAPE treatment prevented the damage to colon epithelial cells caused 
by DSS, which is evident by reduced permeability of FITC in mice treated with 
CAPE as demonstrated in the Figure 3.5. 
However, whether improved epithelial barrier function or indeed cytokine expression 
is the cause or consequence of the protective effects of CAPE remains to be 
elucidated. This critical question will be the topic of further investigations. 
In mice treated with CAPE, in the absence of DSS exposure, there were no 
alterations in MPO or cytokines in the colon and no alterations in colon histology or 
length. This confirms that in the acute 6-day treatment regimen used in this study 
CAPE did not alter physiologic inflammation in normal tissue, but instead 
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suppressed inflammation in the colon when occurred due to DSS induced disruption 
of the barrier function. 
In this study, it showed that CAPE is therapeutic in a mouse model of ulcerative 
colitis. Since CAPE is a natural compound, with no known toxic/side effects 
(Tambuwala, 2016) it would be highly desirable therapeutic over other novel 
compounds with pro-tumorigenic effects; such as DMOG which have shown to be 
protective in experimental colitis (Cummins et al., 2008). The findings of this work 
indicate that CAPE can be used an effective add on treatment for a patient with UC 
to improve their intestinal barrier function and halt the progression of the disease 
while promoting mucosal healing. The next stage of our study will focus on the 
development of nanoparticle based colonic drug delivery of CAPE which could 
allow for local delivery of the drug to the inflamed tissue to ensure effective 
therapeutic outcome using a lower dose. 
 
3.7 Conclusion 
The data obtained after studying the anti-inflammatory activity of free CAPE in 
colitis induce mice reveals that free CAPE able to control the loss in weight 
produced by DSS. The mucosal layer of mice treated with CAPE was protected 
against inflammation. CAPE successfully lowers the primary factor responsible for 
ulcerative colitis such as overstimulated level of NF-kβ, HIF-1α and inflammatory 
cytokine. Therefore, furhter comparative investigation of anti-inflammatory 
therapeutic of free CAPE and CAPE nanoparticles in colitis induce mice will be the 
future study because this natural compound has limited solubility in aqueous media.  
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Chapter 4 
Formulation and in-vitro evaluation of the anticancer properties of 
PIC-loaded albumin NP in colorectal cancer cell lines 
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4.1 Introduction 
Cancer of colon ranks third among all type of cancer diagnosed in humans (Tosi et 
al., 2017., dos Reis et al., 2017). The exact cause of the malignancy has not yet been 
documented. However, it is believed that genetic mutation, environment, living 
habits and previous existence of UC are the pivotal factor of colorectal cancer (Aune 
et al., 2011., Favoriti et al., 2016., Broderick et al., 2017., Turner and Lloyd, 2017). 
Stomach ache, rectal bleeding, bowel obstruction, nausea, loss of appetite, weight 
loss, rectal pain, and lethargy are the early sign of colorectal  cancer (Leiva et al., 
2017).  Colonoscopy screening is the widely used approached to detect colorectal 
cancer (Porté et al., 2017). However, this method is painful and difficult to perform 
in patients. Therefore, other techniques such as faecal occult blood tests, faecal 
immunochemical test (FIT) and stool DNA (sDNA) testing are some other effective 
method to diagnose colorectal cancer.  These methods are inexpensive, non-invasive 
and easily operable (Martin et al., 2017).  Chemotherapy (5-fluorouracil, paclitaxel, 
methotrexate, doxorubicin, and cyclophosphamide), immunotherapy (monoclonal 
antibodies, cytokine therapy,) radiation therapy and nutrition supplement based 
therapy (vitamins, minerals, proteins) are the mostly prescribed therapeutics in 
colorectal cancer (Hébuterne et al., 2014., Sathyanarayanan and Neelapu, 2015., 
Gustavsson et al., 2015., Wallis et al., 2016., Porté et al., 2017). These 
chemotherapies cause fatigue, vomiting, hair fall, infertility, anorexia, stomach 
cramp, bowel obstruction, bone marrow depletion and peripheral neuropathy 
(Saxena et al., 2016.,  (Hofheinz et al., 2017a). Monoclonal antibody prescribed in 
colorectal cancer damage mucosal layer. It also causes electrolyte disturbance, 
diarrhoea, skin rash, nail disorder and pruritus (Costa et al., 2017). Moreover, 
exposure to high dose of radiation (0.125 cGy/min) causes impairment to DNA in 
65 
 
healthy tissue (Rödel et al., 2015). These anticancer agents effect lifestyle and cause 
a burden on the financial condition of patients. The chronic mucosal inflammation is 
the common factor involved in both ulcerative colitis and colorectal cancer (Ma et 
al., 2017b., Guo et al., 2017). Overexpressed pro-inflammatory cytokines responsible 
for over induction of transcription factor nuclear factor kappa beta (NF-kβ) and 
hypoxia inducible factor-1α (HIF-1α) (Colotta et al., 2009b., Eissa et al., 2017).  Due 
to overactivation of NF-kβ and HIF-1α, the event of proliferation, migration and 
invasion increases at the tumour site (Chaudary and Hill, 2007., Gupta et al., 2010a., 
Ben-Neriah and Karin, 2011). Additionally, pro-inflammatory cytokines have been 
documented to overexpress in ulcerative colitis and colorectal cancer patients which 
triggered aberrant activation of NF-kβ and HIF-1α  (Herfarth et al., 2000., Malicki et 
al., 2009., Hegazy and El-Bedewy, 2010., Nathke and Rocha, 2011).  The 
accumulation of NF-kβ and HIF-1α was reported in colorectal cancer cell line such 
as HT-29 and CaCo-2 (Tammali et al., 2011., Mastropietro et al., 2015., Ge et al., 
2016., Owczarek et al., 2017). Therefore, inhibition of overstimulated NF-kβ and 
HIF-1α by natural compound may provide therapeutic cure in colorectal cancer and 
ulcerative colitis. Piceatannol is the natural compound which has anticancer and anti-
inflammatory properties documented by several researchers (Seyed et al., 2016., Lu 
et al., 2017). Piceatannol exists in grapes, passion fruit, red wines and white tea (Lu 
et al., 2017). It arrests the unwanted growth of tumour cell in blood cancer, prostate 
cancer, breast cancer and rectal cancer (Piotrowska et al., 2012). Inhibition potential 
of PIC against NF-kβ and HIF-1α  has been seen in different cancer cell lines   
(Piotrowska et al., 2012., Zhang et al., 2014., Song et al., 2015., Seyed et al., 2016). 
However, PIC is low soluble in water and less absorbable in the intestine which 
alters its therapeutic potential (Kwon et al., 2012., Inagaki et al., 2016). Therefore, 
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fabrication of  PIC-loaded albumin nanoparticle was carried out to overcome the 
limited solubility and absorption to facilitate the efficacy of PIC. Desolvation 
method has been employed to formulate albumin nanoparticles of PIC. This method 
has been widely used to fabricate nanoparticles of natural polyphenolic compound 
(Elzoghby et al., 2012b., Tarhini et al., 2017). Albumin has been incorporated in the 
formulation of PIC nanoparticles due its low toxic, low immunogenisity and 
biodegradable nature (Fallacara et al., 2017., Liu et al., 2017., Louage et al., 2017). It 
increases the gastric residence time and enhance the  accumulation of hydrophobic 
drug at the tumour site (Dennis et al., 2002).  Albumin is attracted to inflammatory 
markers and supply amino acid at tumour site which provide a target delivery to 
anticancer compound (Larsen et al., 2016., Jiang et al., 2017). 
Therefore, based on the accumulating evidence PIC nanoparticles was fabricated 
using albumin to improve solubility, bioavailability, efficacy and targeting potential 
of PIC nanoparticles by desolvation method. 
 
4.2 Summary  
Based on the severity of colorectal cancer and associated side effects with commonly 
prescribed therapeutics, there is a significant urgency to utilize natural compound for 
the treatment and management of colorectal cancer. The natural compound PIC 
needs to reduce particle size to attain higher therapeutic value by increasing the 
solubility. Therefore, nanotechnology can be employed with aid of natural polymer 
to provide targeted delivery of natural nanoparticles.  
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4.3 Hypothesis 
In the current chapter, we hypothesize that the reductions of particle size of natural 
compound PIC will improve the anticancer property to a higher extent than the free 
PIC. 
 
4.4 Aims and objectives 
• Formulation of PIC-loaded albumin nanoparticles 
• Optimisation of PIC-loaded albumin nanoparticles 
• Evaluation of anticancer properties of PIC-loaded albumin nanoparticles in 
CaCo-2 and HT-29 cell lines 
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4.5 Results  
4.5.1Calibration of PIC 
Calibration curve of PIC was plotted as shown in the Figure 4.1 in methanol (1:9) 
and absorbance was measured at 325 nm. 
 
4.5.2 Effect of ethanol amount 
PIC-loaded albumin NP was fabricated by the method described in section 2.3. The 
effects of physiochemical factor such as the amount of ethanol were evaluated. PIC-
loaded albumin NP was fabricated with 4 ml, 8 ml and 12 ml of ethanol. However, 
increase in ethanol amount has no effect on particle size (Figure 4.2A) as well as the 
polydispersity index (Figure 4.2B). A similar pattern of observation was also 
documented by Langer et al (Langer et al., 2003b). The particle size was found to be 
in the range 227 nm to 238 nm and the polydispersity index was in the range of 
0.154 to 0.172. Though, zeta potential (Figure 4.2C) shows a slight decrease in value 
from -13 mV to -18 mV.  (Ardani et al.).  
 
4.5.3 Effect of albumin concentration 
Albumin attracts to neutrophils, provides amino acid to tumour cells, easily digest by 
serum and does not yield any detrimental effect  (Abbasi et al., 2012., Elzoghby et 
al., 2012a., Zhao et al., 2017).  PIC-loaded albumin NP was formulated with a 
different concentration of albumin to observe its effect on parameters such as particle 
size, polydispersity and zeta potential. A significant increase in particle size (Figure 
4.3A) was reported with an increase in albumin content in the formulation. Similarly, 
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June et al also documented an increase in particle size with increase in albumin 
concentration (Jun et al., 2011). The formulation batches show a significant increase 
in particle size from 211 nm to 252 (P<0.01) when albumin content increases from 
0.5% to 2%.  It further increases significantly to 294 (P<0.001) as the concentration 
of albumin increases to 3.5%. Similarly, polydispersity index (Figure 4.3B) increases 
significantly from 0.11 to .27 (P<0.001) with an increase in albumin ratio. 
Additionally, zeta potential (Figure 4.3C) also increases from -19 mV to -12 mV 
upon increasing the albumin content. 
 
4.5.4 Effect of Glutaraldehyde concentration 
Increasing amount of crosslinking agent (glutaraldehyde) was used from 4% to 12% 
to study its effect on particle size, polydispersity index and zeta potential. As 
depicted in Figure 4.4, increase in the concentration of glutaraldehyde increases 
particle size (Figure 4.4A). Rajith et al., 2014 also demonstrated the same pattern of 
increase in particle size as glutaraldehyde concentration increases (Rajith and 
Ravindran, 2014). Particle size increases significantly (P<0.05) from 225 nm to 257 
nm and from (P<0.001) 257nm to 391nm. Though, an increase in glutaraldehyde 
concentration had an inverse effect on polydispersity index (Figure 4.4B), also 
documented by (Langer et al., 2003b). Polydispersity index decreases significantly 
(P<0.001) from 0.20 to 0.14 but it slightly changes with a further increase in 
glutaraldehyde concentration. However, zeta potential (Figure 4.4C) shows 
significant (P<0.01) decrease from -13 mV to -18 mV as glutaraldehyde 
concentration increases. Li et al also stated the similar effect of glutaraldehyde 
increase on zeta potential (Li et al., 2008a). 
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4.5.5 Effect of drug content 
The effect of drug content was studied on particle size, polydispersity index and zeta 
potential. PIC-loaded albumin NP was formulated with 10 mg, 20 mg and 30 mg of 
PIC. A significant increase in particle size (Figure 4.5A) was detected upon 
increasing the drug amount. This increase in particles size may arise due to increase 
amount of drug which increases the viscosity of drug solution. Halayqa et al 
documented the increase in particle size as the drug amount increases due increase in 
viscosity of solvent (Halayqa and Domańska, 2014). The Figure 4.5A shows 
significant (P<0.001) increased in particle size from to 210 nm to 257 nm as the 
amount of drug increased from 10 mg to 20 mg. Similarly, particle size significantly 
(P<0.05) increased to 288 when drug content increased to 30 mg.  The polydispersity 
index significantly (P<0.01) increased from 0.11 to 0.18 as drug amount increases as 
shown in the Figure 4.5B.  Likewise, zeta potential (Figure 4.5C) significantly 
(P<0.001) increases from -20 mV -8 mV to with increased PIC amount in the 
formulation. 
 
4.5.6 NMR spectra of PIC-loaded albumin NP 
The 1H NMR study (in DMSO-d6) of PIC in albumin nanoparticles revealed that the 
signal due four hydroxyl groups appeared as a broad spectrum (brs) around 9.1 ppm 
whereas the two trans olefinic protons a and b resonates at around 6.87 and 6.75 ppm 
respectively. The four singlet aromatic protons (d,f,g,h) appears at around 6.96, 6.71, 
and 6.11 respectively. These data confirmed the PIC in albumin nanoparticles 
structure as shown in Figure 4.6. 
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4.5.7 Entrapment efficiency  
Entrapment efficiency was determined by the procedure given in section 2.6. The 
influence of albumin concentration and drug content was studied on entrapment 
efficiency. Figure 7 represents the pattern of entrapment efficiency of PIC-loaded 
albumin NP which shows significant (P<0.01) increase in entrapment efficiency as 
the concentration of albumin increases as shown in Figure 4.7A. A similar trend of 
increase in entrapment was reported by (Ganesh et al., 2015). Significant (P<0.01) 
increase in entrapment efficiency (approximately 65%) was seen of as the albumin 
content increases from 0.5% to 2%. However, it was found to be 64% when albumin 
concentration increases to 3.5%. Figure 4.7B demonstrates significant (P<0.01) 
decrease in entrapment efficiency from 60% to 39% as the content of drug increases 
to 30 mg (approximately 39%).  This implies that an increase in drug amount 
decreases the entrapment efficiency because the higher amount of drug requires 
more amount of albumin to encapsulate. The similar pattern of entrapment was 
reported by (Sebak et al., 2010). 
 
4.5.8 Percentage yield 
Percentage yield was calculated from the equation given in section 2.7. The effect of 
albumin concentration and drug content was evaluated on percentage yield. Figure 
4.8A represents an increase in percentage yield upon an increase in albumin content 
in the formulation.  Percentage yield increased significantly (P<0.05) from 50% to 
64% when albumin concentration increased from 0.5% to 2%. However, there is a 
slight increase in yield as the albumin concentration increased in the formulation to 
3.5%. This increase in percentage yield may be due to the availability of more 
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amount of albumin for the same amount of PIC.  A similar trend of percentage yield 
can be seen in the Figure 4.8B where percentage yield increase (P<0.05) from 42% 
to 67% when drug amount increases. It slightly increases to 68% when amount of 
drug increases to 30 mg. Kılıçarslan and Baykara also reported the same pattern of 
percentage yield on increasing amount of drug (Kılıçarslan and Baykara, 2003). 
 
4.5.9 In-vitro release 
The release study of PIC nanoparticles was as carried out as described in section 2.8. 
PIC nanoparticles were formulated with a 0.5%, 2% and 3.5% concentration of 
albumin.  These batches show burst release of PIC from nanoparticles after 24 hours 
as shown in the Figure 4.9A. It was noted that increase amount of albumin decreases 
the release of PIC from nanoparticles. The release of 34%, 29% and 22% was 
documented after 24 hours in these batches. Moreover, 70%, 62% and 55% release 
of PIC was reported after 168 hours. Increase in particles size may cause a decrease 
in release due to increase in albumin content. Increase in albumin concentration 
contributes to decrease in the in-vitro release of drug was also demonstrated by  
(Jenita et al., 2014). The effect of the increased amount of PIC from 10 to 30 mg on 
release profile was evaluated. Burst release of PIC from nanoparticle was noticed as 
expressed in the Figure 4.9B. After 24 hours 50%, 37% and 32% release of PIC was 
reported.  After 168 hours the PIC release was 77%, 63% and 50% in batches 
formulated with 10 mg, 20 mg and 30 mg of PIC. A similar trend of release was 
documented by (Azizi et al., 2017). Rapid dissolution of PIC present on the surface 
of albumin may cause the burst release in the dissolution media. 
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4.5.10 Solubility of PIC-loaded albumin NP 
The solubility of PIC-loaded albumin NP was determined by the method given in 
section 2.9. The apparent water solubility of PIC in both free and encapsulated form 
was determined by UV-spectroscopy at 325 nm. The vials in Figure 4.10A depict the 
enhanced solubility of PIC when formulated as PIC-loaded albumin NP vs free PIC 
(10B) in water.  It is evident from the figures that tube A produces a uniform 
dispersion of PIC-loaded albumin NP as shown in Figure 4.10A, whereas free PIC 
was sparingly soluble as shown in Figure 4.10B.   The tube B in the Figure 4.10 
shows turbidity and particles whereas tube A shows the clear solution. The solubility 
of the free PIC was 17.87 µg/ml, whereas that of PIC-loaded albumin NP was 29.26 
µg/ml, which represented an approximate increase in aqueous solubility of PIC-
loaded albumin NP double as compared to the free PIC as shown in 4.10B 
absorbance spectra of PIC-loaded albumin NP and free PIC. 
 
4.5.11 Scanning electron microscopy 
The sample for SEM was prepared by the method mentioned in the section 2.10. 
Figure 4.11 represents the SEM images of the free PIC and different batches of 
nanoparticles such as F1 (PIC 10 mg), F2 (PIC 20 mg) and F3 (PIC 30 mg). The free 
PIC represents the random and solid structure of drug whereas as the nanoparticles 
images shows spherical and smooth surface. Image F1 demonstrate monodisperse 
and smooth textured appearance in the Figure 4.11. However, image F2 and F3 show 
larger particle size and partially disperse texture in the Figure 4.11. Therefore, from 
the above SEM images, it can be concluded that increase in drug content increases 
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the particle size of nanoparticles. Thus, to achieve intracellular targeting smaller 
particle size ranging from 0.1µ to 100nm is desirable (De Jong and Borm, 2008). 
 
4.5.12 Cellular uptake of PIC-loaded albumin NP 
The HT-29 and CaCo-2 cell were incubated with PIC-loaded albumin NP for cellular 
uptake as described in the section 2.12. The nucleus image of cell and uptake of 
nanoparticle was taken under phase contrast microscope for CaCo-2 and HT-29 
cells. Image F1 in the Figure 4.12(A and B) represent CaCo-2 and HT-29 cells with 
no treatment. Image F2 in the Figure 4.12(A and B) shows CaCo-2 and HT-29 cells 
treated with Nile Red coated PIC-loaded albumin NP. The images in F1 depicts 
nucleus without any treatment, however, images in F2 exhibit nanoparticles labeled 
with Nile Red observed under the microscope in both the Figure 4.12(A and B). The 
merged images in F1 as shown in the Figure 4.12(A and B) represent nucleus only 
although fluorescent nanoparticles can be seen around the nucleus in F2 of Figure 
4.12(A and B) of both the merged images.  
 
4.5.13 In-vitro cytotoxicity assay 
The cytotoxicity study was performed by methods as described in the section 2.13. 
The cytotoxic assay was executed to evaluate cell viability as described by (Kumar 
et al., 2014) for free PIC and PIC-loaded albumin NP. The assay was done by MTT 
dye for a period of 24, 48, 72, and 96 hours. The blank nanoparticles had no 
cytotoxicity in colorectal cancer cell lines such as CaCo-2 and HT-29 as evident 
from the Figure 4.13(A and B). The graphs in Figure 4.13(A and B) exhibit dose 
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dependent response to cytotoxicity. The cell viability was reported to be low (65%) 
in PIC-loaded albumin NP than the free PIC (74%) in CaCo-2 after 24 hours of 
incubation at dose of 7.5 μg/ml. Similarly, cell viability was found to be 35% in PIC-
loaded albumin NP and 52% in free PIC after 96 hours of treatment at same dose. 
Moreover, cell viability was noticed to be 57% in PIC-loaded albumin NP and 75% 
in free PIC after 24 hours in HT-29 cells at dose of 7.5 μg/ml.  Similarly, it was 32% 
in PIC-loaded albumin NP and 42% in free PIC after 96 hours of treatment in HT-29 
at same dose. 
PIC-loaded albumin NP sustained the cytotoxic action of the free drug due to the 
enhanced penetration and retention effect inside the colorectal cells (Patil et al., 
2009) (Chavanpatil et al., 2006). It also enhanced the solubility which in turn 
enhances the half-life and bioavailability (Mittal et al., 2007., Anand et al., 2010) 
due to a reduction in particle size of PIC. Therefore, based on the above data it can 
be concluded that PIC-loaded albumin NP improves the cytotoxicity potential due to 
a reduction in particle size, which suggest that albumin nano-particulate formulation 
enhances the biological therapeutic efficacy of PIC over the free PIC. 
 
4.5.14 Migration assay 
The migration study was carried out in CaCo-2 and HT-29 as stated in the section 
2.14. Like other tumour cells, colon cancer cells also migrate from one side to 
another  (Friedl and Wolf, 2003., Qi et al., 2015). Thus, anti-migration potential of 
free PIC and PIC-loaded albumin NP was assessed in CaCo-2 and HT-29. These cell 
lines were transfected with 7.5 µg/ml free PIC and PIC-loaded albumin NP.  Figure 
4.14 and 4.15 display the evaluation of the degree of wound closure in CaCo-2 and 
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HT-29 cells. The PIC-loaded albumin NP treated groups in microscopic Figures 
4.14A and 4.15A show greater void space than free PIC treated cells.   About 77% 
(p<0.001) of void space was reported in CaCo-2 upon treatment with 7.5 µg/ml of 
PIC-loaded albumin NP compare to control. Although, 80% (p<0.01) of void space 
was observed when treated with free PIC closure as shown in Figure 4.14B. 
Likewise, PIC-loaded albumin NP shows a significant reduction in wound closure 
when transfected with the same amount of nanoparticles as compare to free drug in 
HT-29. Approximately, 74% (p<0.001) of clear space was noticed when HT-29 
treated with PIC-loaded albumin NP whereas, free PIC demonstrates only 78% of 
wound opening as shown in Figure 4.15B of the graph. Thus PIC-loaded albumin NP 
shows strong inhibition of migration of the tumour cells in both cell lines, but the 
free PIC has less efficiency against migration of cancer cell in both cell lines. 
Therefore, albumin nanoparticles have high efficiency against migration of cancer 
cells to prevent metastasis of colon cancer cell lines. 
 
4.5.15 Colony formation assay 
The colony formation assay was performed according to procedure stated in Section 
2.15. A colony formation study was performed to determine and compare the long-
term anticancer activity of free PIC and PIC-loaded albumin NP as reported 
previously (Yeung et al., 2010) in CaCo-2 and HT-29 cells. The cells were 
transfected with 7.5 µg/ml of PIC-loaded albumin NP and same amount of free PIC. 
After 7 days the number colonies form were measured in control, blank NP, free PIC 
and PIC-loaded albumin NP treated group under stereo zoom Nikon microscopy as 
shown in Figure 4.16A and 4.17A. The colony formed in healthy cells and cells 
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treated with blank nanoparticles do not have any significant difference as shown in 
the microscopic image. The number of colonies grown in cell treated with 7.5 µg/ml 
of PIC-loaded albumin NP (10) was significantly (P<0.01) less as compare to the 
free PIC (27) in CaCo-2 cells as depicted in the graph 4.16B. Similarly, a total 
number of colonies were found to be significantly less (15) upon transfection with 
PIC-loaded albumin NP than an equivalent amount of free PIC (41) in HT-29 cells 
as represented in the graph 4.17B. 
 
4.5.16 Invasion assay 
The protocol for invasion assay was followed as stated in the 2.16. The effect of 
PIC-loaded albumin NP on invasion activity of colorectal cancer cell lines such as 
CaCo-2 and HT-29 was assessed as reported by (Yuen et al., 2013). Both the 
colorectal cancer cell line was transfected with 7. 5 µg/ml of PIC-loaded albumin NP 
and the corresponding amount of free PIC. The efficiency of PIC-loaded albumin NP 
was significantly (p<0.01) greater than free PIC as illustrated in the microscopic 
images of Figure 4.18A) and Figure 4.19A in both cell lines. The inhibition of 
invasion was significantly (p<0.001) lesser (38 %) when CaCo-2 cells transfected 
with PIC-loaded albumin NP as compare to the free PIC (51%) as shown in the 
graph of Figure 4.18B. Additionally, PIC-loaded albumin NP depicts increase 
efficiency against invasion than the free PIC in HT-29 as presented in the graph of 
Figure 4.19B. Cell invasion was reported to significantly less (p<0.05) in PIC-loaded 
albumin NP group (34%) than the free PIC (57%) in HT-29 cells. Thus, according to 
the above data PIC-loaded albumin NP is more effective against the invasion of 
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CaCo-2 and HT-29 because PIC-loaded albumin NP restored and enhanced the anti-
invasion therapeutic efficiency. 
 
4.5.17 Immunostaining of p65 
The fluorescent images of CaCo-2 (20A) and HT-29 (21A) were captured under 
bright field microscopy after staining cells with p65 antibody as stated in the Section 
2.17. Both the cell line was treated with 7.5 µg/ml dose of PIC-loaded albumin NP 
and an equivalent amount of free PIC. The induced level of NF-kβ such as p65 can 
be noticed in the control and blank NP as shown in the microscopic images of Figure 
4.20A and Figure 4.21A. However, the group was treated with free PIC and PIC-
loaded albumin NP shows a noticeable difference in the level of p65 in the Figure 
4.20B and Figure 4.21B. The graphs in the Figure 4.20B (CaCo-2) and Figure 4.21B 
(HT-29) demonstrate a higher level of p65 in control and blank NP groups. PIC-
loaded albumin NP depicts the significantly low level of p65 protein than blank 
nanoparticles. The expression of p65 in PIC-loaded albumin NP transfected cells was 
significantly (P<0.01) lower than a free PIC transfected cell in CaCo-2 (C). 
Similarly, PIC loaded nanoparticles decrease the p65 expression significantly 
(P<0.001) than free PIC in HT-29 (D). 
 
4.5.18 Immunostaining of HIF-1α 
The Caco-2 (A) and HT-29 (B) were stained with HIF-1α antibody and observed 
under bright field microscopy to study the effect of PIC treatment as stated in section 
2.17. The CaCo-2 and HT-29 cell line were treated with 7.5 µg/ml dose of PIC-
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loaded albumin NP and an equivalent amount of free PIC. The plates were incubated 
for 24 hours and the level of HIF-1α was observed under a microscope. The 
increased expression of HIF-1α was reported as shown in images of Figure 4.22A 
(CaCo-2) and Figure 4.22B (HT-29). The overstimulated expression of HIF-1α was 
found in control and cells transfected with blank NP in both cell lines as depicted in 
the Figure 22A and 22B. Also, the group was treated with free PIC and PIC-loaded 
albumin NP show a noticeable difference in the level of HIF-1α as represented in 
Figure 4.22(A and B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
80 
 
4.5.1Calibration of PIC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Calibration curve of PIC 
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4.5.2 Effect of ethanol amount 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Effect of ethanol amount on particle size (A), polydispersity index (B) and zeta 
potential (C). The above graph shows the effect of ethanol amount on Particle size (A), 
polydispersity index (B) and zeta potential (C). It was reported that ethanol amount does not 
have any significant effect on particle size, polydispersity index and zeta potential. Values 
are mean ± SEM (n = 3). 
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4.5.3 Effect of albumin concentration 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Effect of albumin concentration on particle size (A), polydispersity index (B) 
and zeta potential (C). The above graph represents the effect of increasing albumin 
concentration on Particle size (A), polydispersity index (B) and zeta potential (C). It was 
demonstrated that increase in albumin concentration leads to increase in particles size (A) as 
well as the polydispersity index (B) significantly (P<0.001). Polydispersity increases 
significantly when albumin concentration increases from 0.5% to 2%.  However, it does not 
have any significant effect on zeta potential. Values are mean ± SEM (n = 3), **P<0.01 and 
***P<0.001. 
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4.5.4 Effect of Glutaraldehyde concentration 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: Effect of increasing concentration of glutaraldehyde on particle size (A), 
polydispersity index (B) and zeta potential (C). The above graph represents the effect of an 
increase in glutaraldehyde concentration on Particle size (A), polydispersity index (B) and 
zeta potential (C). It was evident from the graph that glutaraldehyde concentration increases 
particle size significantly (P<0.001) when it increases from 4% to 12%. However, 
polydispersity index decreases significantly (P<0.001) upon an increase in glutaraldehyde 
concentration but later it does not have any effect on PDI. Similarly, increase in 
glutaraldehyde concentration causes a significant (P<0.01) decrease in zeta potential 
initially. Values are mean ± SEM (n = 3). *P<0.05, **P<0.01, and ***P<0.001. 
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4.5.5 Effect of drug content 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: Effect of increase in drug amount on particle size (A), polydispersity index (B) 
and zeta potential (C). The above graph shows the effect of drug amount on Particle size 
(A), polydispersity index (B) and zeta potential (C). It is evident from the above graph that 
increases in PIC amount significantly (P<0.01) increase the particle size and PDI. Similarly, 
zeta potential increases significantly (P<0.001) upon an increase in PIC amount.  Values are 
mean ± SEM (n = 3). *P<0.05, **P<0.01 and ***P< 0.001. 
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4.5.6 NMR spectra of PIC-loaded albumin NP 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: H NMR of piceatannol pf albumin nanoparticles. The above H NMR confirms 
the piceatannol stucture in the nanoparticle form. 
 
 
 
 
 
 
 
 
 
                                            ac,d,e,f,g I    i,j    h     b                                       
k          water        l             dmso-d6 
O
H 
86 
 
4.5.7 Entrapment efficiency  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: Effect of albumin concentration (A) and drug amount (B) on entrapment 
efficiency. The above graph demonstrates effect albumin concentration (A) and drug content 
(B) on entrapment efficiency. Figure 4.7A in the above graph show a significant difference 
(P<0.01) when albumin concentration increases from 0.5% to 2%, however, entrapment 
efficiency slightly increase upon further increase in albumin concentration. Figure 4.7B in 
the above graph illustrates the significant decrease in entrapment efficiency (p<0.01) as the 
drug amount increases from 10 mg to 20 mg but it does not have any significant effect when 
further increases to 30 mg. Values are mean ± SEM (n = 3). **P<0.01.  
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4.5.8 Percentage yield 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8: Effect of albumin concentration (A) and drug amount (B) on percentage yield. 
The above graph represents effect albumin concentration (A) and drug content (B) on 
percentage yield. Figure 4.8A in the above graph reveal a significant difference (P<0.05) 
when albumin concentration increases from 0.5% to 2% although percentage yield slightly 
increases upon further increase in albumin concentration. Figure 4.8B in the above graph 
express no significant difference (P<0.05) as the amount of drug increases. Values are mean 
± SEM (n = 3). *P< 0.05. 
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4.5.9 In-vitro release 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9: effect of albumin concentration (A) and drug amount (B) on In-vitro release 
profile. The above graph illustrates burst release after 24. The above graph depicts that 
increase in albumin and drug concentration leads to decrease the in-vitro of PIC release from 
the formulation. Values are mean ± SEM (n = 3). 
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4.5.10 Solubility of PIC-loaded albumin NP 
.  
 
 
 
 
 
 
 
 
 
Figure 4.10: water solubility of PIC-loaded albumin NP (A) and free PIC (B). The vials in 
the Figure 4.10(A and B) show the solubility of PIC-loaded albumin NP and free PIC, 
respectively. A Clear solution of PIC-loaded albumin NP in Figure A and turbid free PIC in 
Figure 10B can be observed above. Figure 10A indicates enhance in solubility of PIC-loaded 
albumin NP. 
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4.5.11 Scanning electron microscopy 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11: Scanning electron microscopy of different batches of nanoparticles. The above 
Figure 4.11 represents SEM imaging of free PIC, the batch containing 10 mg (F1), 20 mg 
(F2), and 30 mg (F3) of PIC used in the formulation. Batch formulated with 10 mg PIC 
represents smaller particles size whereas batch fabricated with 30 mg PIC shows larger 
particle size. F1 also demonstrate uniformity in size although F2 and F3 exhibit partial 
uniformity. 
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4.5.12 Cellular uptake of PIC-loaded albumin NP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12: Cellular Uptake of optimised PIC-loaded albumin NP in CaCo-2 and HT-29 
cells at 100X. Cellular localization of Nile red-coated PIC-loaded albumin NP was observed 
in CaCo-2 (A) and HT-29 (B) cells and visualized by overlapping under fluorescent 
microscopy. The red fluorescent can be observed in the microscopic images F2 in the Figure 
4.12(A and B). 
B  
F2 
F1 
HT-29 cells stained with DAPI PIC-loaded albumin NP 
stained with Nile red 
Merged image of cells and NP 
HT-29 cells stained with DAPI Merged image of cells  Red channel 
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CaCo-2 cells stained with DAPI PIC-loaded albumin NP 
stained with Nile red 
Merged image of cells and NP 
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4.5.13 In-vitro cytotoxicity assay 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13: Effect of PIC-loaded albumin NP and free PIC on cytotoxicity of CaCo-2 (A) 
and HT-29 (B) cell lines. The cytotoxicity assay was evaluated on CaCo-2 (A) and HT-29 
(B) cell lines. 40×104 cells were seeded on 24 well plates and treated with 2.5 µg/ml, 5 
µg/ml and 7.5 µg/ml of PIC-loaded albumin NP and an equivalent amount of free PIC. The 
absorbance was calculated after 24 hours, 48 hours, 72 hours and 96 hours. PIC-loaded 
albumin NP shows higher cell cytotoxicity as compared to the free PIC. Values are mean ± 
SEM with n = 3. ***P<0.001 compared with same amount of free drug. 
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4.5.14 Migration assay in CaCo-2 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14: Effect of PIC-loaded albumin NP and free PIC on migration potential of CaCo-
2 cell lines. The above image in the Figure 4.14 A (CaCo-2) demonstrate the effect of free 
PIC and PIC-loaded albumin NP on wound closure after 72 hours of treatment. PIC-loaded 
albumin NP demonstrate more void space than the free PIC in wound scratch of cell line as 
compare to control and blank NP. The graph B (CaCo-2) depicts a significant variation of 
anti-migration activity of free PIC (P<0.01) and PIC-loaded albumin NP (P<0.001) after 72 
hours of treatment at equal dose. Values are mean ± SEM with n=3. **P<0.01, ***P<0.001 
compared with blank NP. 
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Figure 4.15: Effect of PIC-loaded albumin NP and free PIC on migration potential of HT-29 
cell lines. The above images in the Figure 4.15A (HT-29) demonstrate the effect of free PIC 
and PIC-loaded albumin NP on wound closure after 72 hours of treatment. PIC-loaded 
albumin NP demonstrate more void space than the free PIC in wound scratch of cell line as 
compare to control and blank NP. The graph 15B (HT-29) shows a significant variation of 
anti-migration activity of free PIC (P<0.01) and PIC-loaded albumin NP (P<0.001) after 72 
hours of treatment at equal dose. Values are mean ± SEM with n=3. **P<0.01, ***P<0.001 
compared with blank NP and ΔΔP<0.01 compared with the same dose of the free PIC. 
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4.5.15 Colony formation assay in CaCo-2 
. 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 4.16: Effect of PIC-loaded albumin NP and free PIC on colony formation ability of 
CaCo-2 cell lines. The above images in the Figure 4.16A (CaCo-2) demonstrate a pattern of 
colon formation in control, blank NP, free PIC and PIC-loaded albumin NP treated the group 
as demonstrated in the microscopic images. The graph B (CaCo-2, P<0.01) represents 
significant variation in colony formation upon treatment with free PIC and PIC-loaded 
albumin NP. It is evident from the figure that PIC-loaded albumin NP shows significant less 
number of colonies than the free PIC. Values are mean ± SEM with n=3. ***P<0.001 
compared with blank NP. ΔΔP<0.01 compared with the same dose of the free PIC. 
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Figure 4.17: Effect of PIC-loaded albumin NP and free PIC on colony formation ability of 
HT-29 cell lines. The above images in the Figure 4.17A (HT-29) exhibit a pattern of colon 
formation in control, blank NP, free PIC and PIC-loaded albumin NP treated the group as 
demonstrated in the microscopic images. The graph B (HT-29, P<0.001) represents 
significant variation in colony formation upon treatment with free PIC and PIC-loaded 
albumin NP. The above figures revealed that PIC-loaded albumin NP shows significant less 
number of colonies than the free PIC. Values are mean ± SEM with n=3.  ***P<0.001 
compared with blank NP. ΔΔΔP<0.001 compared with the same dose of the free PIC. 
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4.5.16 Invasion assay in CaCo-2 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 4.18: Effect of PIC-loaded albumin NP and free PIC on invasion potential of CaCo-2 
cell lines. The above microscopic images in the Figure 4.18A (Caco-2) represents anti-
invasive activity of free PIC and PIC-loaded albumin NP after treatment. The cells which 
appear bright are the one which invaded through the membrane. PIC-loaded albumin NP 
(P<0.01) shows significantly less percentage of invasion than the free PIC. The graph B 
shows that PIC nanoparticles represent significant less invasion than the free PIC in CaCo-2 
(P<0.01). Values are mean ± SEM with n=3. ***P<0.001 compared with blank NP. 
ΔΔP<0.01 compared with the same dose of the free PIC. 
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Figure 4.19: Effect of PIC-loaded albumin NP and free PIC on invasion potential of HT-29 
cell lines. The above microscopic images in the Figure 4.19A (HT-29) represents anti-
invasive activity of free PIC and PIC-loaded albumin NP after treatment. The cells which 
appear bright are the one which invaded through the membrane. PIC-loaded albumin NP 
(P<0.05) shows significantly less percentage of invasion than the free PIC. The graph B 
shows that the PIC nanoparticles have significant less invasion than the free PIC in HT-29 
(P<0.05).  Values are mean ± SEM with n=3. ***P<0.001 compared with blank NP. 
ΔP<0.05 compared with the same dose of the free PIC. 
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4.5.17 Immunostaining of p65 in CaCo-2 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 4.20: Effect of PIC-loaded albumin NP and free PIC on expression of p65 in CaCo-2 
at 40X. The above images in the Figure 4.20A (CaCo-2) were taken under bright field 
microscopy. Control and blank images show induction of p65 whereas images under the free 
PIC and PIC-loaded albumin NP show a reduced level of p65. The graph B demonstrate 
significant reduction in the level of p65 in CaCo-2 (P<0.01). Values are mean ± SEM (n = 
3). *P<0.05 and **P<0.01 as compare to control.  ΔΔP<0.01 compared to same amount of 
free PIC. 
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Figure 4.21: Effect of PIC-loaded albumin NP and free PIC on expression of p65 in HT-29 
at 40X. The above images in the Figure 4.21A (HT-29) were taken under bright field 
microscopy. Control and blank images show induction of p65 whereas images under the free 
PIC and PIC-loaded albumin NP show a reduced level of p65. The graph B reveals 
significant reduction in the level of p65 in HT-29. Values are mean ± SEM (n = 3). 
**P<0.01 and ***P<0.001 as compare to control.  ΔΔΔP<0.001 compared to same amount of 
free PIC. 
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4.5.18 Immunostaining of HIF-1α 
 
 
 
 
 
 
 
.  
 
 
 
 
 
 
 
Figure 4.22: Effect of PIC-loaded albumin NP and free PIC on expression HIF-1α in CaCo-
2 (A) and HT-29 (B) at 40X. The above images in Figure 4.22 show induction of HIF-1α in 
control and blank transfected group, whereas images under the free PIC and PIC-loaded 
albumin NP shows a reduced level of HIF-1α. 
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4.6 Discussion  
Effects of solvent concentration, albumin concentration, glutaraldehyde and amount 
of drug on particle size, zeta potential and polydispersity were studied. Increase 
concentration of desolvating agent ethanol has no significant effects on particle size, 
polydispersity index and zeta potential also reported by (Langer et al., 2003b).  
Nanoparticle prepared with the different concentration of albumin shows an increase 
in the particle size, polydispersity index and zeta potential significantly as confirmed 
in Figure 4.3 with an increase in albumin concentration. Higher concentration of 
albumin produces dense aqueous albumin solution which results an increase of 
physicochemical properties of nanoparticles. Same trend of increase in particle size 
was reported by (Jun et al., 2011). Higher concentration of glutaraldehyde increases 
the particle size significantly and reduces the polydispersity index as reported by 
(Rajith and Ravindran, 2014). However, it has no significant effect on zeta potential 
as shown in Figure 4.4. Increase in drug amount increases the particle size 
significantly, polydispersity index and zeta potential. The increase in particle size 
result due to increase in viscosity of drug solution as the amount of drug increases as 
visible in Figure 4.5. The effect of higher amount of drug on particle size was 
demonstrated by (Halayqa and Domańska, 2014).  We have confirmed the purity of 
PIC in nanoparticles through NMR study as shown in Figure 4.6. Figure 4.7A show 
increase in entrapment efficiency when albumin concentration and PIC amount 
increases. Likewise, Figure 4.8A shows increase in percentage yield as albumin 
concentration and PIC amount increase in the formulation. This increase in 
entrapment efficiency and percentage yield was due to the accessibility of more 
amount of albumin to enclose the same amount of CAPE in the formulation. On the 
other hand entrapment efficiency and percentage yield decrease when the amount of 
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PIC increases as shown in the Figure 4.7B and Figure 4.8B. Effect of higher albumin 
concentration and amount of PIC was studied on in-vitro release behaviour as shown 
in the Figure 4.9. The graph show decrease in in-vitro release as the albumin 
concentration and PIC amount increases due to larger particles size of nanoparticles. 
Solubility study reveals that PIC loaded albumin (Figure 4.10A) exhibit clear 
aqueous solution than the free PIC (Figure 4.10B), which testifies increase in 
solubility of PIC loaded albumin as compared to the free PIC.  Morphological 
evaluation of free PIC and PIC-loaded albumin NP was done by scanning electron 
microscopy. Rough and solid structure of free PIC can be observed in Figure 4.11. 
However, images F1, F2 and F3 show spherical and smooth architecture of 
nanoparticles in the Figure 4.11.  However, increase in particle size can be seen as 
the PIC amount increase in formulation, which also confirm that increase in drug 
amount leads to increase in particle size. CaCo-2 and HT-29 were stained with DAPI 
and observed under a fluorescent microscope as evident in the images F1 of Figure 
4.12(A and B). Images F2 in the Figure 4.12(A and B) Nile Red coated PIC-loaded 
albumin NP can be noticed around the cells. This confirms accessibility of PIC 
nanoparticles to cancer cells. In-vitro cytotoxicity graph in the Figure 4.13(A and B) 
describes dose-dependent effect on cell proliferation CaCo-2 and HT-29.  The lower 
rate of cell proliferation was noted in PIC-loaded albumin NP than the free PIC in 
cancer cells. Decrease percentage of cell migration was reported in PIC-loaded 
albumin NP treated cells than free PIC as illustrated in microscopic images of Figure 
4.14A (CaCo-2) and Figure 4.15A (HT-29) after 72 hours. Graph in Figure 4.14B 
(CaCo-2) and Figure 4.15B (HT-29) revealed significant declines in the migration of 
cancer cell after 72 hours. Figure 4.16A (CaCo-2) and Figure 4.17A (HT-29) 
represent a microscopic depiction of colony formation. Where PIC-loaded albumin 
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NP transfected cells in the Figure 4.16A (CaCo-2) and Figure 4.17A (HT-29) shows 
less colonies as compare to free PIC, blank NP and control group. Similarly, graph in 
the Figure 4.16B (CaCo-2) and 17B (HT-29) confirm the significant reduction in 
colony formation in PIC-loaded albumin NP. Fluorescent microscopic images show 
less number invaded cell upon treatment with PIC-loaded albumin NP as compare to 
free PIC, blank NP and control group in the Figure 4.18A (CaCo-2) and 19A (HT-
29). Significant low invasion rate was reported with PIC-loaded albumin NP treated 
cells than the free PIC in CaCo-2 and HT-29 as depicted in graph of Figure 4.18B 
and Figure 4.19B. Induction of p65 was recognised in control and blank NP group in 
CaCo-2 and HT-29 under bright field microscopy as shown in the Figure 4.20A and 
Figure 4.21A. Although a low level of p65 can be noticed in PIC-loaded albumin NP 
than free PIC. Similarly, low expression of HIF-1α protein was depicted in cells 
treated with PIC-loaded albumin NP as shown in the Figure 4.22(A and B). Hence 
decrease in particle size results in higher solubility of low soluble natural compound 
PIC in nanoparticle form. This nanoparticle down-regulate over activation of p65 
(RelA) and HIF-1  levels to a higher extent than free PIC in colon cancer cell lines.   
Thus PIC nanoparticles increase therapeutic value of the natural anticancer agent via 
suppression of overactivated HIF and NF-kβ pathways during cancer. Hence the 
findings from our work conclude that nanotechnology could be an effective tool to 
enhance the anticancer activity of several natural and/or novel anticancer 
compounds, which are currently not in clinical use due to their limited solubility 
and/or poor bioavailability. 
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4.7 Conclusion 
The data from this chapter reveals that PIC nanoparticles can be formulated by 
desolvation method. Optimisation of nanoparticles assists to dispense suitable 
formulation to carry out the in-vitro characterization in cancer cells. The cell 
proliferation assay established the relation of dose relationship with proliferation in 
CaCo-2 and HT-29 cells and proves that PIC-loaded albumin NP has less cell 
proliferation than the free PIC. PIC enhances anticancer properties which can be 
confirmed from an experiment such as migration, colony formation, and invasion 
assays in nanoparticles form than the free PIC. PIC-loaded albumin NP inhibits 
overestimated levels of p65 and HIF-1α higher extent than free PIC.  Therefore, 
delivery of PIC-loaded albumin NP may provide a therapeutic cure in cancer 
treatment.  
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Chapter 5 
Formulation and in-vitro evaluation of the anticancer properties of 
CAPE-loaded albumin NP in colorectal cancer cell lines 
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5.1 Introduction 
Colorectal cancer is the most common of tumour after breast and prostate cancer 
worldwide (Gadaleta et al., 2017., Klaver et al., 2017., Siegel et al., 2017). The main 
etiology of the disease is not been confirmed. However, it is hypothesized that 
genetic factors, hereditary, lifestyle and prevalence of ulcerative colitis are the key 
regulators of colorectal cancer (Adami et al., 2016., Khan et al., 2017a., Carrat et al., 
2017). Symptoms such as abdominal pain, constipation, diarrhoea, rectal bleeding, 
and excessive weight loss may be the early sign of colorectal cancer (Mitchell et al., 
2008). Colonoscopy is the most widely used technique in the diagnosis of colorectal 
cancer (Martin et al., 2017). However, colonoscopy causes discomfort in colorectal 
cancer patients. Therefore, other techniques like  Faecal occult blood tests, faecal 
immunochemical test (FIT) and stool DNA (sDNA) testing are commonly employed 
by a medical practitioner (Janz et al., 2016). Clinical therapeutics such as 
chemotherapy (5-fluorouracil, paclitaxel, methotrexate and cyclophosphamide), 
immunotherapy (monoclonal antibodies, cytokine therapy, ) radiation therapy and 
nutrition supplement based therapy (vitamins, minerals, proteins) are current first 
line of treatment (Mishra et al., 2013., Mirnezami et al., 2013., Lynch and Murphy, 
2016., Staff et al., 2017., Cuhls et al., 2017). However, these chemotherapeutics 
causes peripheral neuropathy, vomiting, fatigue, anorexia, hair fall, infertility, bone 
marrow depletion, stomach pain, bowel discomfort, impairment of neuron and renal 
function (Denlinger and Barsevick, 2009., Lorusso et al., 2017). Immunotherapy 
casues papulopustular rash, mucosal toxicity, electrolyte imbalances, diarrhoea, 
acne-like rash, nail disorder, infusion reactions and pruritus (Hofheinz et al., 2017b).   
High dose of radiation more than 0.125 cGy/min may cause damage to healthy tissue 
in radiation therapy (Kim et al., 2016). These treatments alter lifestyle and burden 
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financial condition of colorectal cancer patients. It has been reported that chronic 
inflammation produces in ulcerative colitis is the main cause of colorectal cancer 
(Lasry et al., 2016).  The chronic inflammation triggers over activation of pro-
inflammatory mediators. These mediators of inflammation induces overstimulation 
of nuclear factor kappa beta (NF-kβ) and hypoxia-inducible factor (HIF-1α) and 
results into colorectal cancer (Karin, 2009., Nathke and Rocha, 2011., Biddlestone et 
al., 2015a., Fan et al., 2016). The over-expressed NF-kβ and HIF-1α  causes cancer 
cells to proliferate, migrate and invade at the tumour site (Chaudary and Hill, 2007., 
Jana et al., 2017). Overstimulation of inflammatory mediators (TNFα, IL-8, IL-6, 
NF-kβ and HIF-1α) was documented in colorectal cancer patients during a clinical 
trial. (Klampfer, 2011., Hassanzadeh, 2011., Tan et al., 2017b). The potential role of 
overexpressed NF-kβ and HIF-1α  were reported in HT-29 and CaCo-2 colorectal 
cancer cell lines via proliferation, migration and invasion nature of tumour cells 
(Voboril and Weberova-Voborilova, 2006.,  Sakamoto et al., 2009., Tammali et al., 
2011., Jana et al., 2017). Therefore, inhibition may provide a therapeutic cure for 
colorectal cancer. 
Therefore, to inhibit the overexpression of  NF-kβ and HIF-1α  there is a pressing 
need to develop novel and natural anticancer agents that have no side effects and can 
bring about specific drug delivery. It has been documented that cafiec acid phenethyl 
ester (CAPE) posses medicinal value against cancer and inflammation   (Murtaza et 
al., 2014b., Murtaza et al., 2015., Tolba et al., 2016b).  CAPE is derived from 
honeybee hives and rich in phenolic constituents (Yang et al., 2017). CAPE has an 
affinity to inhibit over stimulated NF-kβ and HIF-1α  in clinical patients,  mice and 
cancer cell lines (Borthakur et al., 2008., Choi et al., 2010., Wang et al., 2010b., 
DeDiego et al., 2014). CAPE inhibits overactivation of NF-kβ and HIF-1α 
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responsible for inflammation and colorectal cancer. It also prevents the translocation 
of Ikβ, and phosphorylation of subunit of NF-kβ (p65) (Toyoda et al., 2009., Akyol 
et al., 2013., Murtaza et al., 2014a). However, the low solubility and low 
bioavailability of CAPE limit its therapeutic potential (Tolba et al., 2016b).   
In the current chapter, CAPE-loaded albumin nanoparticles were fabricated. We 
employed desolvation method to fabricate albumin nanoparticles loaded with CAPE. 
As this method has been widely used in the formulation of albumin nanoparticles in 
cancer delivery (Tarhini et al., 2017). Albumin has been used as polymer in the 
nanoparticles formulationdue to its nontoxicity, immunogenisity and 
biodegradability  (Fallacara et al., 2017., Liu et al., 2017., Louage et al., 2017). It 
enhances pharmacokinetic properties of hydrophobic drugs and increases residence 
time at the tumour site (Dennis et al., 2002).  Albumins has an affinity towards 
inflammatory markers and offer amino acid at the tumour site. This affinity of 
albumin helps in targeted delivery of anticancer compounds (Larsen et al., 2016., 
Jiang et al., 2017). 
Based on the accumulating evidence, CAPE nanoparticles were fabricated using 
albumin as a polymer to improve solubility, bioavailability, efficacy and targeting 
potential of CAPE nanoparticles by desolvation method. 
 
5.2 Summary 
Therefore, given the severity of colorectal cancer and the affiliated adverse effects of 
conventional therapeutics, there is pressing need to use novel and natural anticancer 
agents in the treatment and control of colorectal cancer. However, reduction in 
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particle size by nanotechnology may overcome the poor solubility of CAPE. Also, 
the use of albumin as a polymer will serve targeted delivery to the nanoparticles. 
 
5.3 Hypothesis  
In this chapter, we hypothesize that the reduction of particle size will improve the 
anticancer property of CAPE at a higher extent than free CAPE. 
 
5.4 Aims and objectives 
• Formulation of CAPE-loaded albumin nanoparticles 
• Optimisation of CAPE-loaded albumin nanoparticles 
• Evaluation of anticancer properties of  CAPE-loaded albumin nanoparticles 
in CaCo-2 and HT-29 cell line 
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5.5 Results  
5.5.1 Calibration of CAPE 
Calibration curve of CAPE was plotted as shown in the Figure 5.1 in methanol (1:9) 
and absorbance was measured at 425 nm. 
 
5.5.2 Effect of ethanol 
CAPE-loaded albumin NP was fabricated by the method stated in Section 2.3. Effect 
of ethanol amount on particle size was studied by varying the amount of ethanol 
from 4 ml to 12 ml. It was found that increase in the ethanol amount has no 
significant effect on particle size as shown in the graph (Figure 5.2A). The particle 
size was found to be in the range of from 266 nm to 279 nm.  A similar observation 
was also documented by Langer et al (Langer et al., 2003b). In addition 
polydispersity index (Figure 5.2B) also shows no significant difference in an 
increase in ethanol amount. The polydispersity index was reported in the range of 
0.144 to 0.164. Although, zeta potential (Figure 5.2C) decreases slightly from -14 
mV to -18 mV with an increase in ethanol amount. 
 
5.5.3 Concentration of albumin 
Albumin has a tendency to attach to neutrophils, well accepted in the serum and does 
not produce any undesired effect (Abbasi et al., 2012., Elzoghby et al., 2012a). Jun et 
al reported an increase in particle size with increasing concentration of albumin (Jun 
et al., 2011). Moreover, increase in the particle size (Figure 5.3A) was reported in 
the current work. Particle size increases significantly (P<0.001) from 222 nm to 277 
112 
 
nm with increase albumin centration. Similarly, polydispersity index (Figure 4.3B) 
also increases significantly (P<0.01) from 0.05 to 0.27 with an increase in albumin 
concentration. Likewise, zeta potential (Figure 5.3C) slightly increases from -17 mV 
to -13 mV as albumin concentration increases. 
 
5.5.4 Effect of Glutaraldehyde concentration 
The effect of the crosslinking agent on the size of nanoparticles was evaluated with 
varying concentration of glutaraldehyde from 4% to 12%. Increasing concentration 
of glutaraldehyde increases the particle size significantly (P<0.001) from 230 nm to 
394 nm as shown in the graph (Figure 5.4A). Similar trend of particle size was also 
demonstrated by Rajith and Ravindran, 2014. Although increasing concentration of 
glutaraldehyde decreases polydispersity index from 0.23 to 0.18 (Figure 5.4B). 
Decrease polydispersity index pattern was also reported by langer et al, upon 
increase concentration of glutaraldehyde (Langer et al., 2003a).  However, increasing 
the concentration of glutaraldehyde shows no significant effect on zeta potential 
(Figure 5.4C) as documented by Li et al., 2008a. 
 
5.5.5 Amount of drug 
The effect of drug amount on particle size, polydispersity index and zeta potential 
was evaluated by using an increasing amount of CAPE in the formulation.  It 
observed that increase amount of CAPE increases the particle size (Figure 5.5A) of 
nanoparticles. This increase in particle size may cause increase in CAPE amount 
which increase viscosity of drug solution (Halayqa and Domańska, 2014). Particle 
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size very slightly increases from 245 to 274 nm when CAPE amount increase from 
10 mg to 30 mg. Similarly, polydispersity index (Figure 5.5B) also increases slightly 
with an increase in CAPE amount. The polydispersity index increase from 0.139 to 
0.179. Similarly, increase in CAPE amount increases the Zeta potential from 15 mV 
to -9 mV (Figure 5.5C) significantly (P<0.01). 
 
5.5.6 NMR spectra of CAPE-loaded albumin NP 
The 1H NMR study (in DMSO-d6) of CAPE in albumin nanoparticles revealed that 
the signal due two hydroxyl groups appears as a broad spectrum (brs) around 9.5 
ppm, whereas the two trans olefinic protons a and b resonates at around 7.43 and 
6.18 ppm respectively. The signals due to eight aromatic protons appear as multi 
plate stating from 7.28 to 7.07 ppm. A strong peak around 4.29 ppm and 2.92 ppm 
indicates the -OCH2 group and benzylic protons respectively. These data confirmed 
the CAPE structure in albumin nanoparticles as shown in Figure 5.6. 
 
5.5.7 Entrapment efficiency 
The entrapment efficiency of CAPE in nanoparticles was calculated from the 
equation given in section 2.6. The impact of albumin concentration and drug content 
were demonstrated on entrapment efficiency. Figure 5.7A represents the pattern of 
entrapment efficiency of CAPE-loaded albumin NP. Entrapment efficiency increases 
as the concentration of albumin increases in the formulation. A similar trend of 
increase in entrapment was reported by Ganesh et al., 2015. Significant (P<0.001) 
increase in entrapment efficiency from 18% to 61% was reported as the albumin 
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content increases from 0.5% to 2%. However, it shows no change in entrapment 
when albumin concentration increases to 3.5%. Figure 5.7B also demonstrates 
significantly (P<0.01) decrease in entrapment efficiency from 56% to 43% as the 
content of drug increases. This implies an increase in drug amount decreases the 
entrapment efficiency because the higher amount of drug requires more amount of 
albumin for encapsulation. Due to which the drug makes a loose hollow structure 
which might get disperse in the supernatant while washing. The similar pattern of 
entrapment was reported by (Peltonen et al., 2004., Sebak et al., 2010). 
 
5.5.8 Percentage yield 
The percentage yield was measured by the equation given the section 2.7. The effect 
of albumin concentration and drug content was assessed on percentage yield. Figure 
5.8A represents an increase in percentage yield upon an increase in albumin content 
in the formulation.  At 2% albumin concentration, the percentage yield was 67.5% 
shows significant (P<0.001) increase in nanoparticle yield. However, there is a slight 
increase in yield as the albumin concentration increases in the formulation to 3.5%. 
This increase in percentage yield may be due to the availability of more amount of 
albumin for the same amount of CAPE.  A similar trend of percentage yield can be 
seen in the Figure 5.8B where percentage yield increase slightly from 53% to 60 % 
when drug amount increases. It further increases to 64% as the amount of drug 
increases to 30 mg. The amount of albumin here plays a key role in nanoparticles 
yield. Kılıçarslan and Baykara also reported the same pattern of percentage yield on 
increasing amount of drug (Kılıçarslan and Baykara, 2003) 
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5.5.9 In-vitro release 
In-vitro release study was performed by methods mentioned in section 2.8. CAPE 
nanoparticles were formulated with 0.5%, 2% and 3.5% of albumin.  These batches 
show burst release of albumin nanoparticles after 24 hours. It was noted that increase 
amount of albumin decreases the release of CAPE from nanoparticles as illustrated 
in the Figure 5.9A. The release of 44%, 42% and 38% was documented after 24 
hours in these batches. After 168 hours 79%, 66% and 57% release of CAPE was 
reported in three batches. Increase in particles size may cause decreases in in vitro 
release of CAPE when formulated with different concentration of albumin. Increase 
in albumin concentration contributes to decrease in the in-vitro release was also 
demonstrated by  (Jenita et al., 2014). The effect of the increased amount of drug on 
release profile was evaluated and burst release of CAPE from nanoparticle was 
noticed as shown in the Figure 5.9B. After 24 hours 51%, 34% and 31% release of 
CAPE from nanoparticles was reported.  After 168 hours the CAPE release was 
72%, 56% and 51% in the batches formulated with 10 mg, 20 mg and 30 mg of 
CAPE. A similar trend of release was documented by (Azizi et al., 2017). Rapid 
dissolution of CAPE present on the surface of albumin may cause the burst release in 
the dissolution media. 
 
5.5.10 Solubility of CAPE-loaded albumin NP 
The solubility of CAPE-loaded albumin NP and was determined by the method 
given in section 2.9. The apparent water solubility of CAPE in both free and 
encapsulated form was determined by UV-spectroscopy at 425 nm. The vials in 
Figure 5.10A depict shows the enhanced solubility of CAPE when formulated as 
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CAPE-loaded albumin NP vs free CAPE as shown in Figure 5.10B.  It is evident 
from the figures that CAPE-loaded albumin NP (Figure 5.10A) produces a uniform 
clear dispersion throughout the tube, whereas free CAPE (Figure 5.10B)   was 
sparingly soluble and produces turbidity throughout.  The solubility of free CAPE 
was 256.72 µg/ml, CAPE-loaded albumin NP was 435.50 µg/ml, which represented 
an approximately two-fold increase in aqueous solubility as compared to free CAPE. 
 
5.5.11 Scanning electron microscopy  
The sample for SEM was prepared by the method as mentioned in the section 2.10. 
The morphological study of nanoparticles was done by scanning electron 
microscopy. The size, shape and texture of optimized CAPE-loaded albumin NP was 
observed under 50000X magnification as shown in Figure 5.11. Average particle 
size was found to be 157 nm. The images in the Figure 5.11 represents the SEM 
images of free CAPE, F1 nanoparticles with 10 mg CAPE, F2 nanoparticles with 20 
mg CAPE and F3 nanoparticles formulated with 30 mg CAPE. The free drug 
represents the random and solid structure of drug whereas the nanoparticles images 
shows spherical and smooth surface. Image F1 demonstrate monodisperse and 
smooth textured appearance in the Figure 5.11. However, images F2 and F3 show 
larger particle size and partially disperse texture in the Figure 5.11. Therefore, from 
the SEM images, it can be concluded that increase in drug content increases the 
particle size of nanoparticles. Thus, to achieve intracellular targeting smaller particle 
size ranging from 0.1µ to 100 nm is desirable (De Jong and Borm, 2008). 
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5.5.12 Cellular uptake of CAPE-loaded albumin NP 
The CaCo-2 and HT-29 cell were incubated with CAPE-loaded albumin NP as 
described in the section 2.12 for cellular uptake study. The nucleus image of cell and 
uptake of nanoparticle was taken under phase contrast microscope for CaCo-2 and 
HT-29 cells. Image F1 in the Figure 5.12(A and B) represent CaCo-2 and HT-29 
cells with no treatment. Image F2 in the Figure 5.12(A and B) shows CaCo-2 and 
HT-29 cells treated with Nile red-coated CAPE-loaded albumin NP. The images in 
F1 depicts nucleus without any treatment, however, images in F2 exhibit 
nanoparticles labeled with Nile Red observed under the microscope in both the 
Figure 5.12(A and B). The merged images in F1 represent nucleus only although 
fluorescent nanoparticles can be seen around the nucleus in F2 of both the merged 
images. 
 
5.5.13 In-vitro cytotoxicity assay 
The cytotoxicity study was performed by methods as described in Section 2.13. The 
cytotoxic potential of free CAPE and CAPE-loaded albumin NP was evaluated by 
method demonstrated by (Kumar et al., 2014). The cytotoxic study of free CAPE and 
CAPE-loaded albumin NP was carried by MTT assay for a period of 24, 48, 72 and 
96 hours. The data showed that the blank NP had no cytotoxic action on colorectal 
cell lines within the concentration used. Free CAPE and CAPE-loaded albumin NP 
demonstrate dose dependent response to cytotoxicity. The cell death has been 
observed after the first day in CaCo-2 and HT-29 cells upon treatment with free 
CAPE and CAPE-loaded albumin NP. However, the cytotoxic activity was reported 
more in CAPE-loaded albumin NP treated cells as shown in the Figure 5.13(A and 
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B). The cytotoxic activity of CAPE-loaded albumin NP was significantly increased 
as compared to free CAPE in both cell lines after 96 hours of treatment.   The cell 
viability was found to be 88% and 85% when CaCo-2 cells treated with free CAPE 
and CAPE-loaded albumin NP respectively after 24 hours of treatment at highest 
concentration i.e. 7.5µg/ml. Similarly, the viability of cell was reported to be 56% 
and 46% at same concentration after 96 hours respectively. Moreover, cell viability 
in HT-29 was demonstrated to be 91% and 75% upon treatment with free CAPE and 
CAPE-loaded albumin NP at 7.5µg/ml concentration after 24 hours respectively. 
Likewise, the viability of HT-29 was decreased to 57% and 41% at same 
concentration after 96 hours respectively. 
CAPE-loaded albumin NP sustained the cytotoxic action of the free drug due to the 
enhanced penetration and retention effect inside the colorectal cells (Patil et al., 
2009., Chavanpatil et al., 2006). It also improved the solubility which in turn 
enhances the half-life and bioavailability (Mittal et al., 2007., Anand et al., 2010) 
due to reducing the particle size of CAPE. Therefore, based on the above data it can 
be concluded that CAPE-loaded albumin NP enhances the cytotoxicity potential due 
to a reduction in particle size, which suggest that albumin nano-particulate 
formulation enhances the biological therapeutic efficacy of CAPE over free CAPE. 
 
5.5.14 Migration assay 
The migration study was carried out in CaCo-2 and HT-29 as stated in Section 2.14. 
A cancer cell has potential to migrate from one tumour site to another (Friedl and 
Wolf, 2003).   Both the cell lines were treated with 7.5 µg/ml of CAPE-loaded 
albumin NP and same amount of free CAPE for 72 hours.  Figure 5.14 and Figure 
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5.15 shows the evaluation of the degree of wound closure in CaCo-2 and HT-29 
cells. CAPE-loaded albumin NP treated cells have greater void space (P<0.05) than 
free CAPE treated cells as shown in the Figure 5.14A and Figure 5.15A after 72 
hours of treatment. Approximately 76% wound closure was observed when CaCo-2 
cells were treated with 7.5 µg/ml of CAPE-loaded albumin NP. However, it was 
81% of wound closure in an equivalent amount of free CAPE as depicted in the 
graph of Figure 5.14B. Similarly, CAPE-loaded albumin NP also exhibits a 
significant difference (P<0.01) in wound closure as compared to free CAPE in HT-
29. Approximately 72% of wound closure was depicted by CAPE-loaded albumin 
NP but free CAPE illustrates 79% of wound closure in HT-29 cells at an equivalent 
dose as illustrated in the graph of Figure 5.15B. Therefore, CAPE-loaded albumin 
NP illustrates the significantly higher percentage of inhibition of migration potential 
in both cell lines. Whereas, free CAPE demonstrate the lower percentage of anti-
migration potential as compared to control and blank NP at the same dose. Hence, 
albumin nanoparticulate form sustained and improved the anti-migration capacity of 
CAPE which is essential to prevent metastasis of invasive colon cancer cells. 
 
5.5.15 Colony formation assay 
The colony formation assay was carried out as mentioned in section 2.15. Colony 
formation assay was carried out to determine and compare the long term anticancer 
activity of free CAPE and CAPE-loaded albumin NP as described by (Yeung et al., 
2010) in CaCo-2 and HT-29 cells. The colorectal cell lines were treated with 7.5 
µg/ml of CAPE-loaded albumin NP and free CAPE at equal concentration. The 
number of colonies formed after 7 days was calculated in control, blank NP, free 
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CAPE and CAPE-loaded albumin NP treatment under stereo zoom Nikon 
microscopy as shown in Figure 5.16A and Figure 5.17A. The colonies in healthy and 
blank NP treated group were found to be almost equal in both cell lines as shown in 
Figure 5.16A and Figure 5.17A. The number of colonies was significantly reduced 
when CaCo-2 cells treated with 7.5 µg/ml CAPE-loaded albumin NP (P<0.001) and 
an equivalent amount of free CAPE (P<0.01) compare to colonies in control and 
blank NP treated cells as shown in the graph of Figure 5.16B. An average number of 
colonies were found to be 29 when CaCo-2 cells treated with free CAPE whereas it 
was only 14 colonies observed in CAPE-loaded albumin NP treatment in CaCo-2 
cells.  Likewise, the number of colonies was significantly reduced when HT-29 cells 
treated with 7.5 µg/ml of CAPE-loaded albumin NP (P<0.001) an equivalent amount 
of free CAPE (P<0.001) compare to colonies in control and blank NP treatment as 
shown in the graph of Figure 5.17B. The average number of colonies was reported to 
be 29 in free CAPE treatment whereas it the average number of colonies was 10 in 
CAPE-loaded albumin NP treatment in HT-29 cells as shown in the figure. 
 
5.5.16 Invasion assay 
The procedure for invasion assay was described in Section 2.16. Anti-invasive 
activity of CAPE-loaded albumin NP and free CAPE was evaluated on colorectal 
cancer cell lines such as CaCo-2 and HT-29 as describe by (Yuen et al., 2013). 
Colon cancer cells were treated with 7. 5 µg/ml of CAPE-loaded albumin NP and an 
equivalent amount of free CAPE. The anti-invasive potential of CAPE-loaded 
albumin NP was higher than free CAPE treatment in both cell lines as shown in 
Figure 5.18B and Figure 5.19B. CAPE-loaded albumin NP show significant 
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(p<0.05) reduction in invasion potential (36%) than free CAPE (55%) in CaCo-2 
cells as demonstrated in graph of Figure 5.18B. Similarly, CAPE-loaded albumin NP 
show significantly (p<0.01) lower degree of invasion inhibition (33 %) than free 
CAPE (61%) in HT-29 cells as shown in Figure 5.19B. The above data demonstrate 
that CAPE-loaded albumin NP inhibit the invasion capacity of invasive colon cancer 
cells. CAPE-loaded albumin NP sustained and improved the anti-invasive power of 
CAPE which is essential to inhibit metastasis of invasive colorectal cancer cells. 
 
5.5.17 Quantification of p65 
The cell lysates were analyzed for p65 as described in Section 2.17. The fluorescent 
images of CaCo-2 (Figure 5.20A) and HT-29 (Figure 5.21A) were captured under 
bright field microscope after staining the cells with p65 antibody. Both the cell line 
was treated with 7.5 µg/ml dose of CAPE-loaded albumin NP and an equivalent 
amount of free CAPE. The induced level of NF-kβ such as p65 can be noticed in the 
control and blank NP as shown in the microscopic images in Figure 5.20A and 
Figure 5.21A. However, the group was treated with free CAPE and CAPE-loaded 
albumin NP show a noticeable difference in the level of p65. Additionally, CaCo-
2(Figure 5.20B) and HT-29 (Figure 5.21B) treated with CAPE-loaded albumin NP 
show significantly low expression of p65 than free CAPE. The graphs in the Figure 
5.20B (CaCo-2) and Figure 5.21B (HT-29) demonstrate a higher level of p65 in 
control and blank NP groups. CAPE-loaded albumin NP (P<0.01) depicts the low 
level of p65 protein than blank nanoparticles. The expression of p65 was 
significantly (P<0.001) lower than a free CAPE transfected cell in CaCo-2 as shown 
in the Figure 5.20B. Similarly, CAPE loaded nanoparticles decrease the p65 
A  B  
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expression significantly (P<0.05) than free CAPE in HT-29 as represented in the 
Figure 5.21B. 
 
5.5.18 Quantification of HIF-1α 
The CaCo-2(Figure 5.22A) and HT-29 (Figure 5.22B) were stained with HIF-1α 
antibody and observed under bright field microscope to study the effect of PIC 
treatment as shown in the Figure 5.22. The CaCo-2 and HT-29 cell line were treated 
with 7.5 µg/ml dose of CAPE-loaded albumin NP and an equivalent amount of free 
CAPE. The plates were incubated for 24 hours and the level of HIF-1α was observed 
under a microscope. The increased expression of HIF-1α was reported as shown in 
the images of Figure 5.22A (CaCo-2) and Figure 5.22B (HT-29). The overstimulated 
expression of HIF-1α was found in control and cells transfected with blank NP in 
both cell lines as depicted in the Figure 5.22(A and B). Though the group was treated 
with free CAPE and CAPE-loaded albumin NP show a noticeable difference in the 
level of HIF-1α in the Figure 5.22(A and B). Furthermore, CaCo-2(Figure 5.22A) 
and HT-29 (Figure 5.22B) treated with CAPE-loaded albumin NP show significantly 
low expression of HIF-1α than free CAPE. 
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5.5.1 Calibration of CAPE. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Calibration curve of CAPE 
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5.5.2 Effect of ethanol 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: Effect of ethanol amount on particle size (A), polydispersity index (B) and zeta 
potential (C). The above graph shows the effect of ethanol amount on Particle size (A), 
polydispersity index (B) and zeta potential (C). It was reported that ethanol amount does not 
have any significant effect on particle size, polydispersity index and zeta potential. Values 
are mean ± SEM (n = 3). 
 
 
B  A  
C
  
0.00
0.05
0.10
0.15
0.20
4 ml 8 ml 12 ml
P
o
l
y
d
i
s
p
e
r
s
b
i
l
i
t
y
 i
n
d
e
x
0
100
200
300
400
4 ml 8 ml 12 ml
P
a
r
t
i
c
l
e
 s
i
z
e
 (
n
m
)
-25
-20
-15
-10
-5
0
4 ml 8 ml 12 ml
Z
e
t
a
 P
o
t
e
n
t
i
a
l
 (
m
V
)
125 
 
5.5.3 Concentration of albumin 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: Effect of albumin concentration on particle size (A), polydispersity index (B) 
and zeta potential (C). The above graph represents the effect of increasing albumin 
concentration on Particle size (A), polydispersity index (B) and zeta potential (C). It was 
demonstrated that increase in albumin concentration leads to increase in particles size as 
well as polydispersity index significantly. It increases significantly (P<0.001) when albumin 
concentration increases from 0.5% to 2%.  However, it does not have any significant effect 
on zeta potential. Values are mean ± SEM (n = 3). *P<0.05, **P<0.01 and ***P<0.001 
compared with 2% albumin concentration. 
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5.5.4 Effect of Glutaraldehyde concentration 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4: Effect of increasing concentration of crosslinking agent on particle size (A), 
polydispersity index (B) and zeta potential (C). The above graph represents the effect of an 
increase in glutaraldehyde concentration on Particle size (A), polydispersity index (B) and 
zeta potential (C). Increase in glutaraldehyde concentration leads to significant (P<0.001) 
increases in particle size). However, polydispersity index decreases upon an increase in 
glutaraldehyde concentration. Similarly, increasing concentration of glutaraldehyde does not 
have any significant effect on zeta potential. Values are mean ± SEM (n = 3). **P<0.01 and 
***P<0.001 compared with 8% glutaraldehyde concentration. 
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5.5.5 Amount of drug 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5: Effect of increase in drug amount on particle size (A), polydispersity index (B) 
and zeta potential (C). The above graph shows the effect of drug amount on Particle size 
(A), polydispersity index (B) and zeta potential (C). It is evident from the above graph that 
increases in CAPE amount slightly increase the particle size and PDI. Zeta potential 
increases upon an increase in CAPE amount although show significant increase (P<0.01). 
Values are mean ± SEM (n = 3). **P<0.01. 
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5.5.6 NMR spectra of CAPE-loaded albumin NP 
 
 
 
 
 
 
 
 
 
Figure 5.6: H NMR of CAPE in albumin nanoparticles. The above H NMR confirms the 
CAPE stucture in the nanoparticle form. 
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5.5.7 Entrapment efficiency 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7: Effect of albumin concentration (A) and drug amount (B) on entrapment 
efficiency. The above graph illustrates effect albumin concentration (A) and drug content 
(B) on entrapment efficiency. Figure 5.7A in the above graph exhibit significant difference 
(P<0.001) when albumin concentration increases from 0.5% to 2%, however, entrapment 
does not exhibit any change upon further increase in albumin concentration. Figure 5.7B in 
the above graph illustrates the significant decrease in entrapment efficiency (p<0.01) as the 
drug amount increases from 10 mg to 20 mg but it does not have any significant effect when 
further increases to 30 mg. Values are mean ± SEM (n = 3). **P<0.01 and ***P<0.001 
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5.5.8 Percentage yield 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8: Effect of albumin concentration (A) and drug amount (B) on percentage yield. 
The above graph depicts effect albumin concentration (A) and drug content (B) on 
percentage yield. Figure 5.8A in the above graph demonstrates a significant difference 
(P<0.001) in percentage yield when albumin concentration increases from 0.5% to 2%, 
however, percentage yield slightly increases upon further increase in albumin concentration. 
Figure 5.8B in the above graph shows no significant difference as the amount of drug 
increases. Values are mean ± SEM (n = 3). ***P<0.001 
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5.5.9 In-vitro release 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9: Effect of albumin concentration (A) and drug amount (B) on in-vitro release 
profile. The above graph illustrates burst release after 24. The above graph depicts that 
increase in albumin and drug concentration leads to decrease the in-vitro of CAPE release 
from the formulation. Values are mean ± SEM (n = 3). 
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5.5.10 Solubility of CAPE-loaded albumin NP 
 
 
 
 
 
 
 
 
 
 
Figure 5.10: Water solubility of CAPE-loaded albumin NP (A) and free CAPE (B). The 
vials in Figure 5.10A and Figure 5.10B show the solubility of CAPE-loaded albumin NP and 
free CAPE, respectively. A Clear solution of CAPE-loaded albumin NP in Figure 5.10A and 
turbid free CAPE in Figure 5.10B can be observed. 
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5.5.11 Scanning electron microscopy  
 
 
 
 
 
  
 
 
 
 
 
 
Figure 5.11: Scanning Electron Microscopy of CAPE-loaded albumin NP. The above 
Figure 5.11 represents SEM imaging of free CAPE, the batch containing 10 mg (F1), 20 mg 
(F2), and 30 mg (F3) of CAPE in the formulation. Batch formulated with 10 mg CAPE 
represents smaller particles size whereas batch fabricated with 30 mg CAPE shows larger 
particle size. F1 also demonstrate uniformity in size although F2 and F3 exhibit partial 
uniformity. 
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5.5.12 Cellular uptake of CAPE-loaded albumin NP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12: Cellular uptake of optimised CAPE-loaded albumin NP in CaCo-2 and HT-29 
cells 100X. Cellular localization of Nile red-coated CAPE-loaded albumin NP was observed 
in CaCo-2 (A) and HT-29 (B) cells and visualized by overlapping under fluorescent 
microscopy. 
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5.5.13 In-vitro cytotoxicity assay 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.13: Effect of CAPE-loaded albumin NP and free CAPE on cytotoxicity of CaCo-2 
(A) and HT-29 (B) cell lines. The cytotoxicity assay was performed on CaCo-2 (A) and HT-
29 (B) cell lines. 40×104 cells were seeded on 24 well plates and treated with 2.5 µg/ml, 5 
µg/ml and 7.5 µg/ml of CAPE-loaded albumin NP and an equivalent amount of free CAPE. 
The absorbance was measured after 24 hours, 48 hours, 72 hours and 96 hours. CAPE-
loaded albumin NP shows higher cell cytotoxicity as compare to free CAPE. Values are 
mean ± SEM (n = 3). . **P<0.01 compared with same amount of free drug 
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5.5.14 Migration assay  
 
  
 
 
 
 
 
 
 
 
 
 
Figure 5.14: Effect of CAPE-loaded albumin NP and free CAPE on migration potential of 
CaCo-2 cell lines. The above images in the Figure 5.14A (CaCo-2) demonstrate the effect of 
free CAPE and CAPE-loaded albumin NP on wound closure after 72 hours of treatment. 
CAPE-loaded albumin NP demonstrate more void space than free CAPE in wound scratch 
of both cell line as compare to control and blank NP. The graph 5.14B (CaCo-2) depicts a 
significant variation of anti-migration activity of free CAPE and CAPE-loaded albumin NP 
after 72 hours of treatment at equal dose. CAPE-loaded albumin NP demonstrate significant 
low migration rate in CaCo-2 P<0.01) than control. Furthermore, CAPE-loaded albumin NP 
has less migration rate in CaCo-2 (P<0.05) than free CAPE. Values are mean ± SEM with 
n=3. **P<0.01 compared with blank NP. ΔP<0.05 compared with the same dose of the free 
PIC. 
C
o
n
tr
o
l 
B
la
n
k
 N
P
 
C
A
P
E
 N
P
 
72 Hours 
F
re
e 
C
A
P
E
 
A  
0
20
40
60
80
100
Control
Blank NP
Free CAPE 7.5 g/ml
CAPE loaded albu-NP 7.5 g/ml
0 Hour 72 Hours
**
** 
%
 W
o
u
n
d
 c
lo
s
u
r
e
B  
137 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.15: Effect of CAPE-loaded albumin NP and free CAPE on migration potential of 
HT-29 cell lines. The above images in the Figure 5.15A (HT-29) illustrate the effect of free 
CAPE and CAPE-loaded albumin NP on wound closure after 72 hours of treatment. CAPE-
loaded albumin NP demonstrate more void space than free CAPE in wound scratch of both 
cell line as compare to control and blank NP. The graph 5.15B (HT-29) depicts a significant 
variation of anti-migration activity of free CAPE and CAPE-loaded albumin NP after 72 
hours of treatment at equal dose. CAPE-loaded albumin NP demonstrate significant low 
migration rate in HT-29(P<0.01) than control. Furthermore, CAPE-loaded albumin NP has 
less migration rate in HT-29(P<0.01) than free CAPE. Values are mean ± SEM with n=3. 
*P<0.05 and **P<0.01 compared with blank NP. ΔΔP<0.01 compared with the same dose of 
the free PIC. 
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5.5.15 Colony formation assay  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.16: Effect of CAPE-loaded albumin NP and free CAPE on colony formation 
ability of CaCo-2 cell lines. The above images in the Figure 5.16A (CaCo-2) demonstrate a 
pattern of colon formation in control, blank NP, free CAPE and CAPE-loaded albumin NP 
treated the group as demonstrated in the microscopic image. It is evident from the images 
that CAPE-loaded albumin NP shows significant less number of colonies than the control 
group in CaCo-2. The graph 5.16B (CaCo-2) represents significant variation in colony 
formation upon treatment CAPE-loaded albumin NP than the control group in CaCo-2 
(P<0.001). It can be seen from the above graph that CAPE-loaded albumin NP shows less 
number of colonies than free CAPE in CaCo-2 (P<0.05). Values are mean ± SEM with n=3.  
**P<0.01 and ***P<0.001 compared with blank NP. ΔP<0.05 compared with the same dose 
of the free PIC. 
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Figure 5.17: Effect of CAPE-loaded albumin NP and free CAPE on colony formation 
ability HT-29 cell lines. The above images in the Figure 5.17A (HT-29) demonstrate a 
pattern of colon formation in control, blank NP, free CAPE and CAPE-loaded albumin NP 
treated the group as demonstrated in the microscopic image. It is evident from the images 
that CAPE-loaded albumin NP shows significant less number of colonies than the control 
group in HT-29. The graph 5.17B (HT-29) represents significant variation in colony 
formation upon treatment CAPE-loaded albumin NP than the control group in HT-29 
(P<0.001). It can be seen from the above graph that CAPE-loaded albumin NP shows less 
number of colonies than free CAPE in HT-29 (P<0.001). Values are mean ± SEM with n=3.  
**P<0.01 and ***P<0.001 compared with blank NP. ΔΔΔP<0.001 compared with the same 
dose of the free PIC. 
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5.5.16 Invasion assay  
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Figure 5.18: Effect of CAPE-loaded albumin NP and free CAPE on invasion potential of 
CaCo-2 cell lines. The above images in the Figure 5.18A (CaCo-2) represents a microscopic 
depiction of anti-invasive activity of free CAPE and CAPE-loaded albumin NP after of 
treatment. CAPE-loaded albumin NP (P<0.05) shows significantly less percentage of 
invasion than free CAPE (P<0.001). CAPE loaded NP reduced the percentage of invasion 
potential significantly in CaCo-2 (P<0.05) than free CAPE as shown in the graph 5.18B. The 
cells which appear bright are the one which invaded through the membrane.  Values are 
mean ± SEM with n=3. **P<0.01 and ***P<0.001 compared with blank NP. ΔP<0.05 
compared with the same dose of the free CAPE. 
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Figure 5.19: Effect of CAPE-loaded albumin NP and free CAPE on invasion potential of 
HT-29 cell lines. The above images in the Figure 19A (HT-29) represents a microscopic 
depiction of anti-invasive activity of free CAPE and CAPE-loaded albumin NP after of 
treatment. CAPE loaded NP reduced the percentage of invasion potential significantly in 
HT-29 (P<0.01) than free CAPE as shown in the graph 5.19B. The cells which appear bright 
are the one which invaded through the membrane.  Values are mean ± SEM with n=3. 
***P<0.001 compared with blank NP. ΔΔ P<0.01 compared with the same dose of the free 
CAPE. 
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5.5.17 Quantification of p65  
 
 
 
 
 
 
 
 
 
 
 
       
 
 
Figure 5.20: Effect of CAPE-loaded albumin NP and free CAPE on expression p65 in 
CaCo-2 at 40X. The above image in the Figure 5.20A (CaCo-2) was taken under bright field 
microscope. Control and blank images show induction of p65 whereas image under the free 
CAPE and CAPE-loaded albumin NP show a reduced level of p65. Figure 5.20B 
demonstrate a significant reduced level of p65 in CaCo-2 (P<0.01)) as compare to control. 
CAPE-loaded albumin NP also illustrate the significant low level of p65 in CaCo-
2(**P<0.01) than free CAPE. Values are mean ± SEM with n=3. **P<0.01 compared to 
equal amount of free CAPE.  ΔΔΔP<0.001 compared to the same amount of free CAPE. 
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Figure 5.21: Effect of CAPE-loaded albumin NP and free CAPE on expression p65 in HT-
29 at 40X. The above image in the Figure 5.21A (HT-29) was captured under bright field 
microscope. Control and blank images show induction of p65 whereas image under the free 
CAPE and CAPE-loaded albumin NP show a reduced level of p65. Figure 5.21B 
demonstrate a significant reduced level of p65 in HT-29 (P<0.001) as compare to control. 
CAPE-loaded albumin NP also illustrate the significant low level of p65 in HT-29 (P<0.05) 
than free CAPE. Values are mean ± SEM with n=3. **P<0.01 and ***P<0.001 compared to 
equal amount of free CAPE. ΔP<0.05 compared to the same amount of free CAPE. 
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5.5.18 Quantification of HIF-1α 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.22: Effect of CAPE-loaded albumin NP and free CAPE on expression HIF-1α in 
CaCo-2 (Figure 5.22A) and HT-29 (Figure 5.22B) at 40X. The above control and blank 
images show induction of HIF-1α whereas images under free CAPE and CAPE-loaded 
albumin NP show a reduced level of HIF-1α. 
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5.6 Discussion 
Effect of solvent concentration, albumin concentration, glutaraldehyde and amount 
of drug on as particle size, zeta potential, and polydispersity were observed. Increase 
concentration of ethanol has no significant effects on particle size, polydispersity 
index and zeta potential. Formulation of nanoparticles with increase concentration 
albumin depicts an increase in particle size, polydispersity index and zeta potential 
significantly as demonstrated in Figure 5.3. Increase in density of albumin solution 
upon increasing the albumin concentration may responsible for the increase in 
particle size of nanoparticles. Higher concentration of glutaraldehyde has a similar 
effect as the albumin centration on nanoparticles as represented in Figure 5.4. 
Particle size increases significantly with increase in concertation of the crosslinking 
agent. However, it does not have any significant effect on polydispersity and zeta 
potential. Nanoparticles shows an increase in particle size with increase drug amount 
in the formulation as exhibited in Figure 5.5. Although it does not depicts any 
significant difference in particle size, zeta potential and polydispersity index. 
Increase in viscosity of drug solution due to increase in the drug amount play vital 
role in increasing the particle size of nanoparticles. We have done NMR 
spectroscopy of CAPE to confirm the purity of drug in nanoparticles as illustrated in 
Figure 5.6. We have also evaluated the effect of albumin concentration and CAPE 
amount on entrapment efficiency and percentage yield as shown in Figure 5.7 (A and 
B) and Figure 5.8 (A and B). The entrapment efficiency and percentage yield 
increase significantly as the amount of albumin increases. This because the 
availability of more amount of albumin to encapsulate the same amount of CAPE in 
the formulation. Similarly, effect of albumin concentration and CAPE amount on in-
vitro release was reported as illustrated in the Figure 5.9 (A and B). The data 
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obtained elucidate increase in in-vitro release pattern upon increasing albumin 
concentration and CAPE amount due to larger particles of nanoparticles. 
Figure 5.10 express comparison of solubility of CAPE-loaded albumin NP (A) and 
free CAPE (B). Figure 5.10A shows the clear solution of CAPE-loaded albumin NP 
which is due to increase in solubility. Whereas, Figure 5.10B represents the turbid 
solution of free CAPE in water. Twofold increase in aqueous solubility in CAPE-
loaded albumin NP was documented as compare to free CAPE. The morphology of 
free CAPE and nanoparticles of CAPE was evaluated by SEM as shown in the 
Figure 5.11. Solid crystal and large structure of free CAPE was reported by SEM 
imaging. However, spherical and smooth appearance of the nanoparticle was found 
under SEM. Though, increase in particle size can be observed as the CAPE amount 
increases. 
Images F1 in the Figure 5.12(A and B) display CaCo-2 and HT-29 stained with 
DAPI whereas image F2 exhibit localization of CAPE-loaded albumin NP labeled 
with Nile Red in CaCo-2 and HT-29 under a fluorescent microscope. The 
anticipation of Nile Red labeled CAPE-loaded albumin NP in CaCo-2 and HT-29 
establish that nanoparticles are easily taken by cells. Figure 5.13 interpret the effect 
of different dose of free CAPE and CAPE-loaded albumin NP in CaCo-2 (A) and 
HT-29 (B) cells. Decrease event of proliferation was noted with CAPE-loaded 
albumin NP as compare to free CAPE in colorectal cancer cell. 
Figure 5.14A and Figure 5.15A shows microscopic images of migrating cancer cells 
at 0 hours and 72 hours. Both the microscopic appearance shows a decline in 
migration after treatment with CAPE-loaded albumin NP in CaCo-2 and HT-29 as 
compare to free CAPE at 72 hours. Graph in the Figure 5.14A and Figure 5.15A in 
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shows significant reductions in the migration of cancer cell after 72 hours. Figure 
5.16A and Figure 5.17A also represent a microscopic picture of colony formation of 
control, blank NP, free CAPE and CAPE-loaded albumin NP groups in CaCo-2 and 
HT-29 cells. A number of the colony was found to be higher in control, blank NP 
group in both cell lines. However, decrease in colonies can be seen in CAPE-loaded 
albumin NP as compare to free CAPE in both cell line. Graph in the Figure 5.16B 
and 5.17B also confirmed significant reductions in colony formation for CaCo-2 and 
HT-29 cancer cells. 
Figure 5.18A and Figure 5.19A are the representative images from invasion assay in 
CaCo-2 and HT-29 cells captured under a fluorescent microscope. The more number 
of fluorescent cells can be monitored in control and blank NP group as visible in 
Figure 5.18A and Figure 5.19A. However, very few bright cells detected in CAPE-
loaded albumin NP as compare to free CAPE. A significant decrease in invasion was 
reported with CAPE-loaded albumin NP treated cells than free CAPE in CaCo-2 and 
HT-29 as depicted in graph of Figure 5.18B and Figure 5.19B. 
Induction of p65 can be recognized in control and blank NP group in CaCo-2 and 
HT-29 as shown in the Figure 5.20A and Figure 5.21A under a bright field 
microscope. Although a low level of p65 was be observed in CAPE-loaded albumin 
NP than free CAPE in both cell line as represented in the graph of Figure 5.20B and 
Figure 5.21B. Similarly, low expression of HIF-1α was monitored in cells treated 
with CAPE-loaded albumin NP as shown in the Figure 5.22(A and B). 
Hence the reduction in particle size has increases the solubility of low soluble natural 
compound CAPE in nanoparticle form. Nanoparticles down-regulate over activation 
of p65 (RelA) and HIF-1α levels to a higher extent than free CAPE in colorectal 
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cancer cell lines.   Thus, CAPE nanoparticles increased the therapeutic value of the 
natural anticancer agent via suppression of overactivation of NF-kβ and HIF 
pathways during cancer. 
Hence, the findings from this work conclude that nanotechnology could be an 
effective tool to enhance the anticancer activity of several natural and/or novel 
anticancer compounds, which are currently not in clinical use due to their low 
solubility and/or poor bioavailability. 
 
5.7 Conclusion 
The findings from this chapter show that PIC-loaded albumin nanoparticles can be 
fabricated by desolvation technique. Final and optimised batch of NPs were selected 
by optimization and characterization processes to carry out an in-vitro evaluation in 
cancer cell lines. Result from cell proliferation assay showed a dose-dependent 
relationship with proliferation in CaCo-2 and HT-29 cells and ascertained that 
CAPE-loaded albumin NP resulted in less cell proliferation than free CAPE in 
cancer cells lines. CAPE-loaded albumin NP controls migration, colony formation 
and invasion in cancer cells more effectively than free CAPE. CAPE loaded albumin 
reduces the overexpressed level of p65 and HIF-1α higher extent that free CAPE.  
Therefore, CAPE-loaded albumin NP delivery may be of therapeutic potential in 
cancer treatment. 
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Chapter 6 
Albumin nanoparticles loaded with PIC/CAPE are protective in 
experimentally induced colitis via modulation of p65 and HIF-1α 
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6.1 Introduction 
Ulcerative colitis (UC) and Crohn’s disease (CD) are gastrointestinal ailments 
termed as inflammatory bowel disease (IBD) with no specific treatment (Ma et al., 
2017a., Deiana et al., 2017., Karreman et al., 2017). UC and CD have common 
symptoms such as weight loss, diarrhoea, rectal bleeding, and abdominal cramp 
(Peyrin-Biroulet et al., 2010., Jordan et al., 2016).  However, both disorders differ in 
location, UC is sequestered in the large intestine (Sullivan et al., 2017) and CD may 
occur anywhere in the gastrointestinal tract(Vezza et al., 2016). Both disease cause a 
cryptic abscess and alteration in mucosal layer (Vezza et al., 2016).  The exact 
etiology of IBD is not clear but factors such as aberrant immunity, environmental 
factor, genetic disorder and dysregulation of the mucosal layer are responsible for 
colitis (Nitzan et al., 2016., Lane et al., 2017).These factors result in mucosal layer 
hypoxia and cause overactivation of hypoxia-inducible factor 1 (HIF-1α) and nuclear 
factor kappa beta (NF-kβ) (Taylor and Colgan, 2007., Taylor and Cummins, 2009). 
Moreover, an elevated level of HIF-1α and NF-kβ has been documented in human 
colitis (Ma et al., 2016).   
More than 50% of IBD patients develop ulcerative colitis (Tan et al., 2017a). The 
associated healthcare cost is a major burdens for IBD patients in countries like USA, 
Europe, and Asian countries (Singh et al., 2017a., Savani et al., 2017) (Davies et al., 
2017., Dan et al., 2017., Wilson et al., 2017., de et al., 2017). Damaged mucosal 
layer is the main cause of ulcerative colitis (Boal Carvalho and Cotter, 2017., 
Capaldo et al., 2017). The predominant therapies used in the management of 
ulcerative colitis such as amino-salicylic acid, corticosteroids, 6-mercaptopurines, 
azathioprine, cyclosporine, infliximab have several side effects on skin, eyes, muscle 
etc. (Taylor and Gibson, 2017., Danese et al., 2017). These therapeutics also induce 
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bone marrow depletion, lung disorders, liver and pancreas disease (Chumanevich et 
al., 2017., Khan et al., 2017c). Additionally, these treatments are not only non-
selective but also impair lifestyle due to repeated use for a long time (Xiao et al., 
2017., Larussa et al., 2017). Therefore, these therapeutics are not effective in treating 
ulcerative colitis due to which patients have to bear invasive surgeries in chronic 
conditions to prevent further complication such as colon cancer (Abdalla et al., 
2017). 
Novel agents, such as monoclonal antibodies, protease inhibitors, and anti-TNF-α 
compounds have been widely used in the treatment of ulcerative colitis (Vergnolle, 
2016., Martelli et al., 2017). However, these agents also have limitation due to side 
effects, like liver damage, heart disease, infectious disease, skin disease and 
degenerative disorder. (Moćko et al., 2016., Larussa et al., 2017). Therefore, the 
existing treatment option does not offer a permanent cure for ulcerative colitis. The 
associated side effects make it less favourable and non-selectivity reduces the 
efficacy of these treatments. The cost of disease management further violates the 
financial condition of patients (Chumanevich et al., 2017). 
Therefore, there is an urgent need for alternative therapeutics to treat ulcerative 
colitis which provide better healing, increased specificity, reduce side effect, are cost 
effective and patient friendly. A number of natural compounds such as curcumin, 
CAPE and PIC have been recently evaluated for their therapeutic potential against 
ulcerative colitis (Khan et al., 2017c., Chen et al., 2017., Shen et al., 2017). These 
natural compounds possess antioxidant property, stabilize free radicals, control 
inflammation and inhibit over stimulation of NF-kβ and HIF-1α (Yum et al., 2015., 
Alves de Almeida et al., 2017., Kocaadam and Şanlier, 2017). These natural 
compounds modulate overexpression of NF-kβ by inhibiting pro-inflammatory 
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mediators in colitis (Li et al., 2017., Rafa et al., 2017). They prevent the binding of 
NF-kβ with DNA or inhibition of Ikβ in the cytoplasm (Gu et al., 2017). 
The natural compound are effective against a number of diseases however, low 
solubility and poor permeability limit the efficacy of these compounds (A Aljuffali et 
al., 2016.,  Namdari et al., 2017., Loureiro et al., 2017). The phenolic nature of 
herbal compound is responsible for their therapeutic efficacy against several disease 
(Huang et al., 2010).  However, it has been documented that phenolic compound is 
poorly soluble in aqueous media thereby limiting their efficacy. (Queimada et al., 
2009). Therefore, application of nanotechnology may enhance solubility, 
bioavailability and therapeutic effectiveness of natural compound. In the current 
research, nanoparticles of PIC CAPE were formulated. Albumin was used as nano-
carrier to deliver PIC and CAPE because of its ability stabilizes plasma pH, alleviate 
osmotic pressure, and efficient delivery of  proteins to cells (Singh et al., 2017c). 
Albumin nanoparticle is easily taken by damaged tissues due to inflammation at the 
mucosal site (Kinoshita et al., 2017.,  Jiang et al., 2017). 
Based on the accumulating evidence, effect of albumin nanoparticles on mouse 
model of colitis has not been studying till date. Therefore, in the present work we 
have demonstrated and measured effect of albumin nanoparticles of PIC, CAPE and 
free drugs in mouse (C57BL\6) model of colitis. 
 
6.2 Summary 
Based on the detrimental effect of ulcerative colitis and to avoid side effects of 
current treatments, there is demand to utilize natural and novel anti-inflammatory 
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compounds such, as PIC and CAPE, to treat ulcerative colitis. Although these 
compounds have limited solubility in aqueous media, the use of nanotechnology can 
enhance the solubility of these natural anti-inflammatory compounds. Coacervation 
methods will be employed to formulate NPs loaded with PIC and CAPE using 
albumin as a polymer. These albumin NPs will be tested in colitis induced C57BL\6 
mice. 
 
6.3 Hypothesis  
In this chapter, we hypothesize that the reduction of particle size of the natural 
anticancer compound will improve the anti-inflammatory property of PIC and CAPE 
at a higher extent than free PIC and CAPE. 
 
6.4 Aims and objectives  
• Formulation of PIC and CAPE loaded albumin nanoparticles 
• Optimisation of PIC and CAPE loaded albumin nanoparticles 
• Evaluation of anti-inflammatory properties of PIC and CAPE loaded albumin 
nanoparticles in colitis induce C57BL\6 mice 
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6.5 Results 
6.5.1 PIC and CAPE-loaded albumin NP alleviate weight loss and DAI induced by 
DSS  
Mice were assigned to four groups, comprising healthy subjects, DSS treated, free 
drug treated (PIC and CAPE) and NP treated (PIC and CAPE-loaded albumin NPs). 
Colitis was induced with 2.5% DSS as mentioned in section 2.19. Intraperitoneal 
injection of 20 mg/kg of free drug (PIC and CAPE) and equivalent amount of NP 
was administered in distilled water to mice.  The mice under free and NP controls 
also received 2.5% DSS in drinking water. The symptoms of colitis such as 
diarrhoea, weight loss and blood in faeces were reported as composite score of 
disease activity index (DAI).  After dissection weight and shortening in the colon 
was observed (Ogawa et al., 2004., Taghipour et al., 2016., Chassaing et al., 2014b., 
Chen et al., 2007). 
Comparative defense activity of nanoparticles (PIC and CAPE) and free drugs (PIC 
and CAPE) was studied on C57BL\6 mice for six days. Documentation of weight of 
each mouse in all the group were carried out.  PIC and CAPE-loaded albumin 
NP+DSS group demonstrate significantly (P<0.001) less weight loss as compared to 
free PIC+DSS, free CAPE+DSS and DSS alone groups as depicted in the percentage 
weight loss graph in Figure 6.1A and 6.2A. 
Additionally, PIC and CAPE-loaded albumin NP+DSS group exhibit significant 
(P<0.05) lower DAI score than free PIC+DSS, free CAPE+DSS and DSS alone 
group as represented in the DAI graph in the Figure 6.1B and 6.2B.  
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The above finding suggests that PIC and CAPE-loaded albumin NP improve the 
inflammatory symptoms such as diarrhoea, weight loss and blood in faeces 
compared to free PIC and CAPE. 
 
6.5.2 Change in colon length 
Shortening of colon length and alteration in colon structure are other characteristics 
of human colitis and DSS induced colitis in mice (Randhawa et al., 2014). In the 
current study, effect of free drugs (PIC and CAPE) and NP (PIC and CAPE) on 
colon length was observed as shown in Figure 6.3 and Figure 6.4. It was reported 
that colon length of mice treated with PIC and CAPE-loaded albumin NP was 
significantly (P<0.001) longer as compare to free PIC and CAPE treated group as 
shown in the Figure 6.3A and 6.4A. The stool in the healthy group appeared to be 
normal.  The stool in PIC and CAPE loaded NP was found to be semi solid and free 
form a blood clot. However, loose stool with a blood clot was found in the colon of 
the free PIC and CAPE, although colitis induced by DSS in mice showed blood clot 
and shorter colon length. PIC-loaded albumin NP illustrates significant (P<0.01) 
higher colon length than free PIC in Figure 6.3B. Similarly, CAPE-loaded albumin 
NP depicts significant (P<0.05) longer colon than free CAPE in Figure 6.4B. 
Therefore, above data propose that PIC and CAPE-loaded albumin NP prevents 
shortening of the colon more efficiently as compared to the free PIC and CAPE. 
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6.5.3 Wight of colon 
DSS, free PIC and free CAPE treated group exhibited approximately equal amount 
of weight of colon, however, PIC-loaded albumin NP showed significant low weight 
loss as compared to DSS (P<0.01) and free PIC (P<0.05) treated mice as shown in 
the Figure 6.5A.  A similar finding was reported by CAPE-loaded albumin NP 
treated mice. CAPE-loaded albumin NP demonstrated less weight loss as compared 
to DSS (p<0.01) and free CAPE (p<0.05) as illustrated in the Figure 6.5B. 
 
6.5.4 Histological investigation 
Staining of colonic tissue (haematoxylin and eosin) was performed as mentioned in 
section 2.19. Histological investigation of colonic epithelia treated with DSS 
demonstrated an alteration in structural integrity along with permeation of 
inflammatory markers inside the distorted epithelial layer. However, the degree of 
cryptic epithelial damage and infiltration of inflammatory cells was very low in PIC-
loaded albumin NP as compared to free PIC and DSS group as depicted in the Figure 
6.6A. A similar observation was reported in Figure 6.7A, where CAPE-loaded 
albumin NP treated mice showed less extent of epithelial damage and infiltration of 
neutrophils than DSS and free CAPE treated mice. The blinded tissue inflammation 
scores of colon tissue histology demonstrate a significant (P<0.001) reduction of 
colon damage in PIC and CAPE-loaded albumin NP treated mice relative to healthy 
control and free drugs mice as shown in Figure 6.6B and 6.7B. 
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6.5.5 Level of p65 in PIC and CAPE-loaded albumin NP tissue 
The colonic tissue was stained for p65 antibody to express the effect of NP (PIC and 
CAPE) and free drugs (PIC and CAPE) in colonic tissue as discussed in section 2.22. 
This protein was observed under bright field microscopy. The overstimulation of p65 
was reported in DSS treated mice as shown in the Figure 6.8(A and B). However, 
level of this proteins was reported to be low in PIC and CAPE-loaded albumin NP 
than the free drugs as depicted in Figure 6.8(A and B). 
 
6.5.6 Level of HIF-1α in PIC and CAPE-loaded albumin NP treated tissue 
The colonic tissue from mice was stained for HIF-1α antibody. High concentration 
of HIF-1α can be noticed in free drugs (PIC and CAPE) colonic tissue. However, 
tissues under NP (PIC and CAPE) exhibit low level of HIF-1α as observed in the 
Figure 6.9(A and B). 
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6.5.1.1 PIC -loaded albumin NP alleviate weight loss and DAI induced by DSS  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1: Lowered percentage weight loss (A) and DAI score (B) in mice treated with 
PIC-loaded albumin NP+DSS during DSS-induced colitis. PIC-loaded albumin NP treated 
group depicts low percentage in weight loss as compared to the free PIC. DAI of PIC-loaded 
albumin NP was found to be very low than to free PIC. N = 5-6 mice per group. *P<0.05 
and ***P<0.001 
 
 
A 
B 
0 1 2 3 4 5 6
0
2
4
6
8
10
Healthy
2.5%DSS
Free PIC (20mg/kg + 2.5%DSS )
PIC NP (20mg/kg + 2.5%DSS )
Days
D
is
e
a
se
 a
c
ti
v
it
y
 i
n
d
e
x
*
0 1 2 3 4 5 6
70
80
90
100
110
Healthy
DSS (2.5%)
Free PIC (20mg/kg + 2.5%DSS )
PIC NP (20mg/kg + 2.5%DSS )
Days
%
W
e
ig
h
t 
lo
ss
***
159 
 
6.5.1.2 CAPE -loaded albumin NP alleviate weight loss and DAI induced by DSS  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2: Lowered percentage weight loss (A) and DAI score (B) in mice treated with 
CAPE-loaded albumin NP+DSS during DSS-induced colitis. CAPE-loaded albumin NP 
treated group depicts low percentage in weight loss as compared to the free CAPE. DAI of 
CAPE-loaded albumin NP was found to be very low than to free CAPE. N = 5-6 mice per 
group. *P<0.05 and ***P<0.001 
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6.5.2.1 Change in colon length after treatment of PIC-loaded albumin NP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3: PIC-loaded albumin NP+DSS treatment is effective in protecting gross anatomy 
and colon length as compared to DSS group and free PIC. Gross appearance of the colonic 
anatomy shows the effect of PIC-loaded albumin NP+DSS, free PIC and DSS alone groups 
on colon shortening and formation of faecal pellets as shown in the Figure 6.3A. The colon 
of mice treated with PIC nanoparticles closely resembles colon of the healthy group. 
However, free PIC shows loose stool, blood in faeces and shorter colon length same as DSS 
treated group. N = 5-6 mice per group. *P<0.05 and ***P<0.001. ΔΔP<0.01. 
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6.5.2.1 Change in colon length after treatment of CAPE-loaded albumin NP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4: CAPE-loaded albumin NP+DSS treatment is effective in protecting gross 
anatomy and colon length as compared to DSS group and free PIC and CAPE group. Gross 
appearance of the colonic anatomy shows the effect of CAPE-loaded albumin NP+DSS, free 
CAPE and DSS alone groups on colon shortening and formation of faecal pellets as shown 
in the Figure 6.4A. The colon of mice treated with CAPE nanoparticles closely resembles 
colon of the healthy group. However, CAPE shows loose stool, blood in faeces and shorter 
colon length same as DSS treated group. Colon length was measured at post-mortem 
autopsy. N = 5-6 mice per group. ***P<0.001. ΔP<0.05. 
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6.5.3 Change in colon weight after treatment of PIC and CAPE-loaded albumin NP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5: Less weight loss in colon treated with PIC (A) and CAPE-loaded albumin 
NP+DSS (B) as compared to DSS group and free PIC and CAPE group. Mice treated with 
PIC and CAPE-loaded albumin NP+DSS group showed the similar weight of colon than the 
free PIC and DSS group as shown in the Figure 6.5A and 6.5B. N = 5-6 mice per group. 
**P< 0.01. ΔP<0.05.  
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6.5.4.1 Histological investigation after treatment of PIC-loaded albumin NP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6: Improved colon histological outcome in mice treated with PIC (A) loaded 
albumin NP+DSS and lower rate of inflammation score PIC (B). The cryptic structure in the 
epithelial layer of healthy, PIC-loaded albumin NP group is identical as shown in the Figure 
6.6A. However, infiltration of cytokines and the distorted epithelial layer can be recognized 
in the free PIC treated mice. DSS groups demonstrate similar trends of epithelial distortion 
as depicted in the Figure 6A. Significant (ΔΔΔP<0.0001) low inflammation was recorded in 
PIC-loaded albumin NP treated group as shown in the Figure 6.6B. N = 5-6 mice per group. 
*P<0.05 and ***P<0.001. . ΔΔΔP<0.001. 
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6.5.4.2 Histological investigation after treatment of CAPE-loaded albumin NP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7: Improved colon histological outcome in mice treated with CAPE-loaded 
albumin NP+DSS (7A) and lower rate of inflammation score (7B). The cryptic structure in 
the epithelial layer of healthy, CAPE-loaded albumin NP group is identical as shown in the 
Figure 6.7A. However, infiltration of cytokines and the distorted epithelial layer can be 
recognized in the free CAPE treated mice. DSS groups demonstrate similar trends of 
epithelial distortion as depicted in the Figure 7A. The inflammation score graph was 
significantly (ΔΔΔP<0.0001) low in CAPE-loaded albumin NP treated group than free CAPE 
as shown in Figure 6.7B. N = 5-6 mice per group **P<0.001 and ***P<0.001. ΔΔΔP<0.001. 
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6.5.5 Level of p65 in PIC and CAPE-loaded albumin NP tissue 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.8: Low level of p65 in PIC (A) and CAPE-loaded albumin NP+DSS (B) treated 
group at 20X magnification. Low expression of p65 can be seen in colonic tissue of mice 
treated with PIC and CAPE-loaded albumin NP as evident in Figure 8A and 8B. However, 
these proteins are highly elevated in tissue of mice treated with free PIC, CAPE and DSS 
groups as demonstrated in Figure 6.8(A and B). 
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6.5.6 Level of HIF-1α in PIC and CAPE-loaded albumin NP treated tissue 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.9: low level of HIF-1α in in PIC-loaded albumin NP+DSS (A) and CAPE-loaded 
albumin NP+DSS (B) treated group. Lower level of HIF-1α can be observed in colonic 
tissue of mice treated with PIC and CAPE-loaded albumin NP as evident in Figure 6.9A and 
6.9B. However, these proteins are highly expressed in mice treated with free PIC, CAPE and 
DSS groups as illustrated in Figure 6.9(A and B). 
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6.6 Discussions 
The anti-inflammatory potential of PIC and CAPE has been documented in the 
current work, high degree of anti-inflammatory therapeutics in nanoparticles form 
than the free PIC and CAPE in a mouse model of UC was reported. The early sign of 
UC such as weight loss, loose stool, diarrhoea and appearance of blood in stool 
confirm colitis in DSS groups as shown in Figure 1. However, these symptoms are 
absent in PIC and CAPE-loaded albumin NP. Though, free PIC and CAPE 
demonstrate these symptoms to some extent as depicted in the weight loss and DAI 
graph in Figure 6.1(A and B) and Figure 6.2(A and B). 
After dissection of the colon, blood clot, loose stool and shorted colon length was 
reported in DSS, free PIC and CAPE treated group as shown in Figure 6.3A and 
Figure 6.4A. But PIC and CAPE-loaded albumin NP exhibit normal stool, no blood 
and the equivalent colon length as healthy group as depicted in the Figure 6.3A and 
Figure 6.4A. Figure 6.3B and Figure 6.4B demonstrate no significant difference in 
colon length as healthy group. The entire colon weight was recorded and colon of 
PIC and CAPE-loaded albumin NP treated mice illustrate no significant difference in 
weight as visible in the Figure 6.5(A and B). 
Mucosal layer damage has been documented to be a major cause of colitis which can 
be noticed in colons of DSS treated group as shown in Figure 6.6A and Figure 6.7A. 
Moreover, free PIC and CAPE treated mice shows the same extent of colon damage 
as DSS group as evident from the Figure6.6A and Figure 6.7A. However, colon of 
mice treated with PIC and CAPE-loaded albumin NP do not display damage to the 
epithelial layer. Mucosal layer of mice treated with NPs appeared to be normal as in 
healthy group. The blinded histological inflammation score reveals that albumin 
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nanoparticles treated PIC and CAPE colon exhibits significant low inflammation 
score than free PIC and CAPE as shown in the Figure 6.6B and Figure 6.7B. 
Overactivation of nuclear factor p65 was reported in UC which was confirmed in 
animal model of colitis as represented in ICH staining of colonic tissue from DSS 
group as shown in Figure 6.8 (A and B). Furthermore, free PIC and CAPE treated 
mice express the slightly low level of p65 in the colon as visible in Figure 6.8 (A and 
B). Although, PIC and CAPE-loaded albumin NP treated mice exhibit a very low 
level of this protein in colonic tissue as demonstrated in Figure 6.8(A and B). 
Similarly, level of HIF-1α was reduced after mice were treated with PIC and CAPE-
loaded albumin NP compared to free PIC and CAPE as shown in Figure 6.9(A and 
B). 
Therefore, the current work demonstrated the increased efficacy of PIC and CAPE in 
nanopaticulate form. It would be benefit to cure in UC patients over other novel and 
conventional treatments to amend mucosal barrier function, ceased progression of 
onset of disease and promote mucosal healing. 
 
6.7 Conclusion 
The finding of this chapter reveals a high degree of anti-inflammatory properties of 
the natural and novel PIC and CAPE compounds. Nanoparticles of these compounds 
refrained symptoms of colitis such as weight loss, loose stool, diarrhoea and blood in 
faces as to huger extent than free drug. The colon length and weight appear to be 
normal after treatment with nanoparticles of PIC and CAPE. However, colon length 
and weight of PIC and CAPE treated mice does not appear to resist the detrimental 
effects of DSS. Histological images of the colon from PIC and CAPE-loaded 
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albumin NP illustrate the effectiveness of PIC and CAPE in the form of 
nanoparticles. Whereas free drugs fails to produced therapeutic effects due to limited 
solubility. Nanoparticles of drugs such as PIC and CAPE inhibited the 
overstimulated level of p65 and HIF-1α significantly than free drug. Hence 
nanotechnology will play a pivotal role in improving solubility and bioavailability of 
low soluble natural compounds. 
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Chapter 7                                                               
General discussion and future work 
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7.1 General discussion 
UC and colorectal cancer are interlinked with each other in terms of 
pathophysiology, symptoms and treatment (Kim and Chang, 2014). It is believed 
that UC and colorectal cancer bare the common etiology of the disease such as 
genetic alteration, life style, environment, overexpression of transcription protein and 
damage in the epithelial layer of colon (Kim and Chang, 2014). The current 
therapeutic practiced in these complication offers detrimental side effects such as 
immunity damage, oral ulcer, infertility and bone marrow depletion (Hofheinz et al., 
2017). The life style and finical condition violates during management of these 
complication.  Patients have to bare the pain of surgery to remove infected colon in 
chronic condition. Therefore, we have tested anti-inflammatory and anticancer 
activity of natural compounds such as PIC and CAPE in ulcerative model of colitis 
and colorectal cancer cell lines. The effectiveness of free drug was compared with 
albumin nanoparticles of these drugs because these natural compounds are low 
soluble in aqueous media. Therefore, albumin nanoparticles of these natural 
compounds were fabricated to optimise the physicochemical parameters and enhance 
the therapeutic activity in nanoparticle form. Albumin nanoparticles of PIC and 
CAPE were fabricated by desolvation method due to its simplicity robustness 
(D’Ignazio et al., 2017). This method has been used method for the formulation of 
nanoparticles of natural and synthetic compound used in ulcerative colitis and 
colorectal cancer.  
Firstly, the anti-inflammatory activity of free CAPE was evaluated in animal model 
of ulcerative colitis. Where 30 mg/kg of free CAPE was given to mice with 2.5% 
DSS in drinking water and macroscopic parameter such as weight loss, DAI and 
rectal bleeding was monitored during the experiment. Parameters such as DAI, rectal 
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bleeding, shortening of colon length, weight of colon and alteration of epithelial 
layer of colon in DSS induce colitis were also accessed during testing of anti-
inflammatory activity of natural compounds in (Algieri et al., 2014., Bereswill et al., 
2010., Murakami et al., 2003., Islam et al., 2008). It was reported that percentage 
weight loss and disease activity index was less in mice after treatment with free 
molecule of CAPE. However, mice treated with DSS show weight loss and higher 
DAI during the experiment. After the mice were sacrificed appearance, length and 
weight of colon was reported. Mice treated with free CAPE molecules demonstrate 
significant higher colon length and normal faeces than DSS treated mice. 
Additionally the weight of colon of CAPE treated mice weigh significant more as 
compare to colon of mice treated with DSS.  
It was stated that inflammatory markers results overstimulation of transcription 
protein such as NF-kβ and HIF-1α in UC and colorectal cancer and results into 
damage in architect of epithelial layer of colon (Kao et al., 2016., Simiantonaki et al., 
2008., Han et al., 2016). Therefore, presence of inflammatory markers was detected 
in different group of mice colonic tissue lysate. It was observed that the expression 
of inflammatory markers such as interferons, interleukins and TNF-α was higher in 
mice treated DSS as compare mice treated with free molecule of CAPE. Moreover, 
the histological evolution of epithelia layer of colon does not show alteration in 
epithelial layer and infiltration of neutrophils when mice treated with CAPE. 
Whereas, mice treated with DSS only show damage in epithelial layer and 
permeation of neutrophils. The expression of transcription protein such as p65 and 
HIF-1α was also monitored in colon tissue of mice from different group and it was 
found that mice after treatment with free CAPE decrease the expression of these 
proteins.  
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Secondly, during optimisation study it was reported that increase in polymer albumin 
amount increases the particles size of PIC and CAPE which is due to increase in 
viscosity of polymer solution. Similar trend of increase in particle size due to 
increase in albumin concentration was also reported by June et al., 2001. 
Additionally, entrapment efficiency and percentage yield also increase as albumin 
concentration increase as demounted by Ganesh et al., 2015.  The effect of increase 
concentration of crosslinking agent was studied and was reported that as amount of 
glutaraldehyde increases larger particles of PIC and CAPE was produced during 
formulation.  Rajith and Ravindran, 2014 was also documented increase in particle 
size due to increase in glutaraldehyde. After solubility study as have been performed 
by Kim et al., 2011. It was observed that optimised batch of nanoparticles 
demonstrate noticeable increase in solubility as compare to free drugs in distilled 
water. SEM study also confirms formation of smooth, spherical and uniform 
nanoparticles which are localise under cancer cell lines such CaCo-2 and HT-29. 
 After optimisation and cellular uptake studies I performed in-vitro cytotoxic assay in 
cancer cell lines to observe and compare the cytotoxicity of nanoparticles and free 
drugs and it was found that nanoparticles illustrates higher cytotoxic action in cancer 
cell lines than free drugs. Zhang et al have monitored anticancer in colorectal cancer 
cell lines via migration, colony formation and invasion experiments.  Therefore, 
anticancer potential of free PIC and CAPE was measured and compare with 
nanoparticles of these drugs in cancer cells via migration, colony formation and 
invasion assay.  The result obtained from in-vitro anticancer experiment reveals that 
nanoparticle demonstrates significant higher anticancer activity that free drugs. 
Müller-Edenborn et al., 2015 and D’Ignazio et al., 2017 mentioned that inhibtion of 
p65 and HIF-1α mitigate disease condtion in colorectal cancer and UC. Hence 
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expression of transcription protein such as p65 and HIF-1α was evaluated by ICC 
and Invitrogen ELISA assay kit and it was shown that when cancer cells transfected 
with nanoparticle of natural compounds decrease the over induction of transcription 
protein significantly as compare to cell treated with free PIC and CAPE. 
Lastly, after confirmation of anticancer activity of nanoparticles in colorectal cancer 
cell lines such as CaC-2 and HT-29 of PIC and CAPE and the anti-inflammatory 
activity was observed in animal model of UC. The data obtained from the 
experiment confirms that albumin nanoparticles of PIC and CAPE enhance the anti-
inflammatory activity as compare to free molecules based on the weight loss, DAI, 
colon length, histology and expression of p65 and HIF-1α. 
Therefore, formulation of nanoparticles of these natural agents PIC and CAPE 
enhances the anticancer and anti-inflammatory activities due to enhancement in 
physicochemical properties which leads to increase in solubility, morphology and 
cellular uptake. Additionally, albumin nanoparticles also inhibit overstated 
transcription proteins in colonic tissue of colitis induce mice and colorectal cancer 
cell lines. Therefore natural compound in nanoparticles form may provide better 
therapeutic effect in cancer and UC via modulating transcription factors as compare 
to free molecules. 
 
7.2 Future work 
Albumin nanoparticles of natural compound such as PIC and CAPE enhances the 
anti-inflammatory and anticancer at higher degree than free compounds as 
documented from the in-vitro and in-vivo studies in this work. The future work 
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would be to test expression of other transcription protein such as p52, RelA and 
RelB in colorectal cancer cell lines and colonic tissue of colitis induce mice after 
treatment with these nanoparticles. Additionally the anticancer potential of albumin 
nanoparticles would be tested animal model of colorectal cancer. 
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1.1 Introduction 
Curcumin is a well-known anticancer agent found in the rhizomes of the perennial 
herb Curcuma longa.  It has a long history of use in traditional medicine, covering a 
broad spectrum of conditions, from various cancer, diabetes, inflammation and 
Alzheimer’s disease (Naksuriya et al., 2014., Prasad et al., 2014).  The FDA has 
endorsed its status as a safe home-based remedy. In more structured and rigorous 
evaluations, comprising of more than 65 clinical trials, benefit from life-threatening 
diseases has been demonstrated (Yallapu et al., 2013). In relation to inflammatory 
and cancerous disorders, therapeutic action are attributed to its ability via modulation 
of nuclear factor kappa-beta (NF-kβ) transcriptional factor (Thangapazham et al., 
2013., Tambuwala, 2016) and hypoxia inducible factor (HIF) (Birner et al., 2000., 
Bae et al., 2006). Moreover, an elevated level of HIF-1α and NF-kβ has been 
documented in human colitis (Ma et al., 2016). 
 Free curcumin and curcumin nanoparticles have been reported to be of therapeutic 
value in almost all cancer types (Bisht et al., 2007a., Xing et al., 2014., Kamble et 
al., 2016., Bondi et al., 2017) . However, the molecular mechanism of action 
involved in the treatment of cancer under pathophysiological hypoxic tumour 
microenvironment is not clearly understood. This could be one of the major factors 
limiting the clinical use of curcumin as cancer therapeutic. 
The over activation NF-kβ and HIF pathways, due to hypoxic tumour 
microenvironment, have been reported extensively in almost cancers (Redell and 
Tweardy, 2005., Tafani et al., 2013).  This hypoxic micro-environment has been 
blamed for metabolic adaption of cancer cells which result in tumour development, 
progression and reduced effectiveness of cancer therapeutics (Eales et al., 2016).  
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Among all cancer types, breast cancer has been reported as the major cause of death 
among elderly women in Europe and the United States (Chakravarty et al.) 
(Malvezzi et al., 2016). Paclitaxel, 5-fluorouracil, cyclosporine, doxorubicin are 
most commonly prescribed as treatment options for breast and lung cancer (Gladkov 
et al., 2015., Del Mastro et al., 2016., Zhong et al., 2016). However, these 
conventional chemo-therapeutics result in serious side-effects, such as constipation, 
nausea, alopecia, neuronal damage, bone marrow depletion and heart failure 
(Lancellotti et al., 2015., Hanai et al., 2016). Similarly, lung cancer is reported as the 
major cause of cancer-related death in males from developing countries, which 
contributes approximately 18.2% of the total cancer death statistic (Ridge et al., 
2013). Furthermore, tiredness, skin reaction, loss of appetite, neurotoxicity and hair 
loss are some of the general side effects associated with conventional therapeutics 
(Landesman-Milo et al., 2015). Patients suffering from breast and lung cancers 
usually have to undergo surgery and radiation-based treatments in addition to 
chemotherapy. Furthermore, these therapies are not site-specific and cause extensive 
damage to healthy tissue (Pouw et al., 2015). In addition, these interventions 
interfere with the menopause and fertility (Recio-Saucedo et al., 2016). Hence, there 
is a pressing need to develop safer and effective alternatives for treatment of cancer. 
The therapeutic value of curcumin in the treatment of breast and lung cancer have 
been reported, in in-vitro, in-vivo and clinical studies (Coleman et al., 2015.,  Kang 
et al., 2015).  However, these findings highlight solubility issue of curcumin, which 
results in low systemic bioavailability, poor pharmacokinetic profile and sub-optimal 
delivery to the target cells (Ireson et al., 2001., Ireson et al., 2002).  Thus the first 
objective of the present work was to use pharmaceutical technology to formulate a 
drug delivery system for curcumin with improved solubility and intra-cellular 
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delivery properties. Nano-encapsulation of drugs in PLGA matrices has been 
reported to enhance therapeutic efficacy/targeting capabilities (Danhier et al., 2012), 
protect from degradation (Kumari et al., 2010b) and improve aqueous solubility of 
poorly water-soluble drugs (Zhong et al., 2016., Brigger et al., 2002., Haggag and 
Faheem, 2015). Since curcumin is practically insoluble in water, it makes an ideal 
model drug candidate for current investigation (Yallapu et al., 2010).  Nano-
encapsulation is also known to enhance cellular permeability and retention effects, 
which are proposed as mechanisms to target and enhance drug accumulation in solid 
tumour masses (Reddy, 2005).  Since hypoxia plays a critical role in tumour 
development and progression, the primary objective of the work was to investigate 
the molecular mechanism of action of free curcumin and nano-encapsulated 
curcumin towards the expression of the two master transcriptional regulators HIF-1α 
and p65 (Rel A), which are known to be expressed in response to hypoxia and are 
positively associated with almost all cancers (Vaughan et al., 1966., Weichert et al., 
2007). 
It is hypothesize that nano-encapsulation of curcumin will enhance its solubility and 
facilitate intra-cellular delivery of the drug resulting in improved bioavailability and 
anticancer activity via modulation of the over activated NF-kβ and HIF pathways in 
lung and breast cancer cells under hypoxic condition. Thus, resulting in stabilization 
of a tumour and preventing the further development of cancer. In this study, solvent 
evaporation method was employed, using sonication to homogenize the emulsion 
phases, and poly (vinyl alcohol) (PVA) to stabilize and control particle size (Sahoo 
et al., 2002). Optimisations of PLGA and PVA content were carried out to select 
optimum settings during the formulation of curcumin-loaded PLGA NP (cur-PLGA-
NP). The nanoparticle formulation exhibiting superior cellular uptake, retention and 
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in-vitro release was selected for further assessment of anticancer and anti-metastatic 
activity of curcumin in the highly metastatic breast (MDA-MB231) and lung cancer 
(A549) cell lines. 
 
1.2 Summary 
Therefore, due to seriousness and side effects linked with current treatment in lung 
and breast cancer, there is compelling need to formulate nanoparticles of the natural 
compound and study the pathways involved in lung and breast cancer. Therapeutic 
potential of curcumins has been documented by  researchers.  It has low solubility in 
aqueous media which can be improved by nanotechnology. Encapsulation of 
curcumin with PLGA will protect it from stomach degradation and will offer control 
release. As curcumin also modulates transcription factors, therefore, it will also assist 
to study pathways involved in tumour development. 
 
1.3 Hypothesis 
In the current chapter, we hypothesize that reduction of particle size of the natural 
compound will improve the anticancer property of curcumin at a higher extent than 
free curcumin. 
 
1.4 Aims and objectives 
• Formulation of Cur- loaded PLGA nanoparticles 
• Optimisation of Cur- loaded PLGA nanoparticles 
212 
 
• Evaluation of anticancer properties of Cur- loaded PLGA nanoparticles 
in MDA-MB-231 and A549 
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2 Result 
2.1 Calibration curve 
Calibration curve of PIC was plotted in methanol (1:9) and absorbance was 
measured at 430 nm. 
 
2.2 Effect of PLGA concentration 
Three different batches nanoparticles were formulated by solvent evaporation 
techniques as described in section 2.2 with different amount of PLGA and an equal 
amount of curcumin. The effect of an increase in the mass of polymer on 
physicochemical properties of cur-PLGA-NP is shown in Figure 2.  It was found that 
particle size increased significantly from 265 nm to 606 nm (P<0.001) as the 
quantity of PLGA increased (Figure 2A). This increase in size is due to increase in 
the viscosity of polymer solution and formation of larger disperses droplets (Cui et 
al., 2005., Haggag et al., 2016b). It was also observed that increasing the amount of 
polymer increased the zeta potential significantly from –13.7 mV (F1) to -3.1 mV 
(Figure 2B; P<0.01). This is due to the accumulation of ionised carboxylic groups on 
the nanoparticles as result of increasing amount the polymer. Entrapment efficiency 
increased significantly, as the ratio of PLGA increased (Figure 2C). Similar results 
were reported by (Derman, 2015),  along with others, proposes that the increase in 
PLGA in the organic phase increases the viscosity in this phase and slows unwanted 
diffusivity to the water phase (Cun et al., 2010). 
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2.3 Effect of surfactant concentration 
The amount of surfactant plays an important role in stabilization of emulsion and 
prevents the coalescence by lowering the free energy at the interface of nanodroplets 
(Kwon et al., 2001). Insufficient amount of emulsifier may cause aggregation of 
nanoparticles. Particle size significantly (P<0.001) increases from 308 nm to 721 nm 
as the PVA concentration increases to 3.5% as illustrated in the Figure 3A. A similar 
finding was also reported by (Kwon et al., 2001). However, zeta potential fluctuates 
as the PVA concentration increase as shown in Figure 3 (graph B). Figure 3 (graph 
C) depicts that increases in PVA concentration lead to increase in entrapment 
efficiency significantly (P<0.001). It increases from 73% to 89% with an increase in 
PVA concentration.  Increase concentration of PVA may be responsible for increase 
viscosity of aqueous phase which results in higher entrapment efficiency and larger 
particle size. A similar finding was documented by (Song et al., 2008). 
The initial burst release was reported around 32%, 20% and 18% for 1.5 %, 2.5%  
and 3.5% batches respectively (graph D). The percentage release for batches 
formulated with 1.5%, 2.5% and 3.5%  was found to be 89%, 80%and 75% 
respectively after 168 hours. Therefore, increase in the concentration of PVA may 
slow down the diffusion of the drug. It has been also documented by (Sahoo et al., 
2002) where increase concentration of PVA affect diffusion of the drug from 
nanoparticles. 
 
2.4 Effect of drug concentration 
The physicochemical properties such as particle size, zeta potential, entrapment 
efficiency and in-vitro release studies of cur-PLGA-NP were evaluated as shown 
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Figure 4. The average particle size of nanoparticles fabricated with 25 mg, 50 mg 
and 75 mg of curcumin was found to be 233 nm 292 nm and 510 nm, respectively as 
visible in the Figure 4A. This increase in particle size may be due to increase in the 
curcumin concentration which increases the size of nanodroplets in the emulsion 
(Krishnamachari et al., 2007). Cur-PLGA-NP in the graph 4B shows negative zeta 
potential (-6mV, -13mV and -7mV) due to the ionized terminal carboxylic groups of 
PLGA present on the surface of the nanoparticles. Entrapment efficiency of batches 
containing 25 mg and 50 mg ( 4C) were found to be 64% and 78%, respectively. The 
initial burst release was found to be around 25%, 14% and 13% for batch formulated 
with 25 mg,  50 mg and 75 mg of curcumin, respectively (graph D). The percentage 
release for batches formulated with 25 mg,  50 mg and 75 mg of curcumin was found 
to be 88%, 86%and 81% respectively after 168 hours. Therefore, increase in drug 
amount decreases the release of the drug due to increase in viscosity of drug 
solution. 
 
2.5 NMR spectra of cur-PLGA-NP 
The H NMR study of cur-PLGA-NP was performed as per section 2.5. The 1H NMR 
spectrum of curcumin revealed the signals due to six aromatic protons [ 7.13 ppm (d, 
2H, J = 8.1 Hz, B), 7.04 ppm (s, 2H, C) and 6.93 ppm (d, 2H, J = 8.1 Hz, D)], a trans 
trans double bond [ 7.58 ppm (d, 2H, J = 16 Hz, A) and 6.47 ppm (d, 2H, J = 16 Hz, 
E)], one methylene group [ around 5.8 ppm (s, 2H, F)] and methoxy group [3.94 
ppm (s, 6H, OCH3]. These data confirmed the structure of curcumin in nanoparticles 
as shown in Figure 5. 
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2.6 Solubility of cur-PLGA-NP and free curcumin  
The solubility of cur-PLGA-NP and free curcumin was determined by the method 
given in section 2.9. The apparent water solubility of curcumin in both free and 
nano-encapsulated form was determined by UV- spectroscopy at 430 nm. The vials 
in Figure 6AI give a visual representation of the enhanced solubility of curcumin 
when formulated as cur-PLGA-NP vs free curcumin in water.  It is evident that cur-
PLGA-NP produce a uniform dispersion, whereas free curcumin (6AII) was 
sparingly soluble in water.  The solubility of free curcumin was found to be 
0.3446µg/ml, whereas that of cur-PLGA-NP was 3.5128µg/ml. These results 
indicate an approximate ten-fold increase in aqueous solubility of cur-PLGA-NP as 
compared to free curcumin. 
 
2.7 Scanning Electron Microscopy 
The sample for SEM was prepared by the method mentioned in the section 2.10. 
Figure 7 shows SEM images of F1, F2, and F3 formulated with 30 mg, 60 mg and 90 
mg of polymer with equal amounts of curcumin and PVA. F1 exhibited a 
monodisperse appearance, with the smallest particle size. SEM images of cur-PLGA-
NP suggest that an increase in the polymer (PLGA) concentration not only leads to 
an increase in particle size but also results in non-spherical particles. Thus, batch F1 
batch was selected for intracellular delivery due to smaller size (De Jong and Borm, 
2008). 
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2.8 Cellular uptake of cur-PLGA-NP 
The MDA-MB231 and A549  cell were incubated with cur-PLGA-NP as described 
in the section 2.12. The nuclei of MDA-MB231 and A549 cells were stained with 
DAPI and Nile red-tagged cur-PLGA-NP were observed under fluorescent 
microscopy as shown in Figure 8.  Cellular uptake of cur-PLGA-NP labelled with 
Nile red, in MDA-MB231 and A549 cells were visualized by overlaying images 
obtained by fluorescent microscopy. Nile red-coated cur-PLGA-NP can be seen 
within the MDA-MB231 and A549 cells as depicted in the Figure 8A and 8B. Cur-
PLGA-NP in MDA- The result indicates that formulation F1 NP facilitates cellular 
uptake of curcumin, which could result in enhanced therapeutic activity as compared 
vto free curcumin. 
 
2.9 In-vitro cytotoxicity assay  
The cytotoxicity study was performed as described in the section 2.13. The cytotoxic 
action of cur-PLGA-NP on the MDA-MB-231 Figure (9 A) and A549 (9B)  cell 
lines was evaluated by MTT assay after 24, 48, 72 and 96 hours of treatment at 3.68 
µg/ml, 7.36 µg/ml  and 11.05 µg/ml of cur-PLGA-NP and an equivalent amount of 
free curcumin. The results showed that blank NP had no cytotoxicity on breast and 
lung cancer cells within the concentrations used. Free curcumin and cur-PLGA-NP 
showed a dose response cytotoxic effect. Free curcumin exhibited its cytotoxic 
action during the first 24 hours in both cell lines. The cell viability started to increase 
after the first day due to the diminished cytotoxic action of the free drug. The MDA-
MB-231 and A549 cell viability decreased to approximately 60% after 96 h 
treatment with 11.05 µg/ml of free curcumin. Cur-PLGA-NP reduced cell viability 
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and sustained cytotoxic action was achieved up to four days after treatment Based on 
the values depicted in the graph A and B, it is clear that cur-PLGA-NP showed 
significantly higher cytotoxic action and lower cell viability in both cell lines.  Cur-
PLGA-NP sustained the cytotoxic action of the free drug due to the enhanced 
penetration and retention effect inside the cancer cells (Patil et al., 2009., 
Chavanpatil et al., 2006) also due to improving its solubility, and bioavailability 
(Mittal et al., 2007., Anand et al., 2010). The achieved lower cell viability and 
greater cytotoxicity compared to free curcumin was clear after 96 hours of treatment. 
 
2.10 Migration assay 
The migration study was carried out in MDA-MB-231 and A549 as stated in the 
section 2.14. A scratch assay was conducted on both cell lines in this work to 
investigate doses response of free curcumin and cur-PLGA-NP on the migration 
capability of MDA-MB-231 (Figure 10A) and A549 (Figure 10B) cells. Migration of 
cancer cells from the primary tumour site to other sites is a predominant feature of 
metastatic breast and lung cancer cells (Palmer et al., 2011). Figure 10 shows the 
graphical quantification of the degree of wound closure when breast and lung cancer 
cell treated with cur-PLGA-NP and equivalent dose of free curcumin (3.68 µg/ml, 
7.36 µg/ml and 11.05 µg/ml).  Treatment with free curcumin resulted in a mild 
decrease in closure for all concentrations in both cell lines however, cur-PLGA-NP 
extensively enhanced reduction in the degree of wound closure compared to the free 
curcumin after 72 hours of using the same concentrations curcumin (Figure 10A and 
B). These results demonstrated that cur-PLGA-NP have the superior anti-migration 
capability as compared to free curcumin. 
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2.11 Colony formation assay 
The colony formation assay was performed as the procedure mentioned in the 
section 2.15. Colony formation assay has been used to study the long-term anticancer 
activity of curcumin . The number of colonies formed after 7 days was quantified for 
MDA-MB-231 (Figure 11A) and A549 (Figure 11B) cells treated with blank PLGA-
NP as control, along with three different concentrations of free curcumin and cur-
PLGA-NP curcumin (3.68 µg/ml, 7.36 µg/ml and 11.05 µg/ml). Treatment with cur-
PLGA-NP resulted in significantly lower numbers of colonies compared to free 
curcumin as shown Figure 11A and B.  
 
2.12 Invasion assay 
The protocol for invasion assay was given in the 2.16. Invasion assay was conducted 
to investigate the effect of free curcumin and cur-PLGA-NP on the invasion 
capability of MDA-MB-231 (Figure 12A) and A549 (Figure 12B) cells. 
Dissemination of tumour cells from the primary site to distant locations starts with 
cell detachment followed by the local invasion of the normal tissues adjacent to a 
tumour which then can infiltration through the lymphatic drainage (Palmer et al., 
2011). Treatment with cur-PLGA-NP (3.68 µg/ml, 7.36 µg/ml and 11.05 µg/ml) 
resulted in a significant decrease in cell invasion compared to free curcumin for all 
concentrations in both cell lines as shown in Figure 12. These results suggest that 
Cur-PLGA-NP can significantly inhibit the invasion capability of invasive lung and 
breast cancer cells when compared to free curcumin. This enhanced anti-invasive 
effect imparted to curcumin by nano-encapsulation is critical to inhibit metastasis of 
highly invasive breast and lung cancer cells. 
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2.13 Assessment of p65 and HIF-1α levels 
The protocol followed was described in section 2.18. Having assessed the physical 
parameters, aqueous solubility, intracellular uptake and anticancer potential of cur-
PLGA-NP versus free curcumin, we need to investigate the molecular mechanism 
for the improved anticancer potential of curcumin when formulated as PLGA 
nanoparticles. Recent research indicates that metastatic human cancer tumours are 
hypoxic and these cells could have elevated levels HIF-1α and NF-kβ/p65 (Rel A) 
which may result tumour development and progression of cancer (Zhang et al., 
2015., Liu et al., 2015., Chaturvedi et al., 2014., Patel and Simon, 2008., Shukla et 
al., 2004). Hence, to investigate if curcumin treatment has an effect on these 
transcription factors we used whole cell lysates from metastatic breast (MDA-
MB231) and lung (A549) cancer cells treated blank NP, cur-PLGA-NP and free 
curcumin under hypoxic condition (10% O2) to quantify the levels of HIF-1α and 
p65 (Rel A) using ELISA assay. The results from the ELISA assay indicated that 
free curcumin had no significant effect on the levels of HIF-1α and p65 (Rel A) as 
compared to blank NP however, there was a significant reduction in the levels of 
HIF-1α (Figure 13: panel A) and p65 (Rel A) (Figure 13: panel B) in both breast and 
lung cancer cells treated with cur-PLGA-NP (Figure 13; (P<0.001 – 0.01). This 
result indicates that curcumin can suppress the cellular levels of HIF-1α and p65 (Rel 
A) only when delivered as nanoparticles. 
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2.1 Calibration curve 
 
Figure 1: Calibration curve of curcumin 
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2.2 Effect of PLGA concentration 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Effect of polymer amount on particle size (A), zeta potential (B), entrapment 
efficiency (C) and in vitro release (D). The particle size of nanoparticles increases 
significantly as the polymer amount increases from 30 mg to 90 mg (A). Zeta potential 
decreases significantly upon increasing the polymer amount from 30 mg to 90 mg (B). 
Entrapment efficiency increases with increase in PLGA amount (C). The release profile 
depicts initial burst release after 24 hours. Nanoparticles formulated using 60 mg PLGA 
shows the highest percentage release of curcumin (D). Values are mean ± SEM (n = 3). 
*P<0.05, **P<0.01 and ***P<0.001 compared with 30 mg PLGA. 
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2.3 Effect of surfactant concentration 
  
 
 
 
 
 
 
 
 
 
 
Figure 3: Effect of PVA concentration on particle size (A), zeta potential (B), entrapment 
efficiency (C) and in vitro release (D). The particle size of nanoparticles significantly 
increases as the PVA concentration increases from 1.5% to 3% (A). Zeta potential decreases 
significantly upon increasing the PVA concentration but it increases on further increase in 
PVA concentration. Entrapment efficiency shows significant increase with an increase in 
PVA concentration (C). The release profile depicts initial burst release after 24 hours. 
Nanoparticles formulated with1.5% PVA shows the highest percentage release of curcumin 
(D). Values are mean ± SEM (n = 3). *P<0.05, **P<0.01 and ***P<0.001 compared with 30 
mg PLGA 
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2.4 Effect of drug concentration 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Effect of drug amount on particle size (A), zeta potential (B), entrapment 
efficiency (C) and in vitro release (D). Increase in drug amount significantly increases the 
particle size of nanoparticles from 25 mg to 75 mg (A). Zeta potential does not have any 
significant effect as the amount of curcumin increases (B). Entrapment efficiency shows a 
significant increase with an increase in drug amount (C). The release profile depicts initial 
burst release after 24 hours. Nanoparticles formulated with125 mg of curcumin shows the 
highest percentage release of curcumin (D). Values are mean ± SEM (n = 3). *p < 0.05, 
**P<0.01 and ***P<0.001 compared with 30 mg PLGA. 
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2.5 NMR spectra of cur-PLGA-NP  
 
Figure 5: H NMR of curcumin in PLGA nanoparticles. The above H NMR confirms the 
curcumin stucture in the nanoparticle form. 
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2.6 Solubility of cur-PLGA-NP and free curcumin  
 
 
 
 
 
 
 
 
 
Figure 6: Water solubility of cur-PLGA-NP (A) and free curcumin (B). The vials in figures 
shows the solubility of cur-PLGA-NP (A) and free curcumin (B) respectively. The free 
curcumin precipitates and settles down whereas cur-PLGA-NP shows uniform dispersion 
throughout the vial. 
 
 
 
 
 
 
 
 
 
Curcumin precipitation 
227 
 
2.7 Scanning Electron Microscopy 
 
 
 
  
 
Figure 7: Scanning Electron Microscopy of cur-PLGA-NP F1, F2, and F3 containing 30 
mg, 60 mg and 90 mg of PLGA polymer respectively. Scanning electron microscopic 
images of F1, F2 and F3 batches containing 30 mg, 60 mg and 90 mg of PLGA demonstrate 
an increase in particle size. F1 has smaller and uniform particle size as compared to F2 and 
F3. SEM images confirm that increase in polymer amount leads to increase in particle size 
and distortion of particle shape. 
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2.8 Cellular uptake of cur-PLGA-NP 
 
 
 
 
 
 
 
 
 
 
Figure 8: Cellular uptake of cur-PLGA-NP in MDA-MB231 and A549 at 20X. Cellular 
localization of Nile red-coated cur-PLGA-NP was observed in MDA-MB231 (A) and A549 
(B) and visualized by overlapping under fluorescent microscopy. Figure A shows that 
nanoparticles are present in the cytoplasm and nucleus of the MDA-MB231 cells. Curcumin 
nanoparticles were observed only in the cytoplasm of A549 cells (B). 
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2.9 In-vitro cytotoxicity assay  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Effect of cur-PLGA-NP and free curcumin on cytotoxicity of MDA-MB-231 and 
A549 cell lines. Dose dependent response was observed in cytotoxicity assay on MDA-MB-
231 (A) and A549 (B) cell lines. However, of cur-PLGA-N demonstrate higher toxicity than 
free curcumin in both cell lines. Values are mean ± SEM (n = 3). ***P<0.001 compared 
with same amount of free drug. 
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2.10 Migration assay 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Effect of cur-PLGA-NP and free curcumin on migration of MDA-MB231 and 
A549 cell lines. The effect of cur-PLGA-NP and free curcumin on migration capacity of 
MDA-MB231 (A) and A549 (B) cell lines were evaluated. Cur-PLGA-NP shows a 
significant reduction in migration capability of both cell lines as compared to free curcumin. 
Values are mean ± SEM with n=3.  *P<0.05, **P<0.01, ***P<0.001 compared with control 
(blank NP). ΔP<0.05, ΔΔ P<0.01, ΔΔΔP<0.001 compared with the same dose of free curcumin. 
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2.11 Colony formation assay 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Effect of cur-PLGA-NP and free curcumin on colony formation ability of MDA-
MB231 and A549 cell lines. Cur-PLGA-NP significantly reduces the colony formation 
ability of both MDA-MB231 (A) and A549 (B) cell lines. Cur-PLGA-NP shows a 
significant reduction in colony formation capability of both cell lines as compared to free 
curcumin. Values are mean ± SEM with n=3.  *P<0.05, **P<0.01, ***P<0.001 compared 
with control (blank NP). ΔP<0.05, ΔΔP<0.01, ΔΔΔP<0.001 compared with the same dose of 
free curcumin. 
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2.12 Invasion assay 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Effect of cur-PLGA-NP and free curcumin on invasion of MDA-MB231 and 
A549 cell lines. The effect of cur-PLGA-NP and free curcumin on invasion capability of 
MDA-MB231 (A) and A549 (B) cell lines was observed. Cur-PLGA-NP shows a significant 
reduction in invasion capability of both cell lines as compared to free curcumin. Values are 
mean ± SEM with n=3. *P<0.05, **P<0.01, ***P<0.001 compared with control (blank NP). 
ΔP<0.05, ΔΔP<0.01, ΔΔΔP<0.001 compared with the same dose of free curcumin. 
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2.13 Assessment of p65 and HIF-1α levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Effect of cur-PLGA-NP and free curcumin on expression of cellular levels of 
p65 (Rel A) and HIF-1.  Cur-PLGA-NP significantly reduces the levels of p65 (A) and 
HIF-1 (B) in both MDA-MB231 and A549 cell lines. Values are mean ± SEM with n=4. 
**P<0.01, ***P<0.001 compared with blank NP. ΔΔP<0.01, ΔΔΔP<0.001 compared with the 
same dose of free curcumin treatment for 24 hours. 
A 
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
10000
Free curcumin (3.68 µg/ml)
Control
***
Blank NP
Cur-PLGA-NP (3.68 µg/ml)

MDA-MB231
H
IF
1
- 
 (
p
g
/m
l-
)
0
200
400
600
800
1000
1200
1400
1600
1800
2000
***
Control
Blank NP
Free curcumin (3.68 µg/ml)
Cur-PLGA-NP (3.68 µg/ml)

A549
H
IF
1
- 
 (
p
g
/m
l)
0
100
200
300
400
500
600
700
800
900
1000
1100
1200
1300
**
Control
Blank NP
Free curcumin (3.68 µg/ml)
Cur-PLGA-NP (3.68 µg/ml)

MDA-MB231
p
6
5
 (
p
g
/m
l-
)
0
100
200
300
400
500
600
700
800
Control
Blank NP
Free curcumin (3.68 µg/ml)
**
Cur-PLGA-NP (3.68 µg/ml)

A549
p
6
5
 (
p
g
/m
l)
B 
234 
 
3.1 Discussion 
Curcumin has received considerable attention as a potent anticancer (Bollu et al., 
2016) and an anti-inflammatory agent. However, it is not currently used as a clinical 
medicine for treating inflammation or cancer. Our work has demonstrated the effect 
of increase amount of PLGA on particle size, zeta potential, entrapment efficiency 
and in-vitro release. These findings are in agreement with previously published data 
(Pandit et al., 2015). Figure 2 shows that increase in PLGA amount increases the 
particle size, zeta potential and entrapment efficiency significantly. However, 
percentage release decrease with increase in PLGA amount. This may be due to 
increase in the viscosity of polymer solution Similarly, increase in PVA 
concentration also leads to increase in particle size, entrapment efficiency and in-
vitro release significantly as shown in Figure 3. However, increase in PVA 
concentration does not have any significant effect zeta potential. Furthermore, 
increase in drug amount cause increase in particles size, entrapment efficiency and 
in-vitro release but it does not produce any significant result on zeta potential as 
visible in Figure 4. NMR spectroscopy confirms the purity of curcumin in 
nanoparticles forms as depicted in Figure 5. 
We also observed a ten-fold increase in curcumin solubility when formulated as 
PLGA nanoparticles (Figure 6) this increased solubility can increase the 
bioavailability of curcumin and intra-cellular delivery (Tiwari et al., 2014). 
 SEM images from the batches F1, F2 and F3 as shown in Figure 7 demonstrate that 
increase in PLGA amount not only leads to increase in particle size but also distorts 
the spherical structure of the nanoparticles. 
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Current work indicates that curcumin uptake by cancer cells is achieved when it is 
formulated as PLGA nanoparticles (Figure 8), and cytotoxicity study demonstrate 
that curcumin nanoparticles have higher anti-proliferation action than free curcumin 
as noticed in Figure 9. This evidence of cellular uptake and cytotoxic study of 
curcumin nanoparticles forms the basis of our further findings indicating reduce 
migration (Figure 10), colony formation (Figure 11) and decrease invasion power 
(Figure 12) of the breast and lung cancer cells. Similar findings related to the 
anticancer potential of curcumin and curcumin nanoparticles have been reported by 
several researchers (Yallapu et al., 2014., Anitha et al., 2014., Chang et al., 2013., 
Verderio et al., 2013). 
However, there is no study till date reporting the action of curcumin and/or curcumin 
nanoparticles on elevated levels HIF-1α and p65 (Rel A) in breast and lung cancer 
cells under a tumour hypoxic condition. Thus the most important findings of current 
work indicate that nano-encapsulation of curcumin is capable of downregulating the 
expression of HIF-1α and p65 (Rel A) levels in breast and lung cancer cells when 
exposed to hypoxia (10% O2) (Figure 13). This finding suggests that the increased 
therapeutic value of the natural anticancer agent curcumin could be via suppression 
of over activated HIF and NF-kβ pathways, which are predominately responsible for 
adaptation of hypoxic tumours resulting in the development and spread of cancer in 
our body.  
Hence, the findings from this work conclude that nanotechnology based drug 
delivery system could be an effective tool to enhance the anticancer activity of 
several natural and/or novel anticancer compounds, which are currently not in 
clinical use due to their low solubility and/or poor bioavailability.  Future work will 
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involve functionalizing these PLGA-NP using salic acid to selectively target cancer 
tumour cells in in vivo models of lung and breast cancer. 
 
3.2 Conclusion 
The data from this chapter demonstrate that PLGA nanoparticles loaded with 
curcumin can be successfully fabricated by a solvent evaporation method. For in-
vitro characterization, such as cell viability and cellular uptake were carried out after 
optimization process. The cell toxicity experiment demonstrates a dose dependent 
relationship with cell viability in A549 and MDA-MB-231. This implies that Cur-
loaded PLGA NP is more efficacious that free curcumin towards cancer cell toxicity. 
PLGA nanoparticles loaded with curcumin show higher efficiency in controlling 
tumour growth than free curcumin which can be illustrated by migration, colony 
formation and invasion assays. The reduced level of p65 and HIF-1α has been 
depicted in A549and MDA-MB-231 after transfection with curcumin nanoparticles. 
Therefore, polymeric delivery of curcumin nanoparticles may provide therapeutic 
cure to lung and breast cancer based on the above data. 
 
